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Summary 
Uveal melanoma (UM) is the most common primary intraocular malignancy in 
adults and 40% develop fatal metastatic disease. Compared to tumours with 
chromosome 3 disomy, monosomy 3 tumours will nearly exclusively develop 
metastasis. To identify differentially expressed proteins, quantitative label-free 
LC-MS proteomic profiling of 8 primary UM tissues from patients with metastasis 
(M) and 8 from patients without metastasis (NM) was performed. Fifty proteins 
with ≥ 3 peptides matched and p < 0.05 between the two patient groups were 
differentially expressed. Thioredoxin-dependant peroxidase reductase (PRDX3) 
was upregulated and cytosolic non-specific dipeptidase (CNDP2) was 
downregulated in M compared to NM. To identify differentially expressed genes, 
bioinformatic reanalysis of publically available gene expression microarray 
datasets of 63 primary UM tumours was performed. Samples with confounding 
factors (chromosome 3 disomy with metastasis and chromosome 3 monosomy 
without metastasis) and outlying samples in principal component analysis were 
excluded. Eleven monosomy 3 tumours with metastasis (M3M) versus 9 disomy 
3 tumours without metastasis (D3NM) were compared. A total of 449 
differentially expressed genes with fold change of ≥ 1.3 and p < 0.05 were found 
between the two patient groups. Signal-induced proliferation-associated 1-like 
protein 2 (SIPA1L2) was upregulated and contactin 3 (CNTN3) was 
downregulated in M3M compared to D3NM. Pilot immunohistochemical (IHC) 
study of PRDX3, CNDP2, SIPA1L2 and CNTN3 expression in 13 full-face formalin-
fixed paraffin-embedded tissues of patients that did (mUM) and 13 that did not 
develop metastasis (nmUM) showed a trend toward higher expression of PRDX3 
in mUM compared to nmUM (p: 0.061). Expression of CNDP2, SIPA1L2 and 
CNTN3 were not significant (p: 0.752, p: 0.094 and p: 0.099 respectively). IHC of 
PRDX3 in tissue microarray samples of 55 mUM and 37 nmUM tumours showed 
statistically significant difference in expression between mUM and nmUM (p: 
0.001). Significant difference in survival was found based on high and low 
expression of PRDX3 (67.61 vs. 130.64 months respectively, p: 0.013). In 
conclusion, differential proteomic analysis of primary UM tissues from patients 
with and without metastasis has identified PRDX3 to be associated with 
metastasis and poor survival.   
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1. Introduction 
1.1. Introduction to Uveal Melanoma 
 
Uveal melanoma (UM) is the most common primary intraocular malignancy 
in adults. The overall incidence is approximately 5 to 7 cases per million per year, 
and climbs to more than 20 cases per million per year by the age of 70 (1,2). It is 
more common in the Caucasian population, especially those with blue/grey iris. 
The survival rates at 5, 10 and 15 years are 65%, 50% and 45% respectively (2–4). 
Ninety-two percent of cases of UM arise in the choroid while the remainder arise 
in the iris and ciliary body (Figure 1). Choroidal melanomas have the worst 
prognosis, while iris melanomas have the most favourable. The latter may be due 
to earlier presentation, as iris melanomas may be detected by the patient 
externally. Unfortunately, choroidal melanomas are usually detected late, when 
the patient is symptomatic with decreased visual acuity. This may be due to the 
involvement of the macula, or when complicated by secondary retinal 
detachment. There are several treatment options available for uveal melanoma. 
These include eye-preserving plaque radiation brachytherapy for choroidal 
tumours measuring less than 10mm in height and 20mm in basal diameter and 
proton beam therapy for tumours that are small and inaccessible due to its 
posterior location. However, the vast majority of patients require enucleation 
due to large tumour size at presentation (Figure 2). 
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Figure 1: Uveal melanoma may arise anywhere along the uveal tract; choroid 
(92%), ciliary body (5%) and iris (3%).  
 
 
Figure 2: Treatment options for uveal melanoma; (a) plaque radiation 
brachytherapy for choroidal tumours measuring less than 10mm in height and 
20mm in basal diameter; (b) proton beam therapy for tumours that are small and 
inaccessible due to its posterior location; (c) enucleation for large tumours.  
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Uveal melanoma is associated with the development of metastasis in about 
50% of cases, and 40% of patients with UM die of metastatic disease despite 
successful treatment of the primary tumour (5,6). Metastatic spread occurs 
haematogenously, predominantly to the liver in up to 90% of patients with 
metastatic disease (7). Other potential sites include lung, bone and skin, but 
these are rare in the absence of liver metastasis (8). The occurrence of 
metastasis is primarily detected after disease-free intervals following local 
treatment, sometimes after more than a decade. This suggests the presence of 
occult micrometastatic disease at the time of the diagnosis and treatment of the 
primary eye tumour (9). When liver metastasis is diagnosed, treatment options 
are limited and survival is short, averaging 5-8 months (10). Despite progress in 
early diagnosis and treatment of primary UM, mortality rates have remained 
similar over the last 25 years (11,12). This is due to the lack of effective 
biomarkers to identify early metastasis and therapeutic targets for metastatic 
uveal melanoma. 
 
There are several prognostic factors which include clinical, histopathologic 
and cytogenetic factors, the latter being the most accurate and reliable. Until 
recently, cell type was the most used prognostic indicator as epithelioid and 
mixed (consisting of both epithelioid and spindle) tumours are more aggressive 
than spindle cell type. Recent advances in molecular genetics have increased our 
knowledge on the cytogenetic properties of uveal melanoma. Studies have 
shown that UM tumours are characterized by non-random alterations in 
chromosomes 1, 3, 6, and 8 (13). Tumours with loss of chromosome 3 are 
associated with poor prognosis (14). Approximately 70% of patients with 
monosomy 3 in the primary tumour died of metastases within 4 years after the 
initial diagnosis, while tumours with normal chromosome 3 status rarely give rise 
to metastatic disease (14). Monosomy 3 and trisomy 8, partial duplication of 8q, 
or iso-chromosome 8q are the most frequent karyotypic abnormalities present in 
approximately 50% of cases (13). Cytogenetic studies have revealed that deletion 
or loss of heterozygosity of chromosome 3 and gain of chromosome 8 correlates 
with an increased risk of metastasis (15,16). Chromosome 8 abnormalities are 
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also associated with large tumour size and aggressive histology (15). In addition, 
loss of 1p is an independent prognostic factor for increased risk of metastasis 
(17,18). Amplification of 6p is found in approximately 25% of tumours (19,20). 
Chromosome 6p gains are mutually exclusive with monosomy 3 and rarely 
develop metastasis (20). 
 
A number of gene-expression profiling studies have revealed that primary 
UM clusters in two different classes; class 1 tumours that are associated with a 
good prognosis and class 2 tumours with a high metastatic risk (21,22). The most 
common known oncogenic mutations occur in GNAQ or GNA11 which are found 
in about 85% of all primary UM, irrespective of tumour class or stage (23,24). 
These mutations may represent an early event that leads to the development of 
UM. Further downstream, mutations in BAP1 gene located in chromosome 3, 
were found to occur almost exclusively in metastasizing class 2 tumours (25). 
Either BAP1 mutation or loss of chromosome 3 can occur first, but both events 
appear to be necessary for the tumour to metastasise (26). More recently, 
mutations in splicing factor SF3B1 were found to be associated with a better 
prognosis (27). Individuals with SF3B1-mutant tumours tended to have a lower 
metastasis rate than those with tumours with wild-type SF3B1. SF3B1 and BAP1 
mutations were almost mutually exclusive, suggesting that they may represent 
alternative pathways in tumour progression (27).  
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Figure 3: Schematic representation of the transformation of melanocytes to 
naevus, melanoma and ultimately metastatic phenotype. GNAQ/GNA11 
mutation represents an initial event that triggers transformation of melanocytes. 
Class 1 tumours are characterised by chromosome 3 disomy and low risk for 
metastasis. Loss of chromosome 3 leads to class 2 tumours with high risk for 
metastasis. Adopted from Retina, 5th Edition, S Ryan 2013 (28). 
 
Recently, Laurent at al (29) performed gene expression profiling of 28 
primary UM tumours from patients who developed metastasis within 3 years 
compared to 35 primary tumours from patients who did not develop metastasis 
within 3 years or metastasised after 3 years. Protein tyrosine phosphatase type 
IV A member 3 (PTP4A3) was found to be associated with metastasis in UM. 
Overexpression of PTP4A3 in uveal melanoma cell line was found to significantly 
increase invasion and migration in vitro. However, this study has an inherent 
limitation as UM may metastasise after a disease-free interval of more than a 
decade. Thus, a direct comparison of the expression profile of metastatic versus 
non-metastatic primary UM tissue was not determined since tumours from 
patients who metastasised after 3 years were included with UM tumours from 
patients who did not metastasise.   
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1.2. Biology of Uveal Melanoma 
 
Uveal melanocytes, like their epidermal counterpart, are derived from 
pluripotent neural crest cells that migrate out of the neural crest and populate 
the uveal tract. However, uveal melanocytes appear to have a distinct 
developmental lineage compared to epidermal melanocytes. Compared to 
epidermal melanocytes, dermal and uveal melanocytes were shown to be less 
dependent on KIT signalling and highly dependent on endothelin-3 (ET3) and 
hepatocyte growth factor (HGF) signalling (30). ET3 mediates its signalling 
through α g-proteins GNAQ and GNA11 via the endothelin B receptor. In mouse 
models, mutations in GNAQ and GNA11 were shown to result in dermal 
melanocytosis and hyperpigmentation (31). Although, the uveal tract was not 
investigated in this study, these findings are consistent with the suggestion that 
the ET3/endothelin B receptor/GNAQ or GNA11 pathway is an important 
developmental pathway for dermal (and likely uveal) melanocytes, distinct from 
the developmental pathways that result in epidermal melanocytes (32). Uveal 
melanoma tumours seem to have aberrations in these same pathways that are 
crucial to uveal melanocyte development. 
 
Constitutive activation of the RAS-RAF-MEK-ERK (extracellular signal-
regulated kinase) or mitogen-activated protein kinase (MAPK) pathway plays a 
crucial role in uveal melanoma development (33,34). G proteins are a family of 
heterotrimeric protein complex that are coupled to the 7-transmembrane 
spanning cell surface receptors. Ligand binding to and activating these receptors 
catalyses the exchange of GDP for GTP bound to the inactive G protein alpha 
subunit resulting in a conformational change and the subsequent dissociation of 
the Gα from the Gβγ subunits. These 2 subunits are capable of regulating various 
second messengers. GNAQ has an intrinsic GTPase domain at the C terminus 
which causes the hydrolysis of GTP to GDP and the Gα-GDP re-associates with 
Gβγ subunits. The activated Gα subunit mediates its activity through stimulation 
of phospholipase C-β (PLC β), which catalyses PIP2 to IP3 and DAG. DAG goes on 
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to activate protein kinase C (PKC), which activates ras. Ras activates Raf, which 
subsequently activates MAP/ERK (extracellular signal-regulated kinase) kinase 
(MEK). MEK phosphorylates and activates ERK, which dimerises and translocates 
to the nucleus, where it mediates cell proliferation, survival, differentiation, and 
apoptosis. Phosphorylated ERK also activates mTOR, which stimulates cell 
proliferation through translational control of cell-cycle progression regulators. 
 
GNAQ or GNA11 mutations are found in about 85-91% of all UM and 
represents the most common oncogenic mutation (23,24,35). The mutations are 
mutually exclusive and occur in exon 4 (R183) or exon 5 (Q209) in GNAQ or 
GNA11. It is not associated with tumour class, stage or clinicopathological 
parameters and therefore, indicates an early event in the disease pathogenesis 
(23). Unlike cutaneous melanoma, genetic mutations in BRAF or NRAS are rare in 
UM, suggesting that activation of MAPK occurs through a mechanism different to 
cutaneous melanoma (34,36). It has been shown that mutations in the Gqα 
subunits GNAQ or GNA11 are responsible or the constitutive activation of the 
MAPK pathway in the development of UM. Mutant GNAQ/GNA11 are affected at 
the intrinsic GTPase domain where hydrolysis of GTP to GDP and the Gα-GDP re-
association with Gβγ subunits is defective. Thus, this leads to the constitutive Gα 
activation and downstream signalling of the MAPK pathway.  
 
In vitro, exogenous expression of mutant GNAQ increased MAPK 
phosphorylation, whereas knockdown of GNAQ in UM cell lines with mutant 
GNAQ diminished MAPK phosphorylation, decreased pERK expression with 
subsequent reduction in growth and increased apoptosis (24,37–39). More 
recently, it was also shown that the activation of protein kinase C (PKC) pathway 
is as a consequence of GNAQ/GNA11 mutation, with downstream activation of 
the MAPK pathway. Two different protein kinase C (PKC) inhibitors, AEB071 and 
enzastaurin, were shown to independently increase the accumulation of p27Kip1, 
while decreasing the expression of cyclin D1 in three GNAQ-mutated cell lines, 
leading to G1 cell-cycle arrest (40,41). Several studies have demonstrated that 
G1 arrest induced by MEK inhibitors is mediated via inhibition of ERK1/2, 
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characterized by decreased expression of cyclin D1 and accumulation of p27Kip1 
(42–44). The PKC inhibitors also demonstrated antiproliferative effects on these 
cell lines, suggesting that the suppression of Erk1/2 phosphorylation may be 
critical to inhibit proliferation through altering the expression of p27, cyclin D1, 
Bcl-2 and survivin. In mouse models, treatment with PKC inhibitor significantly 
slowed tumour growth but did not induce tumour shrinkage. When combined 
with MEK inhibition, sustained synergistic MAPK pathway inhibition was 
observed, leading to tumour regression (45). This indicates protein kinase C (PKC) 
is a target of GNAQ/GNA11 signalling that ultimately leads to ERK1/2 
(MAPK3/MAPK1) activation. 
 
The PI3K/AKT signalling pathway has also been implicated in UM. PI3K is 
activated by G-protein–coupled receptors and by receptor tyrosine kinases. Once 
activated, PI3K catalyses the conversion of PIP2 to PIP3. AKT activation is 
initiated by translocation to the plasma membrane mediated by activated PIP3. 
Once phosphorylated and activated, AKT phosphorylates many other proteins, 
including the downstream effector mTOR and regulates a wide range of cellular 
processes involved in protein synthesis, metabolism, cell survival, proliferation, 
angiogenesis and migration (46,47). Cellular levels of PIP3 are regulated by the 
opposing activity of PTEN. PTEN, an important tumour suppressor, antagonizes 
PI3K activity by converting it back to PIP2 and thus, decreases AKT activation. 
 
In a study of 75 UM tumours, loss of heterozygosity of the PTEN locus was 
found in 76% of tumours and actual mutations within the PTEN coding region 
was observed in 11% of tumours. Furthermore, downregulation of PTEN 
expression in aggressive compared with less aggressive tumours was shown 
immunohistochemically (48).  Patients with a total loss of PTEN had a median 
survival of 60 months compared with more than 120 months for patients with 
normal or nearly normal PTEN expression (48). Immunohistochemical expression 
of phosphorylated AKT has also been associated with negative prognostic 
indicators in UM (49). Several UM cell lines with chromosomal deletions leading 
to loss of expression of PTEN, show PI3K activation, representing one mechanism 
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of this pathway activation (48,50,51). However, the effect of activated GNAQ or 
GNA11 on signalling through the PI3K/AKT pathway appears to be cell-type 
specific, and has not been determined in uveal melanoma (52,53). An in vitro 
study found that inhibition of MEK, and therefore MAPK signalling results in the 
reciprocal activation of AKT activity in uveal melanoma cell lines, regardless of 
GNAQ/11 mutant status (54). MEK inhibition alone caused cell cycle arrest and 
reduced growth in most UM cells, but only modest apoptosis was observed. 
Similarly, PI3K inhibition alone caused cell cycle arrest and reduced growth, but 
was insufficient to induce apoptosis. However, the combination of MEK and PI3K 
inhibition resulted in a strong induction of apoptotic death. Proteomic network 
analysis revealed a homeostatic relationship between the MEK/MAPK and 
PI3K/AKT pathways in uveal melanoma cells. Inhibition of MEK resulted in a 
relative increase in AKT phosphorylation, whereas, an increase in the 
phosphorylation of MAPK was observed after inhibition of PI3K. Khalili et al 
conclude that the PI3K/AKT pathway is stimulated independent of GNAQ/GNA11 
mutation status, and a combination of MEK and PI3K inhibitor was more 
effective at inducing cell death (54). A more recent study showed that PI3K-α 
inhibitor (BYL719) enhanced the effect of PKC inhibitor (AEB071) in 
GNAQ/GNA11 mutant cell lines (55). AEB071 treatment inhibited growth and 
reduced ERK1/2 but persistent AKT activation was observed. BYL719 had minimal 
anti-proliferative activity in all uveal melanoma cell lines, and inhibited 
phosphorylation of AKT in most cell lines. Combination treatment showed 
synergistic inhibition of cell proliferation and apoptotic cell death in vitro. 
Similarly, in vivo studies showed reduced xenograft tumour in a GNAQ mutant 
model. This suggests that the PI3K/AKT pathway is activated and plays a critical 
role in UM development. 
 
KIT, a member of the PDGFR family of kinases, is a receptor tyrosine kinase 
that is activated by binding of stem cell-derived factor (SCF) and plays an 
essential role in the regulation of various cellular processes including cell survival 
and proliferation, stem cell maintenance, and in melanogenesis (56). KIT 
activates the AKT signalling pathway by phosphorylating PI3K and also transmits 
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signals via GRB2 and activation of RAS, RAF1 and the MAPK pathway (56). 
Mouriaux et al showed KIT expression in normal choroidal melanocytes and 
activation by SCF stimulated proliferation (57). In normal uveal melanocytes, 
stimulation with SCF resulted in activation of both ERK1/2 and AKT but in a KIT-
expressing UM cell line, stimulation led to MAPK pathway activation only (58). 
Immunohistochemical expression of KIT was positive in 62.7-78.2% of primary 
UM tissue and treatment with a KIT inhibitor led to significant decrease in 
proliferation, invasion and cell death in UM cell lines (58,59). An in vitro study 
found constitutive ERK1/2 activation that enabled UM cell proliferation and 
transformation in a KIT dependant manner. Inhibition of UM proliferation was 
observed when depleted of SCF/KIT, but not AKT, suggesting that the 
proliferative effects of the SCF/KIT autocrine loop in uveal melanoma likely 
funnel primarily through the MAPK pathway (60). However, activation-related 
mutations of KIT have not been found (57,61). 
 
The MET proto-oncogene encodes a receptor tyrosine kinase that modulates 
diverse biological functions such as cell motility, proliferation, survival and is 
known to be upregulated in multiple cancers (62–65). Hepatocyte growth factor 
(HGF) binding to MET receptor leads to activation and initiation of downstream 
signalling mediated by GRB2, PI3K, RAS, and SRC (65). Given the preferential 
dissemination of UM cells to the liver, HGF and MET have been investigated in 
several studies. High immunohistochemical expression of HGF and MET in 
primary UM tissues have been reported (66–68). Mallikarjuna et al found a 
significant association between high MET expression and death due to uveal 
melanoma. Interestingly, the 6 tumours with liver metastasis showed higher 
expression of MET and were negative for HGF, suggesting a possible mechanism 
of ligand-independent MET activation (69). The activation of PI3K/AKT pathway 
induced by the HGF/MET was shown to attenuate cell-cell adhesion by 
downregulation of cell adhesion molecules E-cadherin and beta-catenin, 
promoting the enhanced motility and migration of uveal melanoma cells (70,71). 
On HGF stimulation, receptor MET translocated to the nucleus in a ligand-
dependent manner, suggesting that MET may modulate the expression of genes 
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involved in UM cell migration (70). Conversely, downregulation of MET 
expression decreased proliferation and migration by inhibiting AKT 
phosphorylation (67,72). However, no activating mutations of MET in primary 
tumours and cell lines have been found, suggesting that MET activation in is 
most likely through indirect gene activation rather than copy number alteration 
or mutation involving the MET gene (67).  
 
Similar to HGF, insulin-like growth factor 1 (IGF-1) is mainly produced by the 
liver. IGF-1 binds to IGF-1R and activates the intrinsic receptor tyrosine kinase 
activity and phosphorylates insulin receptor substrate (IRS). IRS, a major effector 
of insulin signalling in the liver, stimulates the phosphorylation of AKT via PI3K 
and MAPK to modulate cell proliferation, survival, migration as well as tumour 
invasiveness (73–75). IGF-1R has been shown to be expressed in primary UM 
tissues (66,68,76). In multivariate analysis, a significant association between high 
IGF-1R expression and melanoma-specific mortality was shown (68,76). 
Treatment of UM cell lines with picropodophyllin (PPP), a specific inhibitor of 
IGF-1R, decreased IGF-1R expression, phosphorylation, decreased downstream 
MAPK and PI3K signalling. This led to a decrease in growth and inhibited cell 
adhesion, migration and invasion. Furthermore, PPP significantly delayed 
establishment of uveal melanoma tumours, caused tumour regression and 
reduced the incidence of liver metastasis in mice (77,78). 
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Figure 4: Major signalling pathways in uveal melanoma. The MAPK, P13K 
(phosphatidylinositol-3-kinase), mTOR, and IGF-1R pathways intersect 
significantly in uveal melanoma pathogenesis. Stimulation of GPCR (G-protein–
coupled receptor) results in replacement of GDP for GTP on the Gα subunit. Gα-
GTP is the active form and mediates activation of PLCβ, which promotes cleavage 
of PIP2 [phosphatidylinositol (4,5)-bisphosphate] to inosol triphosphate (IP3) and 
diacyl glycerol (DAG). DAG goes on to activate PKC, which stimulates the MAPK 
signalling pathway. MAPK signalling leads to tumour growth and proliferation. 
The GNAQ mutation inactivates the intrinsic phosphatase of the Gα protein, thus 
preventing hydrolysis of GTP to GDP and enabling constitutive downstream 
MAPK signalling. PI3K mediates phosphorylation of PIP2 to PIP3 
[phosphatidylinositol (3,4,5)-trisphosphate], and PTEN (phosphatase and tensin 
homolog) antagonises this process. PIP3 activates AKT, which promotes tumour 
growth and proliferation. Both ERK and AKT also activate the mTOR-signalling 
pathway, which also mediates tumour growth and proliferation. IGF-1 simulation 
of IGF-1R leads to dimerisation and autophosphorylation of the receptor, 
resulting in recruitment and activation of IRS, which can then activate both the 
PI3K and MAPK pathways. Modified from (79)  
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As monosomy 3 tumours are associated with metastasis and poor prognosis, 
the remaining chromosome 3 genes likely contains mutations on potential 
tumour suppressor genes that can lead to an aggressive phenotype. Harbour et 
al conducted exome sequencing of monosomy 3 UM samples found that BRCA1-
associated protein 1 (BAP1) had mutations on 3p21.1 in 85% of class 2 aggressive 
UM and almost never in class 1 tumours (25). Microarray gene expression 
profiling of 92.1 UM cells transfected with control versus BAP1 siRNA showed a 
shift in the expression profile towards class 2 signature in BAP1 depleted cells 
compared to control cells (25). Interestingly, BAP1 depletion caused an increase 
in mRNA levels of the proto-oncogene KIT, which are highly expressed in class 2 
tumours. Furthermore, RNAi-mediated knock down of BAP1 in 92.1 UM cells, 
which did not contain a detectable BAP1 mutation, recapitulated many 
characteristics of the de-differentiated class 2 UM phenotype (80). Either BAP1 
mutation or loss of chromosome 3 can occur first, but both events appear to be 
necessary for the tumour to metastasise (26). It is localised to chromosome 
3p21.31-p21.2, a region previously noted by Trolet et al to be deleted in UM (81). 
It encodes a deubiquitinating enzyme that interacts with the breast cancer 
susceptibility gene (BRCA1) and BRCA1-associated RING domain protein 1 
(BARD1) to form a tumour suppressor heterodimeric complex (29). It possesses a 
large C-terminal domain which is predicted to coordinate the selective 
association with potential substrates or regulatory components (82). 
Functionally, BAP1 enzyme removes ubiquitin molecules from specific proteins to 
regulate their function. For example, BAP1 removes ubiquitin molecules from 
histone H2A, which causes changes in the expression of specific genes that are 
regulated by this histone (83). It also modulates the assembly of multiprotein 
complexes containing numerous transcription factors and cofactors, and 
activates transcription in an enzymatic-activity–dependent manner, thereby 
regulating the expression of a variety of genes involved in various cellular 
processes (84). BAP1 has been implicated in several types of cancer such as lung, 
breast, and renal cell carcinoma (85–90). Germline BAP1 mutations have been 
described in families with a high risk for hereditary cancer and a novel ‘BAP1 
cancer syndrome’ that includes UM, cutaneous melanoma and melanocytic 
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neoplasm, lung adenocarcinoma, meningioma and malignant mesothelioma, has 
been described (91–95). In HeLa and other cell lines, BAP1 depletion altered the 
expression of genes that were key mediators of cell-cycle progression, DNA 
replication and repair, cell metabolism, survival, and apoptosis (84). In vivo, 
expression of wild-type BAP1 was shown to significantly decrease 
tumourigenicity of a human non-small cell lung cancer cell line in nude mice. 
Conversely, expression of mutant BAP1 that lacks either deubiquitinating activity 
or nuclear localization did not suppress tumourigenicity, implying that both 
deubiquinating activity and nuclear localization are necessary for the tumour-
suppressive activity (96). Depsipeptide, a histone deacetylase (HDAC) inhibitor 
was shown to inhibit proliferation and growth by increasing expression of Fas 
and FasL in 3 UM cell lines derived from primary tumour and 2 cell lines derived 
from liver metastasis. Depsipeptide induced gene upregulation of both Fas and 
FasL in these cells, and an increase in activated caspase-3, apoptosis and cell-
cycle arrest was observed in treated cells compared to non-treated cells (97). 
Landreville et al showed that HDAC inhibitors induced morphologic 
differentiation, cell-cycle exit, and a shift to a differentiated, melanocytic gene 
expression profile in cultured UM cells. Furthermore, it was also shown to inhibit 
growth of UM tumours in vivo (98). Although BAP1 may function as a tumour 
suppressor in UM, the manner in which mutations/loss of this gene plays a role 
in the development of metastatic disease is not yet understood.  
 
More recently, mutations in splicing factor SF3B1 were found to be 
associated with a better prognosis (27). Mutations in SF3B1 are single nucleotide 
point mutations predominantly occurring at arginine-625 and involve only 1 
allele. Individuals with SF3B1-mutant tumours tended to have a lower metastasis 
rate than those with tumours with wild-type SF3B1. SF3B1 encodes a component 
of the spliceosome and is involved in splicing pre-mRNA. Mutations were 
associated with differential alternative splicing of protein coding genes. 
However, it is not clear how this mutation is involved in UM (99). SF3B1 and 
BAP1 mutations were almost mutually exclusive but occur with equal frequency 
in GNAQ versus GNA11 mutations, suggesting that they may represent 
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alternative pathways in tumour progression (27). Another study confirmed this 
finding, along with the identification of mutations in eukaryotic translation 
initiation factor 1A, X-linked (EIF1AX) in 24% of uveal melanomas, which were 
also associated with good prognosis (100). EIF1AX mutations were also found to 
be mutually exclusive with SF3B1and BAP1 mutations (100). EIF1AX encodes a 
protein involved in protein translation and biosynthesis but its function in UM is 
still unclear. Mutations in EIF1AX are non-truncating and heterozygous, which 
are characteristics usually associated with dominantly acting oncogenes (101). In 
UM cells with EIF1AX mutations, only mutant mRNA transcripts were expressed, 
suggesting that the wild-type copy of EIF1AX is epigenetically inactivated, in 
which case EIF1AX mutations might behave in a recessive fashion (100,101). As 
these mutations are mutually exclusive, it suggests that the genes have an 
overlapping function in a common pathway, such that mutation of one gene 
relieves the selective pressure to mutate the other (102).  
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1.3. Treatment of metastatic disease 
 
Although difficult, successful treatment of the primary ocular tumour is 
usually achieved in all patients. These include eye-preserving plaque radiation 
brachytherapy for choroidal tumours measuring less than 10mm in height and 
20mm in basal diameter and proton beam therapy for tumours that are small 
and inaccessible due to its posterior location. The vast majority of patients 
require enucleation due to large tumour size at presentation. However, the most 
challenging aspect in the management of UM patients is the treatment of 
metastatic disease. In vitro, numerous laboratory studies have demonstrated 
favourable or successful therapeutic response by targeting signalling pathways 
that are known to be involved in the pathogenesis of UM. However, clinical trials 
utilising these therapeutic agents have shown poor response to treatment. 
Despite progress in early diagnosis and treatment of primary UM, mortality rates 
have remained similar over the last 25 years (11,12). Treatment of metastatic 
disease includes locoregional therapies and systemic chemotherapeutic agents. 
 
1.3.1 Surgical resection 
In a retrospective study over a 16-year period, surgical resection of liver 
metastases almost doubled survival time, with complete resection increasing 
median overall survival from 14 months to 27 months (103). Development of 
liver metastasis > 24 months after diagnosis of UM, completeness of surgical 
resection, number of metastases resected of ≤ 4 and absence of miliary disease 
were associated with improved survival (103). Similarly, another study 
demonstrated a 3.7 fold increase in survival time of patients who had surgical 
resection compared to those that did not, with complete microscopic resection 
almost doubling the survival time compared to incomplete resection (104). 
Survival of patients with ≤ 5 metastatic lesions were 3.1 times longer than those 
with ≥ 6 lesions (104). A recent meta-analysis of 22 studies (579 patients) found a 
median disease-free survival of 8 to 23 months, and median overall survival of 14 
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to 41 months (105). Conversely, the median survival of non-operated patients 
ranged from 4 to 12 months (105). These studies demonstrate that only a small 
subset of patients would benefit from surgical resection of liver metastases. 
However, liver metastases are usually detected when the disease is 
disseminated, with multiple lesions involving both lobes. Thus, resection of 
metastatic lesions is not feasible in most patients. 
 
1.3.2 Isolated hepatic perfusion (IHP) 
IHP allows delivery of high doses of cytotoxic agents while minimising 
systemic toxicity. Alexander et al (106) investigated the treatment of 
unresectable UM liver metastases with 60-minute IHP using melphalan (11 
patients) and melphalan with TNF (11 patients). There were 2 (9.5%) complete 
responses and 11 (52%) partial responses. The median duration of response was 
9 months and was significantly longer in patients who received melphalan with 
TNF compared to melphalan alone (14 vs. 6 months respectively). The overall 
median survival was 11 months, with one treatment mortality. In a subsequent 
study by Alexander et al (107), 29 patients with unresectable UM liver 
metastases were treated with 60-minute IHP using melphalan. There were 3 
(10%) complete responses and 15 (52%) partial responses with an overall survival 
of 12.1 months. Noter et al (108) evaluated 8 patients with UM liver metastases 
with 60-minute high-dose melphalan IHP. Four patients (50%) responded to 
treatment (partial/complete) with median overall survival of 9.9 months. Similar 
results were found by another study of 8 patients, where 3 demonstrated partial 
response to treatment with an overall survival of 11 months (109). In a recent 
retrospective study of 34 patients who underwent IHP with melphalan, overall 
response in 23 patients (68%) was seen, with complete response observed in 4 
patients (12%). Time to progression was 7 months and the median overall 
survival was 24 months. When compared to a control group consisting of the 
longest surviving UM patients with liver metastases not treated with IHP, a 
significant survival advantage of 14 months was found (110).  
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Figure 5: Illustration of the isolated hepatic perfusion (IHP) circuit. It is an 
invasive surgical procedure that involves laparotomy to isolate the hepatic 
circulation. The arterial inflow is via the gastroduodenal artery and venous 
outflow is collected from a cannula positioned in an isolated segment of 
retrohepatic vena cava. The inflow and outflow cannula are connected to a 
perfusion circuit. On the patient's left is the venovenous bypass circuit that 
shunts inferior vena cava blood flow from the femoral vein back to the systemic 
circulation via the internal jugular vein, thereby avoiding exposure to 
chemotherapeutic agents. Image modified from media.jsonline.com/images 
(111) 
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Figure 6: Survival curves showing significantly longer survival of patients treated 
with IHP (melphalan) compared to all controls and with the 30 longest surviving 
controls (110). 
 
1.3.3. Hepatic intra-arterial chemotherapy (HIA) 
HIA is a treatment modality that involves direct delivery of 
chemotherapeutic agent into the hepatic arterial circulation via a surgically 
placed hepatic artery catheter. This enables maximum local cytotoxic drug 
exposure with rapid systemic clearance. It also allows multiple, and outpatient-
based administration of treatment once the catheter is in place. In a pilot study 
of HIA fotemustine in 7 patients, 2 demonstrated partial response while 3 had 
stable disease and the remaining 2 patients progressed (112). Leyvraz et al 
demonstrated an objective response in 12 of 30 patients who received HIA 
fotemustine, with median duration of response of 11 months and median overall 
survival of 14 months (113). In a larger study of 101 patients, the authors 
demonstrated an overall response rate of 36% with a median overall survival of 
15 months and a 2-year survival rate of 29% (114). Interestingly, Leyvraz et al  
also found that 22 high-risk patients (without metastasis) treated with 6-month 
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course of adjuvant HIA fotemustine (four weekly doses of 100 mg/m2, and after a 
5-week rest, repeated every 3 weeks) demonstrated longer median overall 
survival of 1.6 years compared to randomly selected matched control group 
(from institutional database). The 5-year survival rate for treated patients was 
75% compared to 56% for the non-treated group, but this was not significant 
(115). Melichar et al showed partial response of liver metastasis to hepatic 
arterial infusion of cisplatin, vinblastine and dacarbazine (116). Two patients had 
an objective response, 4 patients had stable disease and 4 patients had 
progressive disease. Patients who responded to treatment or who stabilised 
survived for over a year while those with progressive disease died within 1 year.  
 
1.3.4. Immunoembolisation 
Instead of chemotherapeutic agents, immunoembolisation utilises 
immunologic stimulants such as granulocyte macrophage colony-stimulating 
factor (GM-CSF). This stimulates recruitment of antigen-presenting cells such as 
macrophages and dendritic cells, and enhances elimination of tumour cells 
thereby potentially creating an in-situ tumour vaccine (117). In a phase I trial, 
Sato et al (118) investigated immunoembolisation in 34 patients with liver 
metastases. Two patients had a complete response and 8 patients had a partial 
response and 10 had stable disease. The median overall survival was 14.4 
months and survival rate at 1 and 2 years were 62% and 26% respectively. In a 
subsequent study (119), the authors found that patients treated with high-dose 
(≥1500µg) GM-CSF had longer progression-free survival of 12.4 months 
compared to 5.6 months in patients receiving low-dose immunoembolisation 
(≤1000µg). Patients treated with high-dose immunoembolisation also 
demonstrated a longer median overall survival than patients treated by TACE 
with BCNU (20.4 vs 9.8 months). A further randomised phase II study using 
embolisation with or without GM-CSF in 52 patients showed longer median 
overall survival in patients treated with GM-CSF compared to those who we not 
(21.5 vs. 17.2 months respectively). Interestingly, immunoembolisation was 
shown to only benefit patients with larger volume of metastases (20-50%) where 
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median overall survival was 18.2 months compared to 16 months. In patients 
with tumour volume of <20%, immunoembolisation led to shorter time to 
progression in liver metastases of 3.7 months compared to7.2 months in patients 
treated without GM-CSF, suggesting an ambivalence biological effect of GM-CSF 
(120).  
 
1.3.5. Transcatheter arterial chemoembolization (TACE) 
TACE is an interventional radiological procedure that combines infusion 
of chemotherapeutic agents into the hepatic artery with simultaneous blockage 
of the tumour arterial supply. In a phase II trial using 1,3-bis(2-chloroethyl)-1-
nitrosourea (BCNU) (121), median survival was 5.2 months (range: 0.1 to 27.6 
months). Eighteen of 24 patients enrolled in this study showed response to 
treatment (1 complete response; 4 partial response; 13 stable disease). The 
median survival in patients with complete/partial response and stable disease 
was 21.9 months and 8.7 months respectively (range 7.4-27.6 months and 2.9-
14.4 months respectively). In patients who progressed, median survival was 3.3 
months.  Vogl et al (122) demonstrated mean overall survival of 21 months in 8 
of 12 patients who responded to TACE using mitomycin C and mean overall 
survival of 16.5 months in non-responders. The authors suggest that repeated 
TACE treatment is a palliative option for patients with multiple liver metastases. 
In another study using either fotemustine and/or cisplatin, 14 of 25 patients 
showed stable disease for at least 2 months. The median progression-free 
survival was 3 months (range: 2-4 months) and the median overall survival was 6 
months (range: 5-7 months). It was also found that patients with lactate 
dehydrogenase levels of less than twice the upper limit of normal showed 
clinically detectable response to treatment (123). In 14 patients treated with 
cisplatin and/or carboplatin, 8 patients (57%) achieved partial response, 4 had 
stable disease and 2 patients progressed. Median survival after was 14.5 months 
in patients who responded compared to 10 months in those that did not respond 
(124). In a phase II trial (125), 10 patients were treated with drug-eluting beads 
preloaded with irinotecan. Of these, 6 patients had a major response of 
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reduction in tumour size of 80-90% and four patients had a tumour reduction of 
60-70% following transarterial chemoembolization. The median overall survival 
time was 6.5 months (range: 4 to 9 months). Similarly, Venturini et al report a 
response rate of 80% in 5 patients treated with irinotecan drug-eluting beads 
(126). In a recent retrospective study of 21 patients treated with fotemustine 
chemoembolization (127), an overall response rate of 43% was found with partial 
response was seen in 3 patients (14%). Six patients had stable disease and 12 
patients demonstrated progression (29% and 57% respectively).  
 
 
Figure 7: Hepatic angiogram showing lack of filling of the right hepatic artery 
(white arrow) following administration of contrast agent, indicating successful 
embolisation by Transarterial Chemoembolisation (TACE). (128) 
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1.3.6. Adjuvant treatment 
There are very few studies of adjuvant treatment in metastatic uveal 
melanoma. In a recent study to evaluate the efficacy of IFN-α-2a in high-risk 
patients, 121 patients underwent a 2-year adjuvant IFN-α-2a therapy within 3 
years of radiation or enucleation of the primary tumour. A series of historical 
controls frequency-matched (2:1) to IFN-α-2a treated patients on age, tumour 
size, gender and survival time between primary therapy and initiation of IFN 
therapy were selected for comparison. No significant difference in survival 
between the 2 groups was observed (129). Salmon et al found that adjuvant 
intra-arterial fotemustine and/or DTIC-platinum following surgical resection of 
liver metastases in 61 patients did not show a significant survival advantage 
(130). In a more recent study, 22 high-risk patients (without metastasis) treated 
with adjuvant hepatic intra-arterial fotemustine after proton beam irradiation of 
the primary ocular tumour showed a survival benefit compared to randomly 
selected controls. The 5-year survival rate for treated patients was 75% 
compared to 56% for the non-treated group, but this was not significant (115).  
 
1.3.7. Systemic therapy 
Systemic chemotherapy has been the subject of significant research prior 
to the emergence of other targeted therapies. A meta-analysis of 40 systemic 
chemotherapeutic studies (131) consisting of 841 patients with metastatic uveal 
melanoma showed an overall response rate of 4.6%. In 55% of those studies, no 
response was observed. Median overall survival was reported in 65% of those 
studies and ranged from 5.2 months in pre-treated, predominantly end-stage 
patients (132) to 19.0 months in selected first-line patients (133). Progression-
free survival (PFS) was reported in 52.5% of studies and ranged from 1.8 to 7.1 
months.  
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Studies using single alkylating agents such as dacarbazine (134), 
treosulfan (135) and temozolomide (136) have been disappointing, with overall 
response rate of between 0-8% and overall survival of 6.7-8.7 months. Similarly, 
older generation immunomodulators such as thalidomide (137) and lenalidomide 
(138) have been disappointing with no response shown. Treatment with mitotic 
inhibitors such as DHA-paclitaxel in 22 patients showed partial response in 1 
patient (139) while a pilot study using vincristine in 4 patients showed complete 
response of lung metastasis in 1 patient (140). The safety and efficacy of 
vincristine is currently being investigated in 50 patients with metastatic UM 
(NCT00506142). A retrospective study by Spagnolo et al (141) analysed 25 
consecutive metastatic UM patients (with and without liver disease) treated with 
intravenous fotemustine as first-line treatment. Two patients showed partial 
response while 9 had stable disease with an overall response rate of 8.3% and 
disease control rate of 44%. The median survival was 13.9 months, and the 1-
year survival rate was 60%. In a recent and only randomised phase III trial 
comparing intravenous and HIA fotemustine in 171 patients, Leyvras et al report 
similar results between the two treatment groups, with no significant difference 
or improvement in overall survival (142). In another phase II study, Schmidt-
Hieber et al concluded that bendamustine was ineffective in metastatic UM with 
no response observed in any of the 11 patients (143). 
 
The combination of gemcitabine and treosulfan has been investigated in 
6 phase I and II studies. A pilot study by Pfohler et al in 2003 demonstrated an 
excellent overall response of 28.6% of the 14 patients evaluated, with an overall 
survival of 15.3 months and progression free survival of 7.1 months (144). 
However, subsequent studies have failed to replicate these results, with 5 
studies reporting an overall response of 0-4.2%, overall survival of 7.5-13.3 
months and progression free survival of 2.5-6.8 months (135,145–148). In a 
randomised control phase II study, Schmittel et al compared gemcitabine and 
treosulfan combination therapy to treosulfan alone and did not find any 
significant difference between these regimens (135). In another study by the 
same author, the combination of cisplatin, gemcitabine and treosulfan triple 
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therapy was compared to gemcitabine and treosulfan dual therapy (148). 
Similarly, no significant difference was found.  
 
The immunomodulatory effects of interferon alpha-2b, in combination 
with other chemotherapeutic agents were investigated in several studies. In 
2003, the combination therapy BOLD/INFα-2b (bleomycin, vincristine, lomustine, 
dacarbazine and INFα-2b) was investigated in a multicentre study (149) after 2 
prior phase II studies demonstrated an overall response of 15-20% (150,151). 
However, no response was observed in any of the 24 patients evaluated. A pilot 
study of 6 patients investigating the use of thalidomide/INF-α2b therapy did not 
show any response (152) while 1 patient (8%) responded to a combination of 
fotemustine/INF-α2b/interleukin-2 investigated in 25 patients (153).  
 
1.3.8. Systemic targeted therapies 
The most common known oncogenic mutations occur in GNAQ or GNA11 
which are found in about 85% of all primary UM, irrespective of tumour class or 
stage (23,24). These mutations may represent an early event that leads to the 
development of UM. GNAQ/GNA11 signalling leads to downstream activation 
protein kinase C and the MEK/MAPK and PI3K/AKT pathways (45,79). 
Furthermore, the MEK/MAPK and PI3K/AKT pathways are highly activated in UM 
(33,34,154,155). Further downstream, mutations in BAP1 gene located in 
chromosome 3, were found to occur almost exclusively in metastasizing class 2 
tumours (25). BAP1 loss causes increased histone H2A ubiquitination in 
melanoma cells and melanocytes (156). Either BAP1 mutation or loss of 
chromosome 3 can occur first, but both events appear to be necessary for the 
tumour to metastasise (26).  
 
Drugs targeting the MEK/MAPK/ERK kinase pathways have been 
investigated. In a phase I study of 16 patients treated with trametinib, no 
response was observed (157) while selumetinib treatment in 7 patients was also 
disappointing (158). However, compared with temozolomide, selumetinib was 
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recently shown to extended progression-free survival by nearly 9 weeks(159). 
Imatinib is a tyrosine kinase inhibitor that targets the PI3K/AKT pathways and 
platelet-derived growth factor (PDGF) receptors. However, 2 phase II studies of 
19 patients failed to demonstrate any response to imatinib (160,161), while a 
recent study by Nathan et al (162) showed an overall response rate of 8% (2 
partial response out of 25 patients studied). Landreville et al showed that histone 
deacetylase (HDAC) inhibitors induced morphologic differentiation of UM cells to 
melanocytes, suggesting therapeutic potential for inducing differentiation and 
prolong dormancy of micrometastatic disease in UM (98). Depsipeptide, a HDAC 
inhibitor was shown to inhibit proliferation and growth by increasing expression 
of Fas and FasL in 3 UM cell lines derived from primary tumour and 2 cell lines 
derived from liver metastasis. Depsipeptide induced gene upregulation of both 
Fas and FasL in these cells, and an increase in activated caspase-3, apoptosis and 
cell-cycle arrest was observed in treated cells compared to non-treated cells (97). 
Currently, a phase II clinical trial of the HDAC inhibitor vorinostat is underway 
and is estimated to be completed in June 2015 (clinical trial number: 
NCT01587352). 
 
In vitro studies have shown that UM cells produce vascular endothelial 
growth factor to stimulate and maintain angiogenesis (163,164). Increased levels 
of VEGF was also found in the aqueous and vitreous humour in patients with UM 
(165,166). Furthermore, elevated serum VEGF was shown to correlate with 
number and location of micrometastases in a murine model of uveal melanoma 
(167). In contrast, a recent study demonstrated a paradoxical stimulatory effect 
of the anti-VEGF drug bevacizumab when given as an intraocular injection in 
murine UM model (168). Phase II studies of bevacizumab/INF-α2b (169) and 
bevacizumab/temozolomide (170) found no response to either combination 
regimens. Similarly, Tarhini et al found no observable response to the anti-VEGF 
drug aflibercept (133). 
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Sunitinib and sorafenib are tyrosine kinase inhibitors that specifically 
target VEGF and PDGF receptors. In a pilot study investigating sunitinib as 
monotherapy in 18 patients, Mahipal et al found an overall response rate of 5%. 
Three patients had stable disease for over 12 months after failed previous 
treatments (171). However, a randomised phase II trial comparing dacarbazine 
and sunitinib as first line treatment in 74 patients found no significant difference 
in treatment response or survival (134). Sorafenib has never been investigated as 
a single-agent treatment regime. Kaempgen et al demonstrated an outstanding 
overall response of 42% (3 of 7 patients studied) in patients treated with 
fotemustine and sorafenib (172). However, triple combination treatment of 
carboplatin/paclitaxel/sorafenib in 24 patients showed no response to this 
regimen. Currently, a randomised, placebo-controlled phase II study is underway 
to investigate the safety and efficacy sorafenib in metastatic uveal melanoma 
(clinical trial number: NCT01377025).  
 
Ipilimumab was recently reported to be the first agent to show a survival 
benefit in cutaneous melanoma (173). It is a monoclonal antibody against CTLA-
4. CTLA-4 inhibits cancer cell death by inactivating cytotoxic T lymphocytes. 
Ipilimumab binds to the inactivating CTLA-4 receptor on APC and inactivates this 
inhibitory mechanism and allows cytotoxic T lymphocyte-mediated cell 
destruction. In a recent trial in 5 patients with advanced UM, 2 patients 
remained stable for 11-15 months before progressing while 3 patients did not 
respond to treatment, giving an overall survival of 10.3 months (174). In a large 
study of 82 pre-treated metastatic UM patients, Maio et al demonstrated an 
overall response rate of 5% and a 29% disease stabilisation with 12 month 
survival rate of 31% (175). In 22 patients, Kelderman et al reported a similar 
overall response rate of 4.5%  and 12 month survival rate of 27% (132), while 
Khan et al also reported a response rate of 5% in a study of 20 patients (176). In a 
retrospective study of 39 patients, ipilimumab treatment had a response rate 
and stabilisation rate of 2.6% and 46% respectively at 12 weeks, and 2.6% and 
28.2% respectively at 23 weeks (177).  
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Table 1: Summary of 40 studies of systemic chemotherapy in metastatic uveal melanoma. PR, partial response; CR, complete response; ORR, 
overall response rate; PFS, progression-free survival (months); OS, overall survival (months); IV, intravenous; HIA, hepatic intra-arterial; EAP, 
expanded access program. 
Author Year Drug Study design n 
First 
line 
Non-
first 
line 
Mean 
age 
PR/CR 
ORR 
(%) 
PFS OS 
Flaherty (178) 1998 Diverse  chemotherapies Retrospective 64 unk unk 59 3/1 9 unk 5.2 
Tarhini (133) 2011 Aflibercept Phase II 9 10 0 57 0/0 0 5.7 19 
Schmidt-
Hieber (143) 
2004 Bendamustine Phase II 11 0 11 61 0/0 0 unk unk 
Guenterberg 
(169) 
2011 Bevacizumab/INF-α2b Phase II 5 4 1 64 0/0 0 4.5 10.8 
Piperno-
Neumann 
(170) 
2013 Bevacizumab/temozolomide Phase II 35 35 0 55 0/0 0 3 12 
Nathan (150) 1997 BOLD/INFα-2b Phase II 20 20 0 62 4/0 20 unk unk 
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Author Year Drug Study design n 
First 
line 
Non-
first 
line 
Mean 
age 
PR/CR 
ORR 
(%) 
PFS OS 
Pyrhonen 
(151) 
2002 BOLD/INF-α2b Phase II 22 18 4 60 0/3 15 4.4 12.3 
Kivela (149) 2003 BOLD/INF-α2b Phase II 24 24 0 61 0/0 0 1.9 10.6 
Bhatia (179) 2012 Carboplatin/paclitaxel/sorafenib Phase II 24 20 4 61 0/0 0 4 11 
Schmittel 
(148) 
2005 Cisplatin/gemcitabine/treosulfan Phase II 17 19 0 60 0/0 0 3 7.7 
  
Gemcitabine/treosulfan Phase II 33 28 5 62 1/0 3 2.5 7.5 
Atzpodien 
(180) 
2008 
Cisplatin 
(IV/HIA)/gemcitabine/treosulfan 
Pilot 12 1 11 62 0/0 0 unk 6 
O’Neill (181) 2006 Dacarbacine/treosulfan Phase II 14 15 0 64 0/0 0 3 7.5 
Homsi (139) 2010 DHA-paclitaxel Phase II 22 11 11 56 1/0 4.6 3 9.8 
Leyvraz (142) 2012 Fotemustine Phase III 83 83 0 59 2/unk 2.4 3.7 unk 
Spagnolo (141) 2013 Fotemustine Retrospective 24 24 0 62 2/0 8.3 unk 13.9 
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Author Year Drug Study design n 
First 
line 
Non-
first 
line 
Mean 
age 
PR/CR 
ORR 
(%) 
PFS OS 
Becker (153) 2002 fotemustine/INF-α2b/IL-2 Phase II 25 unk unk 56 1/1 8 unk 15 
Kaempgen 
(172) 
2012 Fotemustine/sorafenib Case series 7 unk unk unk 3/0 42 unk unk 
Pfohler (144) 2003 Gemcitabine/treosulfan Pilot 14 13 1 63 3/1 28.6 7.1 15.3 
Keilholz (145) 2004 Gemcitabine/treosulfan Phase I 33 28 5 62 1/0 3 unk unk 
Terheyden 
(146) 
2004 Gemcitabine/treosulfan Phase II 20 8 14 62 0/0 0 unk 11.6 
Corrie (147) 2005 Gemcitabine/treosulfan Phase I 5 4 1 50 0/0 0 6.8 13.3 
Hofmann (161) 2008 Imatinib Phase II 9 9 3 63 0/0 0 unk 6.9 
Penel (160) 2008 Imatinib Phase II 10 6 7 58 0/0 0 unk 10.8 
Nathan (162) 2012 Imatinib Phase II 25 24 13 63 2/0 8 3 7.4 
Khan (176) 2012 Ipilimumab Retrospective 20 0 20 61 1/0 5 unk unk 
Danielli (182) 2012 Ipilimumab EAP 9 0 13 57 0/0 0 Unk 6 
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Author Year Drug Study design n 
First 
line 
Non-
first 
line 
Mean 
age 
PR/CR 
ORR 
(%) 
PFS OS 
Khattak (174) 2013 Ipilimumab EAP 5 0 5 42 0/0 0 unk 10.3 
Kelderman 
(132) 
2013 Ipilimumab EAP 22 0 22 54 1/0 4.5 2.9 5.2 
Maio (175) 2013 Ipilimumab EAP 82 0 82 62 4/0 5 3.6 6 
Zeldis (138) 2009 Lenalidomide Phase II 16 unk unk 53 0/0 0 unk unk 
Bedikian (140) 2008 Liposomal vincristine Pilot 4 unk unk 56 0/1 25 unk unk 
Ellerhorst 
(183) 
2002 Nitro-camptothecin Phase II 14 0 14 59 0/0 0 unk unk 
Kirkwood 
(158) 
2011 Selumetinib Phase II 7 20 0 57 0/0 0 unk unk 
Mahipal (171) 2012 Sunitinib Pilot 18 3 17 69 1/0 5 4.2 8.2 
Bedikian (136) 2003 Temozolomide Phase II 14 9 5 53 0/0 0 1.8 6.7 
Reiriz (137) 2004 Thalidomide Phase II 5 0 5 59 0/0 0 unk unk 
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Author Year Drug Study design n 
First 
line 
Non-
first 
line 
Mean 
age 
PR/CR 
ORR 
(%) 
PFS OS 
Solti (152) 2007 Thalidomide/INF-α2b Pilot 6 0 6 59 0/0 0 3.6 9 
Falchook (157) 2012 Trametinib Phase I 16 1 15 53 0/0 0 1.8 unk 
Schmittel 
(135) 
2006 
Gemcitabine/treosulfan Phase II, 
randomised 
24 15 9 63 0/1 4.2 3 unk 
Treosulfan 24 17 7 58 0/0 0 2 unk 
Sacco (134) 2013 
Dacarbazine Phase II, 
randomised 
37 37 0 unk 3/unk 8 3.9 8.7 
Sunitinib 37 37 0 unk 0/0 0 2.8 6.4 
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1.4. Proteomics 
 
Gene expression profiling/transcriptomic studies identify an intermediate 
carrier (mRNA) of the genetic information between the genome and proteome. 
However, genetic and transcriptomic studies alone are not sufficient to fully 
understand the molecular basis for the association between these cytogenetic 
alterations and aggressive phenotype, with several investigators reporting a poor 
correlation between mRNA and protein abundance (184,185). This is due to the 
fact that a single gene can encode for more than one mRNA species through 
differential splicing, and proteins can undergo as many as 200 post-translational 
modifications (186). The regulatory role of micro-RNAs in gene expression at the 
post-transcriptional level adds to the limitations of genetic studies (187). While 
genomics is significantly improving our understanding of the molecular basis of 
this disease, identifying targets suitable for treatment is difficult. Pharmacologic 
targeting of genetic mutations is complex and challenging. Direct inhibition of 
mutant GNAQ or GNA11 may prove difficult because these mutations abrogate 
the intrinsic GTPase activity that would normally allow these proteins to return 
to their GDP-bound, inactive state (26). Loss of BAP1 also poses a difficult 
therapeutic challenge, as it is seems to represent a classic loss of a tumour 
suppressor, and direct therapies would require the reinitiation of function (188). 
Proteomics delineates the functional units of a cell, proteins and their intricate 
interaction network and signalling pathways for the underlying disease (189). 
Proteomic studies have been successfully used to identify several protein 
alterations in tumour cells, leading to biomarker discoveries (190–193). Progress 
has been made in several areas of cancer research using proteomics technology, 
including breast (194), lung (195), oral (196), and colorectal cancers (197).  
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1.4.1. Current proteomic technologies and overview 
 
Proteomics seeks to study the total proteins expressed in any given 
system, whether by abundance, activity, structure, state of post-translational or 
other modification, or how these proteins interact with each other in networks 
or complexes (198). Proteomics workflow involves 2 stages: separation of the 
biological protein sample to increase visualisation and resolution (gel-based or 
gel-free) and identification of peptide fragments/proteins using mass 
spectrometry. These data are then analysed using bioanalytical softwares and 
databases to identify novel targets for further validatory studies. Proteomics 
techniques can be broadly divided into top-down or bottom-up strategies. Top-
down strategy analyses the proteome at the intact level, thereby retaining the 
biochemical properties and post-translational modifications of proteins. In 
contrast, bottom-up strategy involves enzymatic cleavage of complex protein 
samples, relying on modern chromatography and electrophoretic strategies to 
simplify the peptide fragment populations (199,200). Thus, bottom-up 
proteomics usually involves heavy use and reliance on high speed tandem mass 
spectrometry instruments and high throughput database searches to relate mass 
spectra to peptide sequences, then peptides to their parent protein (201). Figure 
8 illustrates the basic proteomic workflows using both gel-based (i.e. 2D gels) 
and gel-free/LC-MS based approaches. 
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Figure 8: Basic proteomic workflows using both gel-based (i.e. 2D gels) and gel-
free/LC-MS based approaches. 2DE=2-Dimensional Electrophoresis. 2D DIGE=2-
Dimensional Difference Gel Electrophoresis. SILAC= Stable Isotope Labeling 
by/with Amino acids in Cell culture. ICAT=Isotope-Coded Affinity Tag. 
iTRAQ=Isobaric Tag for Relative and Absolute Quantitation. MALDI=Matrix-
Assisted Laser Desorption/Ionization. TOF=Time-of-flight. ESI=Electrospray 
Ionization. SRM=Selected Reaction Monitoring. MRM=Multiple Reaction 
Monitoring. ELISA=Enzyme-Linked Immunosorbent Assay. WB=Western Blot. 
IHC=Immunohistochemistry  
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1.4.2. 2D PAGE and Mass Spectrometry 
 
Conventionally, proteomic profiling usually involves separating the 
complex biological protein mixture using two-dimensional gel electrophoresis (2-
DE) prior to their analysis and identification by the mass spectrometer. This 
process enables assessment of relative protein levels by comparing protein 
samples from two disease groups. Protein molecules are first separated in one 
direction based on its isoelectric point (pI), usually using immobilized pH gradient 
(IPG) strips.  The IPG strip is then loaded at the top of a second gel where 
proteins are separated in a second direction based on its mass (Da). For 
visualisation, the gel is stained using a number of different techniques, such as 
Colloidal Coomassie blue, zinc imidazol, and silver nitrate/diamine (Ag) stains for 
the visible range, and fluorescence staining, such as Spyro Ruby for the 
nonvisible range (202). The resultant gel is analysed using 2D gel analysis 
software which compares the stained protein spots’ patterns and detects protein 
changes, both qualitative (presence/absence) and quantitative (spot intensities). 
Protein spots of interest are then excised from the gel for identification using 
mass spectrometry (MS). 
 
To overcome the challenges of gel-to-gel variability, reproducibility and to 
increase reliability of protein quantification, two-dimensional difference gel 
electrophoresis (2D-DIGE) was developed (203). This method utilizes two (e.g. 
healthy and disease) samples that are differentially labelled with fluorescent 
dyes. Subsequently, the two samples are resolved simultaneously within the 
same gel and compared to a master gel of a pool of both samples. Using 
differential analysis software, statistically significant proteins spots that are 
differentially expressed can be determined and processed for mass 
spectrometry.  
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Advances in mass spectrometry technologies have increased the 
reliability, reproducibility and efficiency of proteomic studies. Ionisation 
techniques such as electrospray ionization (ESI) and matrix-assisted laser 
desorption/ionization (MALDI) are now the most commonly used methods 
(204,205) and are regarded as the key to success of MS in life science research 
(198). These soft ionization techniques are able to ionize large and polar 
molecules without physically destroying them. Since ESI utilises a liquid solvent, 
it can be coupled with liquid chromatography for additional sample separation. 
The evolution of combined quadrupole-time of flight (Q-TOF) mass analysers 
offer higher sensitivity, improved resolution and mass accuracy. More recently, 
mass analysers such as the quadrupole and Fourier transformation ion traps 
offer a superior mass resolution of >100,000 and mass accuracy of <1ppm (206). 
 
The strengths of MS are not only based on its ability to resolve ppm, but 
also its ability to perform tandem mass spectrometry. MS/MS fragment 
information is significantly more discriminating in terms of specificity and 
identification accuracy than MS alone (207). Once a peptide sequence is 
determined, it is fragmented to generate partial amino acid sequence for further 
MS (MS/MS). Tandem mass spectrometers contain two mass analysers (tandem 
in space) or perform the experiment sequentially inside the same mass analyser 
(tandem in time). There are many different methods that are employed for 
peptide fragmentation, such as collision induced dissociation (CID), surface 
induced dissociation (SID), electron capture dissociation (ECD) and electron 
transfer dissociation (ETD) amongst many others. The most commonly used 
fragmentation methods in proteomics are CID and ETD (208).  
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1.4.3. Gel –free Quantitative proteomics 
 
As biomarker discovery requires accurate measurements of quantitative 
difference between diseased and healthy biological analytes, quantitative 
proteomics has seen a rapid evolution in the last decade. Essentially, two 
methods are employed in quantitative proteomics; incorporation of metabolic or 
isobaric label or label-free analysis of MS/MS spectra. As the former implies, 
proteins/peptides from different analytes are labelled using various technologies 
such as metabolic labelling (e.g. SILAC) or chemical labelling (e.g. ICAT, iTRAQ, 
AQUA peptides, 18O2). Quantitation is then determined based on the mass 
increase provided by the labels and the relative signal intensities between the 
labelled and unlabelled analytes. 
 
1.4.3.1. Stable Isotope Labelling by Amino acids in Cell 
culture (SILAC)  
 
In cell line models, Stable Isotope Labelling by Amino acids in Cell culture 
(SILAC) is one of the most popular methods used in quantitative proteomics. 
Cells are cultured in growth media containing amino acids with isotopes such as 
15N or 13C, thus incorporating these heavy elements into the cell. Near complete 
incorporation of labels typically occurs after five to 10 doubling of cells grown in 
SILAC media (209). Proteins/peptides from the “heavy” and “light” cells are then 
distinguished by MS and quantified. Metabolic labelling is regarded as one the 
most accurate techniques as it reflects the immediate metabolic state of the cell 
(210). 
 
In contrast to metabolic labelling, chemical labelling relies on biochemical 
reactions to label protein/peptide samples. Technologies such as isotope-coded 
affinity tags (ICAT) modify cysteine residues in peptides and link them to a biotin 
tag that contains either a heavy or light isotopic variant. Two separate samples of 
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interest are tagged with the light and heavy isotopes, pooled (allowing 
comparison e.g. between healthy vs. disease samples) and digested. The labelled 
and unlabelled peptides are then isolated with the aid of the biotin tags using 
affinity chromatography, followed by quantification by MS.  
 
1.4.3.2. Isobaric Tag for Relative and Absolute 
Quantification (iTRAQ) 
 
Similar to ICAT, iTRAQ labelling also enables parallel identification and 
quantification. After labelling, samples are pooled and fractionated using LC.  For 
quantification, these technologies utilise the MS/MS information rather than MS 
alone. In a single MS mode, the same peptides with different labels are identical 
in mass. However, in MS/MS mode, where the peptides are fragmented, each 
tag generates a unique reporter ion. The reporter ions can be used to relatively 
quantify the peptides and the proteins from which they originated with simul-
taneous identification based on the associated sequence information (211). The 
tagging reagents are available in up to eight isotope-coded variants (8-plex), all 
with an identical molar mass (isobaric) allowing simultaneous profiling and 
comparison of up to 8 different samples in a single run.  
 
1.4.3.3. Absolute QUAntification of proteins (AQUA) 
 
Another method, known as synthetic spiking or absolute quantification of 
proteins or AQUA (212), involves introducing a synthetic standard peptide of 
known concentration to analytes. Quantitation is performed by comparing the 
mass shift produced by the standard peptides and sample peptides. These 
peptides can also be synthesized with covalent attachments to mimic protein 
post-translational modifications such as phosphorylation, methylation, and 
acetylation (206). However, AQUA is not usually suitable for global discovery 
proteomics due to the complexity and high cost associated with producing large 
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numbers of synthetic peptides (213). To address these limitations, a de novo 
gene design (QconCAT) was developed using Escherichia coli, in which artificial 
“signature peptides” are expressed at a much reduced cost. As signature 
peptides are introduced early in the workflow, potential bias is reduced, and 
accuracy and sample coverage is increased. Despite these, the narrow detection 
range of mass spectrometers causes difficulties in determining the amount of 
standard peptides to be used without overshooting the detection range. 
 
1.4.3.4. 18O labelling 
 
An inexpensive and relatively simple method of isotopic quantitation is by 
18O labelling. During or following protein digestion, the C-termini of peptides are 
labelled with two 18O isotopes. The resulting mass shift between “heavy’ and 
“light’ proteins can be used for identification, characterization and quantitation 
(214). Since 18O labels are stable at low pH but can be lost at high pH values, this 
type of label is suitable for the mild acidic conditions typically utilized for ESI- and 
MALDI-MS (206). However, good levels of incorporation are usually difficult to 
achieve, complicating interpretation and quantification (215). Furthermore, this 
method limits throughput as it only allows for simultaneous comparison of 2 
analytes. 
 
1.4.4. Quantitative Label-free proteomics 
 
Despite the strengths of chemical and metabolic labelling technologies, 
achieving complete proteome coverage is difficult and challenging. In contrast to 
labelling technologies, label-free proteomics utilises the technological 
advancements made in both mass spectrometry and bioinformatics capabilities. 
Without artificially labelling analytes, sample handling and potential 
contaminants are reduced. Thus, sample bias are minimised and throughput is 
significantly increased. The basic principle of this technology is based on direct 
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comparison of MS signal intensities between different analytes. However, it is 
more sensitive to technical deviations between LC/MS runs as information is 
compared between different measurements (216). Significant advances in liquid 
chromatography, mass spectrometry and bioinformatic software algorithms have 
increased the reliability, reproducibility and accuracy of label-free proteomics.  
 
Samples containing the digested peptide complex are separated on a 
liquid chromatography column. After elution from the column, analytes are 
continuously injected into the mass spectrometer. Stacking individual MS runs 
yields a multidimensional dataset or map, from which quantification can be 
determined. The bioinformatic analysis of label-free data consists of two main 
steps; raw MS data signal processing, and quantification. Signal processing steps 
comprise data reduction procedures such as removal of baseline signal, noise, 
and centroiding. The raw MS data are processed in order to eliminate baseline 
signals and high-frequency noise attributed to the detector, solvents, buffers and 
contaminants. MS data that have been adjusted for baseline and noise signals 
are then subjected to centroiding and charge estimation. For most MS data, the 
intensity of a centroided peak is determined using the peak volume, which 
corresponds directly to the ion count while for high-resolution spectra, the 
height of the peak is used. To interpret the MS data for quantification, two 
different techniques are employed; spectral counting and peptide ion intensity 
counting. The intensity-based measures avoid stochastic effects in ion sampling 
and are therefore slightly more accurate, and they potentially provide higher 
reproducibility while spectral counting is easy to implement and fast (216). 
Figure 9 illustrates the principles of quantitative label-free proteomic methods. 
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Figure 9: Quantification methods employed in label-free proteomics. The sample 
cohort that can be analysed via label-free proteomics is not limited in size. Each 
sample is processed separately through the sample preparation and data 
acquisition pipeline. For data analysis, the data from the different LC-MS runs are 
combined. Adopted from Nahnsen et al (216) 
 
Spectral counting depends on high-throughput data acquisition for both 
identification and quantitation. The simple rational is that the more of a protein 
there is in a sample, the higher the number of tandem mass spectra the mass 
spectrometer will acquire for this protein (206). The number of mass spectra for 
a specific protein is determined and quantitation is derived by comparing it to 
the protein’s abundance. MS runs from multiple analytes can be compared to 
determine relative abundance and differential quantification of proteins. As this 
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method relies on simple counting of acquired spectra rather than measuring 
physical data, the spectral counting method is controversial (217). Furthermore, 
as the peak is being sampled more than once, the identification dynamic range is 
limited, and low-level ions may be missed in preference to the higher intensity 
ions, limiting the application of spectral counting to moderately to highly 
abundant proteins, or to proteins whose abundance varies significantly between 
the samples (218) However, it has been further developed and is widely used 
(219). Modified spectral counting that take into account aspects influencing the 
number of spectral counts, like physicochemical properties of peptides as well as 
the lengths of the corresponding proteins, may be employed (220). These 
approaches are known as absolute protein expression (APEX) (221) and 
normalised spectral abundance factor (NSAF) (222,223). More recently, 
normalised spectral index (SIN) which combines peptide count, spectral count 
and fragmentation intensity was shown to eliminate variances between replicate 
measurements, increase reproducibility and reliable quantification (224). 
Spectral counting approaches are also strongly influenced by the acquisition 
methods, in particular those which are normally optimized to limit the number of 
MS/MS events for an individual peptide, such as the dynamic exclusion 
parameters and the exclusion width (218). Spectral total ion chromatogram (TIC) 
generates more tryptic peptide and takes the average of the total ion count for a 
protein for quantification, thereby eliminating bias towards larger and more 
abundant proteins (225). It also expands the dynamic range of quantification 
compared to basic spectral counting methods (225).  
 
In peptide ion intensity counting, individual analytes are subjected to LC-
MS. Central to this are bioanalytical softwares that process complex raw LC-MS 
data for quantification. This includes signal processing (discussed above), feature 
detection, alignment of retention times, normalisation of MS intensities, peak 
picking and quantification. Advances in high-resolution mass spectrometers have 
made signal processing and peak picking simpler than lower resolution 
instruments (216). Peptides are eluted over time from the LC column, ionised 
and are injected into the mass spectrometer. Measurements are taken in 
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regular, short intervals thereby sampling the amount of the eluting ion over 
time, resulting in an elution profile. Each peptide of a particular charge and mass 
generates a mono-isotopic mass peak based on its atomic composition. Extracted 
across a time domain, the intensity of the peak is visualised in an extracted ion 
chromatogram (XIC), which is used to integrate the LC elution peak of the 
compound of interest. The area under the curve (AUC) of extracted peptide ions 
intensities at a specific retention time in an LC-MS run is correlated linearly with 
the protein abundance, which makes their measurement feasible for 
quantification (226,227). Under well-standardised LC-MS conditions, the AUC of 
features of interest can compared with those of other analytes to produce 
relative quantification. To achieve this, the map of peptide ion features from 
individual LC-MS runs are aligned using software algorithms. This is done based 
on the assumption that the chromatographic elution time of a peptide, as well as 
its ionisation behaviour, stays relatively constant between measurements and 
that the measured mass-to-charge ratio does not differ (216). Whereas the 
differences in the mass-to-charge ratio are rather marginal, the shifts in 
retention time can become very large and frequently show some nonlinearity 
(216). Once aligned, systematic biases in the measured intensities are adjusted 
(intensity normalisation) to account for variability in intensity signals from errors 
in experimentation, sample preparation, chromatography and mass 
spectrometry (228). Accurate map alignment is important for quantification 
using peptide ion intensity counting, while in spectral counting the identification 
of the peptide can be used to assign corresponding quantities across maps. 
Recent and continued improvements made in bioinformatic softwares and 
algorithms have enabled accurate and reproducible map alignments and 
intensity normalisation across multiple LC-MS runs, and has improved the ability 
to process peptides shared amongst proteins and minimise false discovery rates 
(229–231). Peptide ion intensity counting also relies on obtaining a highly 
reproducible LC profile to maximise mass resolution, accuracy and proteome 
coverage (198). The LC retention time in has to be managed closely, either by the 
incorporation of retention time markers or using software algorithms to realign 
and optimise the chromatographic profiles of peptides (206). Improvements 
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made in LC systems, such as the nanoflow-LC reduces misalignment and ensures 
good reproducibility in elution.  
 
1.4.5. Selected Reaction Monitoring (SRM)/Multiple 
Reaction Monitoring (MRM) 
 
 Once an interesting protein biomarker has been identified, several 
methods may be employed for validation. Typically, antibody-based techniques 
are utilised such as ELISA. However, these methods are costly and usually take a 
long time to be developed and optimised. As an alternative, targeted proteomic 
technologies have been developed (selected reaction monitoring, SRM and 
multiple reaction monitoring, MRM).  These MS-based technologies are highly 
sensitive, specific and high throughput, making it attractive in many systems 
biological applications that require the repeated measurement of a predefined 
set of proteins (232). In the SRM/MRM technique, a triple quadrupole mass 
spectrometer is used to assay the presence target peptides by focusing the first 
quadrupole on one particular peptide of interest followed by fragmentation of 
this peptide inside the second quadrupole and collection of one (SRM) or a few 
(MRM) particular fragment ions in the third quadrupole (206). As specific 
proteins of interest are preselected for analysis, only ions of interest are 
monitored and recorded. By rejecting all other ions entering the mass 
spectrometer, this mode of operation translates into an increased sensitivity by 
one or two orders of magnitude compared with conventional “full MS-scan” 
techniques (233). This also allows the detection of low-abundance in high 
complex mixtures (234,235). The sensitivity of MRM is also considerably 
increased when used in combination with stable isotope standards and capture 
by antipeptide antibodies (SISCAPA), a method for enriching target peptides 
using antipeptide antibodies (236). 
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1.5. Proteomics in uveal melanoma 
A number of proteomic studies have been carried out to date, investigating 
the biology of the metastatic phenotype of uveal melanoma. A summary of these 
studies is outlined in Table 2. The majority of these studies have used cultured 
cell line models (237–242). More recently proteomic studies on tissue from uveal 
melanoma patients has been carried out; one study compared the proteome of 
monosomy 3 to disomy 3 tumours (243) while a second study from our group 
compared primary tumours from patients who developed metastatic disease 
compared to primary tissue from patients who did not develop metastatic 
disease (244). 
 
Table 2: Summary of proteomic studies in uveal melanoma 
Studies Study type Principal findings 
Pardo et al., 
2005 (239) 
Global proteome of UM 
cell line 
683 proteins, 96% of which were novel 
in UM 
Pardo et al., 
2006 (238) 
Differential proteomics 
of UM cell lines  
Upregulation of DJ-1, HMG-1 and 
MUC18 in aggressive UM 
Pardo et al., 
2007 (237) 
Global secretome of 5 
UM cell lines 
Cathepsin D, gp100 and syntenin-1 
Zuidervaart et 
al., 2006 (242) 
Differential proteomics 
of UM cell lines derived 
from primary and 
metastatic tumours 
Upregulation of HSP-27, αB-crystallin 
and cofilin in metastatic cell line 
Coupland et al., 
2010 (243) 
Differential proteomics 
of primary tissues  
Downregulation of HSP-27 in 
monosomy 3 UM tumours 
Linge et al., 
2012 (244) 
Differential proteomics 
of primary tissues  
Upregulation of FABP3 and TPI1 in 
aggressive primary UM tumours 
Wang et al., 
2013 (240) 
Differential proteomics 
of irradiated UM cell line  
Downregulation of S100A11, PHB1, 
PHB2,TPI1 and upregulation of HSP-27 
in irradiated cells.  
Yan et al., 2013 
(241) 
Differential proteomics 
of irradiated UM cell line 
Downregulation of PKFM and 
upregulation LDHB in irradiated cells.  
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1.5.1. Cell line studies 
 
In 2005, Pardo et al (239) published the first proteomic study in uveal 
melanoma. They analysed the global proteome of a primary UM cell culture 
(UM-A). Ninety-six percent of the proteins have never been reported in UM 
before. Sixty-nine proteins (18%) identified have been previously described as 
cancer related. The majority were involved in invasion and metastasis (33%), 
such as melanoma-associated antigen MUC 18. It has been implicated in 
facilitating melanoma cells to interact with cellular elements of the vascular 
system, enhancing haematogenous spread. Albelda et al suggested that it may 
play a major role in metastasis by not only mediating melanoma cell-cell 
interactions, but also melanoma-endothelial cell adhesion (245). Other proteins 
were involved in drug resistance (10%), cell division and proliferation (14%) and 
oncogenes (6%). Eleven percent (11%) of the proteins were heat shock proteins 
(HSPs) and chaperones (11%). HSPs will be discussed in tissue studies, where it 
was identified in a differential proteomic tissue study by Coupland et al (243). 
 
In a follow-up study (238), differential proteomic analysis of UM primary 
cell culture (UM-A < 7) and the resulting cell line (UM-A > 7) was analysed. UM-A 
< 7 showed a low degree of metastatic potential compared to cell lines derived 
after passage 7 (UM-A > 7).  New nuclear proteins were identified in UM-A > 7, 
such BRCA-1, proteins associated with myc, and gene expression regulating 
protein HMG-1. The latter has been reported to play a role in the transcription of 
many genes involved at different steps in the metastatic cascade and has been 
linked with cancer in human and animal models (246). Other proteins that were 
only present in UM-A > 7 cell lines include HSP60β and cell adhesion protein 
MUC18. The expression of HMG-1 and MUC18 were determined in UM-A and 
other UM cell cultures (UW-1, SP6.5, OCM-1, 92.1 and normal melanocytes). 
HMG-1 was found to be higher in the invasive UM-A cell line (UM-A > 7) than in 
primary culture (UM-A < 7). It was also overexpressed in all other cell lines 
assayed. However, a clear correlation between HMG-1 expression and invasion 
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potential was not found.  As for MUC18, low levels were identified in UM-A < 7, 
UM-1 and 92.1. It was overexpressed in UM-A > 7, OCM-1 and SP6.5 while in 
normal melanocytes, it was absent. There was a positive correlation between 
MUC18 expression in UM cultures and invasion potential. However, no 
significant correlation was found in one cell line (92.1), suggesting that more 
than one molecular event may govern invasion (238). 
 
The authors also studied DJ-1, a novel oncogene identified in the first 
proteomic study. It was expressed in all cell lines and found in the culture media. 
As expected, it was absent in normal melanocyte cell line or culture media. 
Malignant cells have been described to secrete DJ-1 and it plays a role in 
tumourigenesis in breast cancer, non-small cell lung carcinoma and prostate 
cancer (247,248). Kim et al identified DJ-1 as a negative regulator of the tumour 
suppressor PTEN, promoting cell survival in primary breast and lung cancer 
patients (249). A recent study suggested serum DJ-1 level as a potential 
biomarker for the diagnosis and prognosis prediction of patients with pancreatic 
cancer (250). Recently, it was shown that elevated DJ-1 was found to be 
significantly associated with risk factors for malignant transformation of 
choroidal naevus, namely nevus thickness greater than 1.5 mm, diameter larger 
than 8 mm, and presence of acoustic hollowness on ultrasonography (251). This 
interesting finding, coupled with the identification of DJ-1 in UM tissue by our 
group (244) warrants further investigation into the potential role serum DJ-1 may 
play in tumourigenesis and monitoring of patients at risk for malignancy. 
 
In a subsequent study (237), media containing proteins secreted from the 
UM cell lines (UM-A, UW-1, OCM-1, SP5.6, and 92.1) during the incubation 
period were subjected to 2-DE proteomic analysis. Twenty-three secreted 
proteins were common in all 5 cell lines' media. These included cathepsin D, 
melanocyte protein Pmel (gp100) and mda-9/syntenin 1, amongst many others. 
Correlation between cathepsin D tissue concentration and tumour 
aggressiveness has been found in lung cancer and cutaneous melanoma 
(252,253). Gp 100  is normally expressed at low levels in quiescent adult 
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melanocytes but overexpressed by proliferating neonatal melanocytes and 
during tumour growth (237). Gp 100 expression in uveal melanoma has been 
identified in numerous studies (254–257). Proteomic analysis of 11 UM patients' 
serum (without metastasis) and 8 healthy subjects' serum found higher levels of 
cathepsin D and gp100 in UM patients’ serum compared to those of healthy 
subjects.  Mda-9/syntenin 1 was not detected in either group of serum samples. 
However, the authors did not determine the expression of this protein in serum 
of patients that developed metastatic disease, given the role it plays in the 
development of metastasis.  
 
Several studies demonstrate the role of mda-9/syntenin in promoting 
metastasis in both uveal (258) and cutaneous melanoma (259,260). High 
expression of mda-9/syntenin 1 has been found in advanced metastatic 
cutaneous melanoma compared to benign naevi and primary cutaneous 
melanoma (261). Mda-9/syntenin, through interaction with c-Src/FAK, activates 
the p38 MAPK/NFkB pathway with subsequent induction of genes involved in 
migration and invasion (262). The Raf kinase inhibitor RKIP was shown to inhibit 
mda-9/syntenin-mediated metastasis in cutaneous melanoma, by inhibiting cell 
invasion, anchorage-independent growth and in-vivo dissemination of tumour 
cells (263). In UM, high levels of syntenin protein expression in primary tumour 
was found to be significantly associated with earlier metastatic progression and 
correlated with metastatic risk as strongly as monosomy 3. Furthermore, UM 
liver metastases also showed higher syntenin expression compared to primary 
tumours (258). The authors also demonstrated that inhibition of syntenin 
expression reduces the activation of FAK, Src and AKT. Src has been shown to be 
an upstream tyrosine kinase for ERK1/2 activation in primary UM (264). Similarly, 
MAPK pathway has been implicated in uveal melanoma (33,34,154).Dasatinib, a 
Src family kinase inhibitor, was recently shown to inhibit MAPK and induce 
growth arrest in monosomy 3 UM cell cultures (265). Taken together, mda-
9/syntenin may be critical in metastatic formation and dissemination in UM, and 
warrants further investigation as a therapeutic agent in this disease. 
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Zuidervaart et al (242) found 24 differentially expressed proteins 
between primary and metastatic uveal melanoma in three cell lines. One cell line 
was derived from primary uveal melanoma (Mel 270) and two were derived from 
liver metastases from the same primary tumour (Omm 1.3 and Omm 1.5). By 
studying cell lines derived from the same patient, they hypothesized that 
differential protein expression between the three cell lines may identify proteins 
related to tumour progression and metastatic growth. Of those that are 
upregulated in metastatic cell lines, HSP-27 and αB-crystallin are proteins that 
are fundamentally involved in cellular defence against various stimuli and stress. 
HSP-27 was also identified by (243) in primary UM tissue, with high HSP-27 
indicating a favourable prognosis. This supports the different roles HSP-27 may 
play in primary and metastatic tumours (discussed in Tissue studies, section 1.5.2 
below). Another protein, phosphorylated inactive cofilin was also upregulated in 
metastatic cell lines.  PAK1, a cofilin-inactivating enzyme that leads to stimulation 
of cell spreading activities (266), has been associated with an increased invasive 
potential in uveal melanoma (267). Promotion of cell motility and stabilization of 
cell shape may be enhanced during acquisition of the metastatic phenotype by 
phosphorylation of cofilin and could therefore be of great importance for the 
metastatic potential of uveal melanoma cells (242). Another proteomic study 
supports this finding, indicating that phosphorylation of cofilin, together with 
HSP-27, is altered in response to angiogenesis inhibitors, affecting the 
endothelial cell cytoskeleton to prevent endothelial migration (268). 
 
More recently, Wang et al (240) studied 92.1 UM cell line 15 and 48 hours 
post X-ray radiation to identify proteins associated with cell cycle arrest. At 15 
hours post radiation, 290 proteins were found to be down-regulated by more 
than two-fold, while 86 were up-regulated by more than two-fold. At 48 hours 
post radiation, 97 were down-regulated while 78 were up-regulated by more 
than two-fold. Proteins that were downregulated in both groups were 
predominantly associated with cell death and apoptosis, suggesting an important 
role in cell cycle suspension. Of these, S100A11 belongs to the S100 protein 
family and is involved in regulation of cell cycle progression and differentiation. It 
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has also been shown to be overexpressed in many other types of cancers, such 
as prostate (269), bladder (270), colorectal (271) and breast cancer (272), 
Elevated serum S100β was shown to predict the development of hepatic 
metastasis in UM, suggesting its potential use in monitoring patients at risk for 
metastasis (273,274). Prohibitins PHB1 and PHB2 are mitochondrial proteins that 
have a wide range of cellular functions including cell death and senescence (275). 
They have also been shown to play an important role in cancer cell proliferation, 
propagation, adhesion and survival (276). High expression of PHB1 was found in 
other types of malignancies such as lung (277), breast (278), prostate (279) and 
gastric cancer (280,281). In a previous study by the same group, 92.1 cells were 
found to exhibit senescence-like phenotype when cell cycle suspension was 
induced after 3 days of X-ray irradiation (282). Since significantly lower levels of 
PHB1 and PHB2 were found by Wang et al, this strongly suggests that irradiation-
induced decrease in expression of these proteins may play a role in cell cycle 
suspension, and subsequently senescence of 92.1 cells. Interestingly, this study 
also identified TPI1 and HSP-27, both of which were identified by recent UM 
tissue studies by Linge et al and Coupland et al respectively.  
 
Similarly, Yan et al (241) analysed the proteome of 92.1 UM cell line 15 
hours post irradiation. Lactate dehydrogenase B (LDHB) showed the highest fold-
change in irradiated cells. In contrast to Wang et al, the authors validated their 
findings by immunoblotting. LDHB is involved in glycolysis and is also released in 
response to tissue injury, necrosis or apoptosis (283). Elevated serum levels were 
found to correlate with the clinical stage of non-small cell lung cancer (284). 
LDHB promoter hypermethylation occurred at a higher frequency in prostate 
cancer compared to benign prostate tissues, leading to loss of LDHB expression 
in cancer tissues. Similarly, LDHB expression was higher in normal prostate 
tissues compared to prostate cancer, and was absent in secondary metastatic 
tissues (285). This supports the high expression of LDHB found in irradiated 92.1 
cell line, suggesting that an increase in LDHB level may be related to a halt in 
growth and progression of UM. PFKM (phosphofructokinase, muscle) is also a 
glycolytic enzyme, but was found to be downregulated in irradiated 92.1 cells. 
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Tumour cells demonstrate high metabolic rate to support rapid growth and 
turnover rate. In a metabolomics study, significantly elevated activating 
phosphorylation levels of phosphofructokinase and pyruvate kinase in lung 
tumours confirmed hyperactive glycolysis (286). Activation of PFKM is regulated 
by the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase (PFKFB), which in turn is regulated by protein kinases such as 
AKT and MAPK (287). It has been shown that the MEK/MAPK and PI3K/AKT 
pathways are highly activated in UM (33,34,154,155). In an on-going phase II 
study, the MEK inhibitor selumetinib extended progression-free survival by 
nearly 9 weeks and reduced tumour size by 50% in patients with UM (288). 
Taken together, this downregulation of PFKM may reflect a shift in the energy 
demand of tumour cells post radiation, possibly via the inhibition of MAPK and 
AKT pathways. The proteins identified by (240) and (241) in irradiated UM cells 
warrants further investigation in order to understand the molecular 
characteristics of UM cells that undergo cell-cycle suspension. Identification of 
other interacting proteins and therapeutic targets may provide novel, medical 
treatment strategies for primary UM thereby reducing the need for radiation 
therapy and its associated side-effects to surrounding ocular structures. 
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1.5.2. Tissue studies 
 
Coupland et al (243) performed proteomic analysis of primary uveal 
melanoma tissue, the first study to do so. They determined differential protein 
expression between four monosomy 3 and three disomy 3 tumours using 2-DE 
analysis. Differentially expressed proteins of statistical significance were HSP-27 
and vimentin. HSP-27 was downregulated in monosomy 3 tumours while the 
latter was upregulated. The expression of these two proteins were examined in 
41 formalin-fixed paraffin-embedded tissue slides by immunohistochemistry. 
Twenty of these were monosomy 3 tumours, while 21 were disomy 3. Expression 
of HSP-27 was found to be significantly lower in monosomy 3 uveal melanoma 
when compared with disomy 3 tumours. No statistical significance was found in 
the expression of vimentin.  
 
A follow-up study (289) analysed the immunohistochemical expression of 
HSP-27 on 99 formalin-fixed paraffin embedded tumour samples. The possibility 
of using HSP-27 expression score to predict monosomy 3 was also assessed. 
Samples were selected based on their chromosome 3 status; 49 disomy 3 and 50 
monosomy 3 tumours were analysed. Monosomy 3 tumours were found to have 
a significantly lower HSP-27 expression compared to disomy 3 tumours, 
demonstrating a significant negative correlation between reduced HSP-27 
expression and a predicted survival of < 8 years. However, HSP-27 score alone 
did not predict monosomy 3 with high-enough specificity. When using a model 
incorporating other clinicopathological factors such as largest tumour diameter, 
presence of closed extravascular loops and cell type, monosomy 3 was predicted 
with greater accuracy (sensitivity 78% and specificity 72%).  
 
HSP-27 is a cytoplasmic protein involved in the inhibition of cell 
proteolysis and protein conformation stabilisation (290,291). It is overexpressed 
in a variety of cancer cells and is associated with a poor prognosis in gastric, 
prostate, and node-negative breast carcinoma (292–294). In contrast, high levels 
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of HSP-27 expression indicate a good prognosis in non–small-cell lung 
carcinomas and ovarian carcinomas (295,296). This suggests that HSP-27 may 
play different roles in different tissues or that there are other elements present 
in some malignancies that can override or bypass any effects HSP-27 may have 
(297). Of interest, HSP-27 overexpression has been shown to inhibit cell 
proliferation and reduce cell invasiveness in one human cutaneous melanoma 
cell line (298). From this, it was postulated that underexpression of HSP-27 in 
melanoma cells results in increased tumour cell motility and invasiveness.  
 
More recently, our group (244) performed 2D-DIGE proteomic analysis 
comparing 9 primary UM tumour samples from patients who developed 
metastatic disease versus 16 primary UM tumour samples from patients who did 
not develop metastatic disease, with a minimum of 7 years follow-up. Nine 
proteins were upregulated in primary UM tissue that developed metastasis. 
These were disulphide-isomerase A3 precursor (PDIA3), selenium-binding 
protein 1 (SELENBP1), alpha-enolase, F-actin capping protein subunit alpha-1 
(CAPZA1), endoplasmic reticulum protein ERp29 precursor, triosephosphate 
isomerase (TPI1), protein DJ-1 (PARK7), and fatty acid-binding protein, heart-type 
(FABP3). The 5 proteins that showed decreased expression in primary UM tissue 
that developed metastasis were eukaryotic translation initiation factor 2 subunit 
1, proteasome subunit alpha type 3, 40S ribosomal protein SA, tubulin beta chain 
and tubulin alpha-1B chain. Follow-up immunohistochemical study was 
performed to determine the expression of FABP3, TPI1, CAPZA1, PDIA3, 
SELENBP1 and PARK7 on 8 formalin-fixed paraffin-embedded (FFPE) primary UM 
tissue from patients who developed metastasis and 8 FFPE primary UM tissue 
from patients who did not develop metastasis. Of these, increased expression 
levels of FABP3 and TPI1 correlated with the 2D DIGE results. Further validation 
by siRNA knockdown of these 2 proteins in one primary UM cell line (92.1) 
showed significant reduction in invasion and migration. 
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FABPs are expressed in a variety of tissues, playing role in fatty acid 
metabolism (299) and are suggested to be involved in a number of biological 
processes such as cell differentiation, cell growth, and apoptosis (300). One 
proteomics study showed a heterogeneous but unique FABP expression pattern 
in the different subtypes of renal cell carcinoma, suggesting its use for 
classification of this disease (299). Expression of FABP was significantly high in an 
aggressive small cell lung cancer cell line, suggesting that it may influence mitosis 
and cell growth (301). Another proteomic study identified FABP as a biomarker 
to predict gefininib treatment response in patients with lung adenocarcinoma 
(302). FABP was also shown to be expressed in human gastric carcinoma, and 
was associated with disease progression, tumour aggressiveness and poor 
patient survival (303). In contrast, ectopic expression of FABP3 in breast cancer 
cells was shown to reduce tumourigenicity in nude mice (304). This suggests a 
complex relationship between FABP and cancer. TPI1 is an enzyme that's critical 
in glycolysis and gluconeogenesis (305) and a high rate of glycolysis is required to 
support tumour growth (306). Functional inactivation of TPI induced apoptosis in 
cervical cancer cells (307). It has also been shown to be involved in the 
aggressiveness of breast cancer (308). Other proteomic studies found it to be 
significantly increased in lung cancer tissue (309), cell lines and patients' plasma 
(310), and in prostate cancer (311), suggesting its use as a serum biomarker. 
Interestingly, TPI1 was also shown to be expressed in uveal melanoma primary 
cell cultures by Pardo et al in the first proteomic study in UM. 
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1.6. Deficiencies in current knowledge of the 
molecular biology of metastatic disease 
 
Progress made in molecular genetics has led to significant improvement in 
prognostic stratification of patients into high-risk and low-risk for developing 
metastatic disease. This has enabled closer surveillance of patients at-risk for 
metastasis, and earlier detection and treatment of metastatic disease. It has also 
increased the understanding of the triggering events that lead to the 
development of UM. However, very little is known about the molecular biology 
of the development of metastasis, and pathways involved in this fatal disease. 
Proteomic studies of malignancies have yielded information about tumour 
biology and led to the discovery of many biomarkers. However, this technique 
has not been used to study UM as extensively as other cancers. While numerous 
genomic studies have led to the identification of novel genes involved in the 
developmental biology and prognostic classification of patients, there is a distinct 
lack of effective therapeutic targets for these patients. Although only a few 
proteomic studies have been carried out so far, the results are very encouraging. 
Many of these proteins have not been described in the biology of UM before. 
Novel proteins involved in cell growth, proliferation, adhesion and metastasis 
have been identified. Most studies have been performed using cell lines, with 
only 2 studies using primary UM tissue. These studies were predominantly 
performed using the older 2-DE method. However, recent advances in proteomic 
technologies provide the opportunity for high-throughput quantitative studies to 
be performed using various biological material such as the primary tumour and 
metastatic tissue, vitreous, and serum. This would be an important step towards 
the identification of effective biomarkers and therapeutic targets for 
personalised medicine in uveal melanoma. 
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1.7. Objectives 
 
To identify differentially expressed proteins and genes between primary UM 
tissue from patients who developed metastatic disease, versus primary UM 
tissue from patients who did not develop metastasis. 
 
This will be achieved as follows; 
 
1. Quantitative Label-free LC-MS proteomic profiling to identify 
differentially expressed proteins between primary UM tissue from 
patients who developed metastatic disease, versus primary UM tissue 
from patients who did not develop metastasis 
 
2. Bioinformatic reanalysis of publically available gene expression 
microarray datasets of monosomy 3 tumours that developed metastatic 
disease versus disomy 3 tumours that did not develop metastatic disease 
 
3. Immunohistochemical validation of targets of interest from objective 1 
and 2 using formalin-fixed paraffin-embedded tissues and tissue 
microarrays of primary uveal melanoma tissue from patients who did and 
did not develop metastatic disease 
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2. Materials and methods 
2.1. Uveal melanoma tissue label-free LC-MS 
2.1.1. Sample collection, consent and ethics 
 
Sixteen fresh frozen primary UM tissue specimens from patients with a 
minimum clinical follow-up of 7 years were used for label-free proteomic 
analysis. Of these, 8 patients subsequently developed metastasis while 8 patients 
did not. Tissue specimens were accessioned from the National Ophthalmic 
Laboratory, Royal Victoria Eye and Ear Hospital, Dublin.  Fresh uveal melanoma 
samples were obtained from patients who had enucleation and stored at -80°C. 
Samples were also formalin-fixed and paraffin-embedded and cut in 4-µm 
sections for morphological assessment by immunohistochemistry. Cytogenetic 
analysis of chromosome 3 status was performed using fluorescent in situ 
hybridisation (FISH) by the Merseyside and Cheshire Genetics Laboratory, Crown 
St., Liverpool, UK. A number of the patients have since died as samples were 
collected between 1994 and 2003.  As per the recommended guidelines of the 
Irish Council for Bioethics: “Human Biological Material: Recommendations for the 
collection, use and storage in research 2005”- chapter 3, pg 52, there is a waiver 
to consent (312). Ethical approval was obtained from the Research and Ethics 
Committee of the Royal Victoria Eye and Ear Hospital, Dublin (Title: Proteomic 
analysis of tissue samples from uveal melanoma patients; expiry date: 25 July 
2014; reference number: 250711SK; principal investigator: Professor Susan 
Kennedy). 
 
Prospectively, matched clinical samples were collected after obtaining 
informed consent from patients. These include the enucleated eye, vitreous fluid 
and patient serum for future biomarker studies. The project was funded by the 
Royal Victoria Eye and Ear Research Foundation. The research adhered to tenets 
of the Declaration of Helsinki.  
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2.1.2.  Sample preparation and mass spectrometry 
 
Fresh frozen uveal melanoma tissue specimens were removed from -80°C 
and allowed to thaw at room temperature. To homogenise the tissue sample, a 
small piece of tumour was added to Sample Grinding Kit (GE Healthcare, Little 
Chalfont, Buckinghamshire, UK) with 300 µL of 2D lysis buffer containing 7 M 
urea, 2 M thiourea, 4% (wt/vol) CHAPS, 40 mM dithiothreitol (DTT), and 0.5% 
immobilized pH gradient (IPG) buffer pH 3 to 11 (GE Healthcare) as per the 
manufacturer’s recommendation. The sample was grinded with the grinding kit 
pestle for approximately 3 minutes at room temperature. Insoluble material was 
removed by centrifugation at 14,000 rpm for 5 minutes at room temperature, 
and supernatants were stored at -80°C until required. This sample prep was 
carried out by Dr Annett Linge and Deirdre O’Flynn. The samples used for this 
label-free proteomic analysis were a subset of samples that were used in a 
previous 2D-DIGE proteomic study (244) 
 
For label-free proteomic analysis, stored samples were removed from -
80°C  and allowed to thaw at room temperature. To remove interefering 
detergents from the 2D lysis buffer in order to make the samples compatible for 
use by LC-MS, sample clean-up was performed using ReadyPrep 2D-clean-up kit 
as per manufacturer’s instructions (Bio-Rad, Hemel-Hempstead, Hertfordshire, 
UK). 300 µL of precipitating agent 1 was added to 100 µg of protein sample in 
100 µL and mixed well by vortexing. After incubating on ice for 15 minutes, 300 
µL of precipitating agent 2 was added and mixed. The sample was centrifuged at 
14,000 rpm for 5 minutes and the supernatant discarded. 40 µL of wash reagent 
1 was added on top of the protein pellet and centrifuged at 14,000 rpm for 5 
minutes. The supernatant was removed and 25 µL of ultrapure water was added 
to the pellet and mixed. 1 mL of wash reagent 2 (prechilled at -20°C for 1 hour) 
and 5 µL of wash 2 additive was added. The sample was mixed by vortexing for 1 
minute. The mixture was incubated at -20°C for 30 minutes. During this 
incubation period, the sample was mixed by vortexing for 30 seconds every 10 
92 
 
minutes. Samples were centrifuged at 14,000 rpm for 5 minutes and the 
supernatant discarded. The resultant white pellet was air-dried at room 
temperature until translucent but for no more than 5 minutes. Protein pellets 
were resuspended in label-free solubilisation buffer, consisting of 6 M urea, 2 M 
thiourea and 10 mM Tris, pH 8.0 in LC-MS grade water. Protein suspensions were 
vortexed, sonicated and centrifuged to ensure pellets were fully resuspended. 
Protein concentrations were determined using the thiourea-compatible Quick 
Start Bradford Protein Assay Kit (Bio-Rad Laboratories Inc., Hercules, CA). For 
label-free MS analysis, volumes were kept to a minimum and initially equalized 
using label-free solubilisation buffer. Samples were reduced for 30 min with 10 
mM DTT and alkylated for 20 minutes in the dark with 25 mM iodoacetamide in 
50 mM ammonium bicarbonate. Initial proteolytic digestion was carried out with 
sequencing grade Lys-C at a ratio of 1:100 (protease/protein) for 4 h at 37ºC. The 
samples were subsequently diluted with 4 times the initial sample volume in 50 
mM ammonium bicarbonate. A second digestion step was performed with 
sequencing grade trypsin at a ratio of 1:25 (protease/protein) overnight at 37oC. 
Trifluoroacetic acid was added to a final concentration of 0.5% and incubated at 
room temperature for 5 minutes. The digest was snap-frozen in dry ice and 
stored at -20oC until MS analysis. (Annett Linge, Deirde O’Fylnn)  
  
Nano LC–MS/MS analysis was carried out using an Ultimate 3000 nanoLC 
system (Dionex) coupled to a hybrid linear ion trap/Orbitrap mass spectrometer 
(LTQ Orbitrap XL; Thermo Fisher Scientific). Five microlitres of digest were loaded 
onto a C18 trap column (C18 PepMap, 300 µm ID×5 mm, 5 µm particle size, 100 
Å pore size; Dionex) and desalted for 10 min using a flow rate of 25 µL/min in 
0.1% trifluoroacetic acid. The trap column was then switched online with the 
analytical column (PepMap C18, 75 µm ID×250 mm, 3 µm particle and 100 Å 
pore size; Dionex) and peptides were eluted with the following binary gradients 
of solvent A and B: 0–25% solvent B in 120 min and 25–50% solvent B in a further 
60 min, where solvent A consisted of 2% acetonitrile (ACN) and 0.1% formic acid 
in water and solvent B consisted of 80% ACN and 0.08% formic acid in LC-MS 
grade water. Column flow rate was set to 350 nL/min. Data were acquired with 
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Xcalibur software, version 2.0.7 (Thermo Fisher Scientific). The mass 
spectrometer was operated in data-dependent mode and externally calibrated. 
Survey MS scans were acquired in the Orbitrap in the 300–2000 m/z range with 
the resolution set to a value of 60,000 at m/z 400. Up to seven of the most 
intense ions (1+, 2+ and 3+) per scan were CID fragmented in the linear ion trap. 
A dynamic exclusion window was applied within 40 s. All tandem mass spectra 
were collected using normalised collision energy of 35%, an isolation window of 
3 m/z, and one microscan. All samples were set up and run by LC-MS by Mr 
Michael Henry, DCU. 
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2.1.3. Progenesis label-free LC-MS bioinformatic analysis 
 
The acquired spectra for all 16 samples (Thermo raw files) were loaded to 
Progenesis label-free LC–MS software version 3.1 (NonLinear Dynamics, 
Newcastle upon Tyne, UK) for analysis. The software processes the raw data in 
two steps. Firstly each sample run was subjected to alignment which involved 
aligning the data based on the LC retention time of each sample; this allows for 
any drift in retention time giving an adjusted retention time for all runs in the 
analysis. The sample run with the most number of features (i.e. peptide ions) 
was selected as the reference run (run NM5), to which retention time of all of 
the other runs were aligned and peak intensities were normalised. This was done 
by manually reviewing each run, and aligning as many vectors as possible. 
Samples M1-8 were assigned to “metastatic” group, while samples NM1-8 were 
assigned to “non-metastatic” group. 
 
Prior to exporting the MS/MS output files to MASCOT 
(www.matrixscience.com) for protein identification, a number of criteria were 
used to filter the data. These are (i) mass peak features with charge states from 
+1, +2 and +3 (ii) greater than 3 isotopes per peptide and (iii) peptide features 
with ANOVA p-value < 0.01 between experimental groups. All MS/MS spectra 
were exported from Progenesis software as a MASCOT generic file (mgf) and 
used for peptide identification with MASCOT (version 2.2) searched against the 
UniProtKB–SwissProt database (taxonomy: Homo sapiens, downloaded 1st 
October 2012). The search parameters used were as follows: (i) peptide mass 
tolerance set to 10 ppm (ii) MS/MS mass tolerance set at 0.5 Da (iii) up to two 
missed cleavages were allowed (iv) carbamidomethylation set as a fixed 
modification (v) methionine oxidation and deamination set as a variable 
modification. Only peptides with ion scores of 30 and above were considered 
and re-imported back into Progenesis LC–MS software for further analysis.  
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The Progenesis peptide quantification algorithm calculates peptide 
abundance as the sum of the peak areas within its isotope boundaries. Each 
abundance value is then transformed to a normalised abundance value by 
applying a global scaling factor. Normalization corrects for factors resulting from 
experimental variation and was automatically calculated over all features in all 
samples. It results in a unique factor for each sample that corrects all features in 
the sample in a similar way for experimental variation. Protein abundance was 
calculated as the sum of the abundances of all peptide ions which have been 
identified as coming from the same protein. 
 
Proteins with 1 matched peptide and proteins with peptide conflicts were 
excluded to remove false positive identifications. For validation studies, a 
number of criteria were applied to assign a protein as significant; proteins with ≥ 
3 peptides matched, and an ANOVA p-value between experimental groups of ≤ 
0.05. The distribution of protein abundance for each statistically significant 
protein was reviewed to identify proteins that demonstrated good separation 
between the M and NM disease groups. Enrichment analysis of proteins with p ≤ 
0.05 and ≥ 2 peptides matched against GO (gene ontology) was conducted using 
the DAVID interface (http://david.abcc.ncifcrf.gov/) (313,314) to determine if any 
biological processes were overrepresented. Proteins were also analysed using 
the PANTHER Database (Protein ANalysis THrough Evolutionary Relationships, 
http://www.pantherdb.org/) (315–317) for protein categorization according to 
biological process, molecular function, protein class and PANTHER pathway. 
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2.2. Bioinformatic reanalysis of gene expression 
microarray data 
 
Laurent et al (29) compared 28 tumours from patients who developed 
metastasis within 3 years vs. 35 from patients who did not develop 
metastasis/metastasised after 3 years. They identified high expression of PTP4A3 
gene in high risk UM. Gene expression microarray and comparative genomic 
hybridization microarray data published by Laurent et al was obtained from GEO 
database (http://www.ncbi.nlm.nih.gov/geo/), under accession number 
GSE22138. This dataset was reanalysed to remove confounding clinical samples 
and samples with poor quality control. From 63 samples present in the original 
study, samples with chromosome 3 monosomy but without metastasis, and 
samples with chromosome 3 disomy with metastasis were excluded. Samples 
with other potential confounding factors were also excluded; tumours with 
extrascleral extension/no extrascleral extension information and tumours 
anterior to the equator (e.g. ciliary body tumours) were excluded. Quality control 
of the microarray data was conducted using hierarchical cluster analysis and 
principal component analysis. In total, 11 monosomy three tumours with 
metastasis and 9 disomy three tumours without metastasis were selected for 
transcriptomic analysis. Genes were considered to be differentially expressed 
upon observation of a fold change ≥ 1.3 and a P-value < 0.05 (Padraig Doolan). 
Enrichment analysis of genes with p ≤ 0.05 and ≥ 2 peptides matched against GO 
(gene ontology) was conducted using the DAVID interface 
(http://david.abcc.ncifcrf.gov/) (313,314) to determine if any biological processes 
were overrepresented. Genes were also analysed using the PANTHER Database 
(Protein ANalysis THrough Evolutionary Relationships, 
http://www.pantherdb.org/) (315–317) for gene categorization according to 
biological process, molecular function, gene class and PANTHER pathway. 
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2.3.  Immunohistochemistry 
2.3.1. Preparation of full-face uveal melanoma section tissue 
slides 
 
A total of 13 patients who developed metastasis and 13 patients who did 
not develop metastasis were identified and selected for pilot 
immunohistochemical studies. These samples were accessioned from the 
National Ophthalmic Laboratory, Royal Victoria Eye and Ear Hospital, Dublin. 
Immediately after enucleation, the globe is fixed in 10% neutral buffered 
formalin for 24 to 48 hours. Tissue block(s) of approximately 5 to 10mm 
thickness are selected and placed in numbered processing/embedding cassettes. 
The tissue cassettes are dehydrated in graded alcohols cleared in Xylene and 
saturated with paraffin wax according to the overnight process of the Sakura VIP 
automatic Tissue Processor. The tissue sections are then embedded in solid 
paraffin wax utilising the Tissue Tek Embedding Station. After removing the 
blocks from the embedding moulds the paraffin blocks are trimmed, cut at 4µm 
on the Microm HME 325 Microtome and floated out on deionised water at a 
temperature of 59 °C. The paraffin sections are then mounted on VWR 
SuperFrost Plus slides appropriately labelled with the specimen identification 
number and dried in a 37 °C incubator overnight followed by two hours at 60 °C 
in an oven chamber to maximise tissue adhesion to the slides. (Damien Tiernan) 
 
2.3.2. Preparation of uveal melanoma tissue microarray 
slides 
 
Details of archived tissue in the National Ophthalmic Laboratory, Royal 
Victoria Eye and Ear Hospital Dublin were reviewed. To identify UM tissues with 
suitable clinical follow-up information (metastatised/non-metastatised 
information, survival, date of death from metastatic disease) for TMA 
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construction, patients’ clinical notes were reviewed. Further information was 
obtained by contacting patients’ primary care physicians and the National Cancer 
Registry Ireland (www.ncri.ie). A total of 92 UM patients were identified as 
suitable for further study and tumours selected for TMA construction. Of these, 
55 tumours were from patients who developed metastasis while 37 were from 
patients who did not. Tissue blocks were retrieved from the archive (National 
Ophthalmic Laboratory, Royal Victoria Eye and Ear Hospital Dublin, 1966-2009) 
and a fresh full face 5 μm haematoxylin and eosin stain (H&E) section was cut 
and reviewed under the light microscope. The area of interest was identified and 
marked on the glass slide so that the corresponding area on the tissue block can 
be sampled. A smaller diameter tissue arrayer needle (0.4 mm) was used to 
extract the paraffin core from the recipient block in order to create the space for 
the core from the donor UM block. A larger diameter tissue arrayer needle (0.6 
mm) was used to extract the tissue core from the donor UM block. Both needled 
were positioned with the aid of micrometers for accuracy of placement. An 
adjustable depth stop was used to enable a constant depth of hole to be created 
in the recipient block. The hole in the recipient block was created, and the donor 
core extracted and inserted into the recipient block with the help of the steel 
stylet. After the recipient hole is filled, the needles are moved along the x axis to 
the right using the micrometer. This is repeated until the designed plan of 
microarray map is achieved. Throughout the whole process, both the block of 
origin and the TMA position of each individual core were carefully documented 
to ensure that the tissue microarray corresponded accurately with the pre-
designed microarray map. Once completed, the blocks were placed upside down 
onto a glass slide and into an oven at 40°C overnight to facilitate bonding of the 
donor cores with the paraffin wax of the recipient blocks. The following morning, 
the glass slide attached to the TMA block was used to level the TMA block 
surface by gently pushing the cores into the block if necessary. After cooling, the 
TMA block was cut into 4µm sections using a microtome, and placed onto VWR 
SuperFrost Plus glass slides. To achieve maximal concordance with the results 
from full tissue sections, four cores per tumour were used. Two cores of control 
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tissue were placed at the top-right of each TMA to aid in orientation of tumour 
tissues. (Damien Tiernan, Fionnuala McAree) 
 
2.3.3. Immunohistochemical staining of uveal melanoma 
slides 
 
All immunohistochemical staining was performed using the DAKO 
Autostainer (Dako). Dewaxing and antigen retrieval was done in the PT Link 
system (Dako) using Target retrieval solution (Dako, Glostrup, Denmark) pH 9 for 
PRDX3, SIPA1L2, and CNTN3 for 20 minutes at 97°C. For CNDP2, a longer 
duration of 40 minutes at 97°C was done. After heating the slides at 97°C for the 
duration mentioned above, it was allowed to cool down to 65°C. The slides were 
then immersed in 1X wash buffer (Dako). On the autostainer, slides were blocked 
for 10 minutes with 200 µL of HRP Block (Dako). The slides were washed with 1X 
wash buffer and 200 µL of antibody solution added to the slides for 30 minutes 
for PRDX3 (GeneTex, Inc., Irvine, California [GTX111887]; dilution 1:400 vol/vol 
for full face UM section slides and 1:430 vol/vol for TMA slides), CNTN3 (Atlas 
Antibodies, Stockholm, Sweden [HPA003341]; dilution 1:30 vol/vol for full face 
UM section slides) and SIPA1L2 (Atlas Antibodies, Stockholm, Sweden 
[HPA024181]; dilution 1: 35 vol/vol for full face UM section slides. For CNDP2, an 
incubation time of 40 minutes was used (GeneTex, Inc., Irvine, California 
[GTX116375]; dilution 1:50 vol/vol for full face UM section slides). Antibodies 
were diluted using rabbit polyclonal antibodies in Dako REAL Antibody Diluent. 
Slides were washed again with 1X wash buffer and then incubated with 200 µL 
REAL EnVision (Dako) for 30 minutes. Slides were washed again with 1X wash 
buffer and then stained with 200 µL 3-amino-9-ethylcarbazole (AEC) substrate 
chromogen (Dako) for 5 minutes and this was repeated once more. All slides 
were counterstained with haematoxylin (Dako) for 5 minutes and rinsed with 
deionised water, followed by wash buffer. Once staining was completed, each 
slide was mounted with a coverslip using Faramount mounting solution (Dako). 
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Negative control slides were incubated with Dako REAL Antibody Diluent only; 
the primary antibody was omitted.  
 
The immunohistochemical staining for the selected proteins were 
assessed by two observers who were blinded to all clinicopathologic and 
cytogenetic details including metastatic/non-metastatic information (Pathma 
Ramasamy, Anne-Marie Larkin)). A scoring system similar to the one first 
described by Remmele and Stegner (318), and adapted by Coupland et al (243) 
was used. The full face UM section slides were scored based on intensity of 
staining (A) and percentage of tumour cells that stained (B). Intensity was graded 
as 0 for no staining, 1+ for weak, 2+ for moderate and 3+ for strong staining. A 
percentage score was assigned as follows: 1 (0-49%), 2 (50-74%), 3 (75-89%) and 
4 (90-100%). A total score was obtained by multiplying (A) and (B). Thus, a 
minimum score of 0 and a maximum score of 12 was obtained. The TMA slides 
were scored based on staining only, as all cases demonstrated 100% staining 
given the small tumour core size. The staining intensities observed in TMA 
tumours were either negative, weak or strong. Each tumour had 4 representative 
cores, and each core was assigned a score of 0-2. No staining was scored as 0, 
weak staining as 1 and strong staining as 2. A total score for each patient was 
obtained by adding the scores of all 4 cores. Thus, a minimum score of 0 and a 
maximum score of 8 was obtained. The total score was divided into 2 categories: 
0-3 as low expression and 4-8 as high expression. In order for a patient to be 
categorised as “low expression”, a minimum of at least 1 core per patient would 
be required to demonstrate negative staining. The minimum staining for a 
patient to be categorised as “high expression” requires all 4 cores to 
demonstrate weak staining, 1 strong with 2 weak staining or 2 strong with 2 
negative staining tumour cores.  Thus, tumours with heterogenous PRDX3 
staining in 4 cores would be classified as low or high based on the presence or 
absence of negative staining. Using this method, 4 weak staining cores would be 
appropriately categorised as a positive result. 
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All data were processed in SPSS for statistical analyses (version 22.0; SPSS 
Science, Chicago, IL, USA). The data analysed were ordinal, and thus, 
nonparametric analyses were conducted. The Fisher's exact test (two-tailed), 
Pearson correlation and Spearman correlation was used to assess the association 
between clinical, histopathological and cytogenetic factors with 
immunohistochemical expression score. Differences of immunohistochemical 
expression score between samples of patients that developed and those that did 
not develop metastasis were examined by Mann-Whitney U test. Kaplan-Meier 
survival curves were produced for metastatic/non-metastatic information and 
PRDX3 expression based on immunohistochemical analysis in tissue microarray. 
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3. Results 
3.1. Uveal melanoma tissue label-free proteomics 
 
To identify differentially expressed proteins between primary UM tissue 
from patients who developed metastatic disease versus primary UM tissue from 
patients who did not develop metastatic disease, quantitative label-free LC-MS 
proteomic profiling was performed. Sixteen fresh frozen primary UM tissue 
specimens from patients with a minimum clinical follow-up of 7 years were used. 
Of these, 8 patients subsequently developed metastasis (M) while 8 patients did 
not (NM). The clinical and histopathological characteristics of these samples are 
detailed in Table 3. 
 
3.1.1. Label-free LC-MS analysis 
 
All samples were prepped (Annett Linge, Deirde O’Fylnn), and run as 5 
hour gradients by LC-MS (Michael Henry). The resultant LC-MS files were 
analysed using Progenesis software to look for differentially expressed proteins 
between experimental groups. Several criteria were applied to MS/MS data for 
identification; (i) mass peak features with charge states from +1, +2 and +3 (ii) ≤ 
3 isotopes per peptide and (iii) peptide features with ANOVA p-value < 0.01 
between experimental groups. A total of 1316 features matched these criteria 
and were identified with MASCOT (version 2.2) searched against the UniProtKB–
SwissProt database (taxonomy: Homo sapiens, downloaded 1st October 2012). 
Proteins with peptide conflicts and those with 1 peptide matched were excluded 
to reduce possible false positive results. A number of criteria were applied to 
assign a protein as significant; an ANOVA between experimental groups of ≤0.05, 
proteins with ≥3 peptides matched. No fold change cut off was applied.  
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Table 3: Clinical and histopathological details of 16 fresh-frozen uveal melanoma tissue samples used for quantitative label-free LC-MS 
proteomic analysis.  
Sample Sex 
Age at 
diagnosis 
(years) 
Metastatic 
sites 
Survival 
after 
diagnosis 
(years) 
Ciliary 
body 
involveme
nt 
Extraocular 
extension 
Cell type LTD (mm) Chr. 3 
1 F 40 Liver, lung 2 Y N S 18 NA 
2 F 49 Kidney NA N N S 12 Monosomy 
3 M 71 Liver 7 Y Y E 20 Monosomy 
4 F 58 Liver 5 Y N M 15 Monosomy 
5 M 71 Lung 2 N N M 11 Monosomy 
6 F 69 Liver 11 N N S 12 Monosomy 
7 F 51 Liver 1 N N E 15 Monosomy 
8 M 64 Lung 10 Y N M 10 Disomy 
9 F 76 N 
 
N N M 8 Disomy 
10 F 46 N 
 
N N E 23 Disomy 
11 F 74 N 
 
N N M 14 NA 
12 M 68 N 
 
Y N S 20 Disomy 
13 F 52 N 
 
N Y M 10 Disomy 
14 F 75 N 
 
N N S 22 Disomy 
15 F 42 N 
 
N N S 17 Disomy 
16 M 50 N 
 
N N M 17 Disomy 
N, no; Y, yes; S, spindle cells; E, epitheloid cells; M, mixed cells; LTD, largest tumour diameter; NA, not available. 
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In total, 216 differentially expressed proteins were identified which had an 
ANOVA p ≤ 0.05 between the two patient groups (supplementary data appendix I, ). 
Of these, 106 and 110 proteins were differentially upregulated and downregulated, 
respectively, in primary UM samples that metastasised (M) compared to those that 
did not (NM). There were 122 proteins with 1 peptide, 44 with 2 peptides and 50 
proteins with 3 or more peptides assigned (Table 4).  
 
Table 4: Eight fresh frozen primary UM tissue specimens from patients who 
developed metastasis versus 8 fresh frozen primary UM tissue specimens from 
patients who did not develop metastasis, with a minimum clinical follow-up of 7 
years were subjected to quantitative label-free LC-MS proteomic profiling. Table 4 
shows proteins identified with MASCOT with mass peak features with charge states 
from +1 to +3, greater than 3 isotopes per peptide and peptide features with 
ANOVA p-value < 0.01 between experimental groups.  
 
 
Number of proteins 
p ≤ 0.05 216 
1 peptide 122 
2 peptides 44 
3 or more peptides 50 
 
 
Of the 50 proteins with ≤ 0.05 and ≥ 3 peptides assigned, 29 were upregulated in 
primary UM tissue of patients that metastasised (M), while 21 proteins were 
downregulated in M (Table 5 and Table 6 respectively). The feature data and 
peptide measurements are detailed in supplementary data appendix I ( and ). 
Complete protein information including peptide count, confidence score, p value, 
fold change, normalised abundance, raw abundance and spectral counts are 
provided in supplementary data appendix I (). The distribution of protein 
abundance for each sample was reviewed to identify proteins that demonstrated 
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good separation between the M and NM disease groups. Of the 50 proteins, 7 
showed good separation between the two disease groups. Six were upregulated in 
M and 1 was downregulated. Upregulated proteins in M are elongation factor 1-
gamma (EF1G), thioredoxin-dependent peroxide reductase (PRDX3), importin 
subunit beta-1 (IMB1), rab GDP dissociation inhibitor beta (GDIB), heterogeneous 
nuclear ribonucleoprotein K (HNRPK) and glucose-6-phosphate isomerase (G6PI). 
Cytosolic non-specific dipeptidase (CNDP2) was downregulated in M. The fold 
change, p value, and number of peptides assigned to these proteins are outlined in 
Table 7. For each of the 7 protein, the standardised normalised abundance in 
samples 1-16 are shown in Figure 10.
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Table 5: Details of 29 differentially upregulated proteins in 8 primary uveal melanoma tissues of patients who metastasised (M) compared to 8 
primary uveal melanoma tissues without metastasis (NM), with p ≤ 0.05, and ≥ 3 peptides assigned to each protein. Proteins are presented 
from lowest to highest p value. 
Protein Accession Anova (p) Fold Peptides 
matched 
Ion 
score 
Description 
P26641 EF1G 0.000387 2.02 3 142.69 Elongation factor 1-gamma 
P06733 ENOA 0.000726 1.68 10 662.16 Alpha-enolase 
P15531 NDKA 0.000947 1.89 5 235.99 Nucleoside diphosphate kinase A 
P30048 PRDX3 0.00218 1.58 4 273.05 Thioredoxin-dependent peroxide reductase, mitochondrial 
P55072 TERA 0.00262 1.45 4 301.59 Transitional endoplasmic reticulum ATPase 
P11142 HSP7C 0.00268 1.54 5 306.74 Heat shock cognate 71 kDa protein 
Q14974 IMB1 0.00292 1.47 4 271.69 Importin subunit beta-1 
P50395 GDIB 0.00314 1.61 5 280.72 Rab GDP dissociation inhibitor beta 
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Protein Accession Anova (p) Fold Peptides 
matched 
Ion 
score 
Description 
P60709 ACTB 0.00512 3.54 5 259.7 Actin, cytoplasmic 1 
P61978 HNRPK 0.00617 1.56 3 189.73 Heterogeneous nuclear ribonucleoprotein K 
P43320 CRBB2 0.00619 42.66 3 168.38 Beta-crystallin B2 
P60174 TPIS 0.00664 1.79 8 523.06 Triosephosphate isomerase 
P11021 GRP78 0.00779 1.45 6 488.32 78 kDa glucose-regulated protein 
P62937 PPIA 0.0084 1.33 3 169.95 Peptidyl-prolyl cis-trans isomerase A 
P10721 KIT 0.00874 4.85 6 273.77 Mast/stem cell growth factor receptor 
P02768 ALBU 0.01 2.66 4 292.09 Serum albumin 
P35749 MYH11 0.02 9.99 5 262.63 Myosin-11 
P06865 HEXA 0.02 3.04 7 484.38 Beta-hexosaminidase subunit alpha 
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Protein Accession Anova (p) Fold Peptides 
matched 
Ion 
score 
Description 
P62140 PP1B 0.02 2.04 3 128 Serine/threonine-protein phosphatase PP1-beta catalytic subunit 
P08670 VIME 0.02 1.98 23 1409.7 Vimentin 
P16615 AT2A2 0.02 1.76 6 342.56 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 
P06744 G6PI 0.02 1.54 5 461.9 Glucose-6-phosphate isomerase 
P08758 ANXA5 0.03 3.98 3 172.89 Annexin A5 
P36957 ODO2 0.03 1.99 3 128.45 
Dihydrolipoyllysine-residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, mitochondrial 
P13639 EF2 0.03 1.8 5 228.5 Elongation factor 2 
P19338 NUCL 0.03 1.75 10 726.89 Nucleolin 
P11940 PABP1 0.03 1.37 3 167.51 Polyadenylate-binding protein 1 
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Protein Accession Anova (p) Fold Peptides 
matched 
Ion 
score 
Description 
P05413 FABPH 0.04 2.46 4 289.17 Fatty acid-binding protein, heart 
P07686 HEXB 0.04 2.39 6 413.84 Beta-hexosaminidase subunit beta 
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Table 6: Details of 21 differentially downregulated proteins in 8 primary uveal melanoma tissues of patients who metastasised (M) compared 
to 8 primary uveal melanoma tissues without metastasis (NM), with p ≤ 0.05, and ≥ 3 peptides assigned to each protein. Proteins are 
presented from lowest to highest p value. 
Protein Accession Anova (p) Fold Peptides 
matched 
Ion 
score 
Description 
Q96KP4 CNDP2 0.00132 1.75 6 304.06 Cytosolic non-specific dipeptidase 
Q13813 SPTA2 0.00187 2.3 8 352.15 Spectrin alpha chain, brain 
P15428 PGDH 0.00446 38.81 4 234 15-hydroxyprostaglandin dehydrogenase [NAD+] 
Q9UNF0 PACN2 0.00619 3.53 3 104.12 Protein kinase C and casein kinase substrate in neurons protein 2 
Q8WUM4 PDC6I 0.00761 2.27 4 247.14 Programmed cell death 6-interacting protein 
Q9NQ79 CRAC1 0.02 1.97 3 116.9 Cartilage acidic protein 1 
P29401 TKT 0.02 3.43 5 257.21 Transketolase 
P02511 CRYAB 0.02 4.27 3 179.54 Alpha-crystallin B chain 
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Protein Accession Anova (p) Fold Peptides 
matched 
Ion 
score 
Description 
P31937 3HIDH 0.03 1.46 4 344.15 3-hydroxyisobutyrate dehydrogenase, mitochondrial 
Q9BZQ8 NIBAN 0.03 1.66 5 314.36 Protein Niban 
P05023 AT1A1 0.03 1.81 3 178.83 Sodium/potassium-transporting ATPase subunit alpha-1 
Q99536 VAT1 0.03 2.09 4 170.67 Synaptic vesicle membrane protein VAT-1 homolog 
P61313 RL15 0.03 4.63 3 129.17 60S ribosomal protein L15 
P01009 A1AT 0.04 1.99 4 204.7 Alpha-1-antitrypsin 
P27816 MAP4 0.04 2.33 14 730.03 Microtubule-associated protein 4 
Q03252 LMNB2 0.04 2.36 3 136.84 Lamin-B2 
P08107 HSP71 0.04 3.16 3 189.72 Heat shock 70 kDa protein 1A/1B 
P02649 APOE 0.04 5.82 10 594.63 Apolipoprotein E 
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Protein Accession Anova (p) Fold Peptides 
matched 
Ion 
score 
Description 
P04350 TBB4 0.05 1.41 8 706.15 Tubulin beta-4 chain 
P04792 HSPB1 0.05 1.56 6 464.12 Heat shock protein beta-1 
P11216 PYGB 0.05 1.95 11 678.11 Glycogen phosphorylase, brain form 
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Table 7: Details of 7 proteins with p ≤ 0.05, ≥ 3 peptides assigned to each protein and showing good separation between primary uveal 
melanoma tissue of patients who metastasised (M) compared to those that did not metastasise (NM). A positive fold change value represents 
the differential upregulation of a protein in M versus NM, while a negative fold change value represents downregulation in M compared to 
NM. Proteins are presented from lowest to highest p value. 
Protein Accession Anova (p) Fold Peptides 
matched 
Ion 
score 
Description 
 P26641 EF1G 0.000387 2.02 3 142.69 Elongation factor 1-gamma 
 Q96KP4 CNDP2 0.00132 ̶ 1.75 6 304.06 Cytosolic non-specific dipeptidase 
 P30048 PRDX3 0.00218 1.58 4 273.05 Thioredoxin-dependent peroxide reductase, mitochondrial 
 Q14974 IMB1 0.00292 1.47 4 271.69 Importin subunit beta-1 
 P50395 GDIB 0.00314 1.61 5 280.72 Rab GDP dissociation inhibitor beta 
 P61978 HNRPK 0.00617 1.56 3 189.73 Heterogeneous nuclear ribonucleoprotein K 
 P06744 G6PI 0.02 1.54 5 461.9 Glucose-6-phosphate isomerase 
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Figure 10: LC-MS/MS label-free results showing expression levels of 7 proteins with 
good separation of abundance between the 2 disease groups: (i) elongation factor 
1-gamma, 2.02 fold upregulated in metastatic group, p: 0.000387 (ii) cytosolic non-
specific dipeptidase, 1.75 fold downregulated in metastatic group, p: 0.00132 (iii) 
thioredoxin-dependent peroxide reductase, 1.58 fold upregulated in metastatic 
group, p: 0.00218 (iv) importin subunit beta-1, 1.47 fold upregulated in metastatic 
group, p: 0.00292 (v) rab GDP dissociation inhibitor beta, 1.61 fold upregulated in 
metastatic group, p: 0.00314 (vi) heterogeneous nuclear ribonucleoprotein K, 1.56 
fold upregulated in metastatic group, p: 0.00617 (vii) Glucose-6-phosphate 
isomerase, 1.54 fold upregulated in metastatic group, p: 0.02 in eight primary UM 
tissues from patients who developed metastasis and eight primary UM tissues from 
patients who did not develop metastasis. The graph shows average normalised 
abundance volumes of the identified proteins from LC-MS/MS analysis of each 
sample (adapted from output from Progenesis LC-MS analysis software). The 
horizontal axis represents the individual biological replicates from the 8 patients 
who developed metastatic disease (M1-M8) and the eight patients who did not 
develop metastatic disease (NM1-NM8). The vertical axis represents normalised 
abundance volumes (log). 
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For these 7 proteins, the standardised normalised abundances (SNA) in 
individual samples were reviewed to identify proteins that demonstrated the best 
separation between M and NM disease groups. Outliers are samples with 
differential expression of standardised normalised protein abundance that were in 
the opposite trend compared to other samples within the sample group of M or 
NM. EF1G and GDIB had 3 samples that were outliers.  The remaining proteins had 
2 samples that were outliers except CNDP2, which only had 1 outlying sample. 
EEF1G was differentially upregulated by 2.02 fold in M. The outlying samples were 
M5 and M6, where the standardised normalised abundances (SNA) were 
differentially downregulated while that of sample NM6 was upregulated. GDIB was 
differentially upregulated by 1.61 fold in M. Samples M1 and M2 were outliers 
where the SNA were differentially downregulated while the SNA of sample NM7 
was upregulated. EEF1G and GDIB were not considered for further follow-up based 
on the presence of 3 outliers. G6PI was upregulated by 1.54 fold in M and had 2 
samples that were outliers. These are M7, where its expression was differentially 
downregulated more than all NM samples except NM8. Sample NM7 was also an 
outlier, where its expression was differentially upregulated with only two other M 
samples demonstrating higher expression. Thus, G6PI was excluded from further 
follow-up due to the significant outliers. IMB1 was differentially upregulated by 
1.47 fold in M. No outlying samples were present in M, but 2 outliers were found in 
NM. These were samples NM6 and NM7, both of which demonstrated higher 
differential upregulation than 4 of 8 primary UM samples from patient with 
metastatic disease. For this reason, IMB1 was not considered for further validation. 
HNRPK was upregulated by 1.56 fold in M with 2 outlying samples. In sample M7, 
the differential expression level of HNRPK was found to be lower than three NM 
samples, while that of NM2 was differentially upregulated higher than 2 primary 
UM samples of patients who subsequently developed metastatic disease. PRDX3 
was upregulated by 1.58 fold in M, with 2 samples that were outliers. In sample M3, 
PRDX3 was differentially downregulated lower than two NM samples while in 
sample NM5, it was differentially upregulated higher than 4 M samples. Both 
HNRPK and PRDX3 demonstrated similar number and patterns of outliers. Based on 
stronger statistical strength, PRDX3 was selected for validation studies (p: 0.00218 
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vs. p: 0.00617 for PRDX3 and HNRPK, respectively). Furthermore, PRDX3 had 4 
assigned peptides, compared to 3 peptides matched to HNRPK. CNDP2 was the only 
protein that was differentially downregulated in M compared to NM, which also 
demonstrated good separation between the two groups of samples. It was 
downregulated by 1.75 fold in M and had the most number of peptides assigned to 
it (6 peptides). Furthermore, only 1 outlying sample was present (M6). For these 
reasons, CNDP2 was chosen for validation studies by immunohistochemistry. 
 
  
119 
 
3.1.2. Gene ontology analysis of uveal melanoma tissue label-
free LC-MS results 
 
Gene ontology (GO) enrichment analysis of 50 differentially expressed 
proteins with p ≤ 0.05 and ≥ 3 peptides matched was conducted using the DAVID 
interface (313,314) to determine if any biological processes were overrepresented. 
Due the small number of proteins with ≥ 3 peptides matched, no significant results 
were found. For all subsequent GO analysis, 94 proteins with ≥ 2 peptides matched 
with p ≤ 0.05 were included; 49 were upregulated and 45 were downregulated in 
primary UM tissues that developed metastatic disease compared to those that did 
not. Table 8 shows the enriched GO biological processes for proteins with a 
Benjamani Hochberg adjusted p of ≤ 0.05.  
 
Table 8: List of Gene Ontology enriched biological processes of 94 differentially 
expressed proteins identified by quantitative label-free LC-MS profiling, with ≥ 2 
peptides assigned and ANOVA p ≤ 0.05 between experimental groups, of 8 primary 
uveal melanoma tissue of patients who developed metastatic disease and 8 primary 
tissues of patients who did not develop metastatic disease. Data presented in this 
table are those with Benjamani Hochberg adjusted p ≤ 0.05, in ascending order. 
Biological process Count 
% of 
proteins 
p 
value 
Benjamini 
Hochberg 
adjusted p 
value 
Proteins 
GO:0006006~glucose 
metabolic process 
11 11.702 
6.03E-
08 
7.90E-05 
TPI, CRYAB, 3HIDH, 
PPP1CB, PGAM1, 
PGM2, ENOA, G6PI, 
PKM2, PYGL, PYGB 
GO:0005996~monosac
charide metabolic 
process 
12 12.765 
2.16E-
07 
1.41E-04 
TPI, CRYAB, 3HIDH, 
PPP1CB, PGAM1, 
PGM2, ENOA, G6PI, 
PKM2, PYGL, HEXB 
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Biological process Count 
% of 
proteins 
p 
value 
Benjamini 
Hochberg 
adjusted p 
value 
Proteins 
GO:0019318~hexose 
metabolic process 
11 11.702 
5.05E-
07 
2.20E-04 
TPI, CRYAB, 3HIDH, 
PPP1CB, PGAM1, 
PGM2, ENOA, G6PI, 
PKM2, PYGL, PYGB 
GO:0016052~carbohyd
rate catabolic process 
9 9.5744 
5.64E-
07 
1.84E-04 
TPI, 3HIDH, PGAM1, 
ENOA, PYGB, G6PI, 
PKM2, PYGL, HEXB 
GO:0044275~cellular 
carbohydrate catabolic 
process 
8 8.5106 
1.37E-
06 
3.58E-04 
TPI, 3HIDH, PGAM1, 
ENOA, PYGB, G6PI, 
PKM2, PYGL 
GO:0043069~negative 
regulation of 
programmed cell death 
13 13.829 
3.84E-
06 
8.37E-04 
PRDX3, SYUA, APOH, 
ALBU, NDKA, KIT, 
HSP71, CRYAB, 
APOE, HSPD1, 
GRP78, ANXA5, 
HSP27 
GO:0010033~response 
to organic substance 
18 19.148 
3.84E-
06 
7.17E-04 
SYUA, SORBS1, 
COL1A1, HSP72, 
MGP, NDKA, HSP7C, 
HSP71, FABP3, 
CRYAB, APOE, GNB2, 
HSPD1, PRDX3, 
SERPINA1, ANXA5, 
HSP27, TERA 
GO:0060548~negative 
regulation of cell death 
13 13.829 
3.95E-
06 
6.46E-04 
PRDX3, SYUA, APOH, 
ALBU, NDKA, KIT, 
HSP71, CRYAB, 
APOE, HSPD1, 
GRP78, ANXA5, 
HSP27 
GO:0006091~generatio
n of precursor 
metabolites and 
energy 
12 12.765 
6.25E-
06 
9.09E-04 
TPI, PP1B, PGAM1, 
SYUA, ENOA, PYGB, 
G6PI, PKM2, ODO2, 
PYGL, CISY, NNTM 
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Biological process Count 
% of 
proteins 
p 
value 
Benjamini 
Hochberg 
adjusted p 
value 
Proteins 
GO:0043066~negative 
regulation of apoptosis 
12 12.765 
1.99E-
05 
0.002595 
PRDX3, SYUA, APOH, 
ALBU, NDKA, HSP71, 
CRYAB, APOE, 
HSPD1, GRP78, 
ANXA5, HSP27 
GO:0006007~glucose 
catabolic process 
6 6.3829 
3.83E-
05 
0.004549 
TPI, 3HIDH, PGAM1, 
ENOA, G6PI, PKM2 
GO:0010035~response 
to inorganic substance 
9 9.5744 
5.99E-
05 
0.006512 
APOE, CRYAB, SYUA, 
PRDX3, COL1A1, 
SERPINA1, MGP, 
ACTB, IMPA1 
GO:0019320~hexose 
catabolic process 
6 6.3829 
8.88E-
05 
0.008900 
TPI, 3HIDH, PGAM1, 
ENOA, G6PI, PKM2 
GO:0046365~monosac
charide catabolic 
process 
6 6.3829 
1.02E-
04 
0.009473 
TPI, 3HIDH, PGAM1, 
ENOA, G6PI, PKM2 
GO:0006986~response 
to unfolded protein 
6 6.3829 
1.02E-
04 
0.009473 
HSP7C, HSP71, 
HSPD1, HSP72, 
TERA, HSP27 
GO:0046164~alcohol 
catabolic process 
6 6.3829 
1.90E-
04 
0.016468 
TPI, 3HIDH, PGAM1, 
ENOA, G6PI, PKM2 
GO:0006096~glycolysis 5 5.3191 
2.52E-
04 
0.020372 
TPI, PGAM1, ENOA, 
G6PI, PKM2 
GO:0015980~energy 
derivation by oxidation 
of organic compounds 
7 7.4468 
3.69E-
04 
0.027995 
PPP1CB, SYUA, 
PYGB, ODO2, PYGL, 
CISY, NNTM 
GO:0051789~response 
to protein stimulus 
6 6.3829 
6.91E-
04 
0.048995 
HSP7C, HSP71, 
HSPD1, HSP72, 
TERA, HSP27 
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As shown in Figure 11, the majority of proteins are involved in carbohydrate 
catabolic and metabolic processes, and negative regulation of apoptosis.  
 
 
Figure 11: Graphical representation of statistically significant (Benjamani Hochberg 
adjusted p ≤ 0.05) Gene Ontology enriched biological processes of 94 differentially 
expressed proteins identified by quantitative label-free LC-MS profiling, with ≥ 2 
peptides assigned and ANOVA p ≤ 0.05 between experimental groups, of 8 primary 
uveal melanoma tissue of patients who developed metastatic disease and 8 primary 
tissues of patients who did not develop metastatic disease. 
 
Proteins in each disease group of primary UM tissue that and did not 
develop metastatic disease were also analysed and compared directly using the 
PANTHER Database (http://www.pantherdb.org/) (315–317), for protein 
categorization according to biological process, molecular function, protein class and 
PANTHER pathway. Figure 12 shows the biological processes of proteins that were 
upregulated in primary UM tissues of patients who did (M) and did not develop 
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metastatic disease (NM). A similar number of proteins in most biological process 
were observed. A higher number of proteins involved in metabolic process (32 vs. 
28) and biological regulation (9 vs. 6), and a lower number of proteins involved in 
biological adhesion (0 vs. 5), multicellular organismal process (3 vs. 8) and response 
to stimulus (4 vs. 8) were found in M compared to NM.  
 
 
Figure 12: Graphical representation of biologic processes of 49 vs. 45 proteins that 
were upregulated in 8 primary UM tissue of patients that developed metastasis and 
8 primary UM tissue of patients that did not develop metastatic disease, 
respectively. A total of 94 differentially expressed proteins were identified by 
quantitative label-free LC-MS profiling, with ≥ 2 peptides assigned and ANOVA p ≤ 
0.05 between experimental groups.  
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Table 9 shows statistically significant biological process enrichment based on 
differential protein expression levels in M compared to NM. Processes involving 
adhesion and skeletal system development were found to be significantly lower 
while those involving cytokinesis and mitosis were higher in M compared to NM.  
 
Table 9: Statistically significant biological process enrichment based on differential 
protein expression levels in 8 primary UM tissue from patients who developed 
metastatic disease (M) compared to 8 primary UM tissue from patients who did not 
metastasise. A total of 94 differentially expressed proteins were identified by 
quantitative label-free LC-MS profiling, with ≥ 2 peptides assigned and ANOVA p ≤ 
0.05 between experimental groups. ↑ and ↓ indicate increased and decreased 
expression in M. 
Biological Process 
Number of 
proteins 
Expression 
in “M” 
P value 
Cell adhesion 5 ↓ 0.0124 
Biological adhesion 5 
↓ 
0.0124 
Cell-cell adhesion 3 
↓ 
0.0161 
Cytokinesis 2 ↑ 0.0256 
Skeletal system 
development 
2 ↓ 0.0292 
Mitosis 4 ↑ 0.0389 
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Figure 13 shows the molecular function of proteins that were upregulated in 
M and NM. A higher number of proteins with binding (15 vs. 11) and catalytic 
activity (26 vs. 16), and lower number of proteins with structural molecule (8 vs. 12) 
and receptor activity (0 vs. 5) were found M compared to NM. Based on differential 
protein expression levels, receptor activity was significantly enriched in NM 
compared to M (p: 0.0124). The difference in other categories was not significant.  
 
 
Figure 13: Graphical representation of molecular function of 49 vs. 45 proteins that 
were upregulated in 8 primary UM tissue of patients that developed metastasis (M) 
and 8 primary UM tissue of patients that did not develop metastatic disease (NM), 
respectively. A total of 94 differentially expressed proteins were identified by 
quantitative label-free LC-MS profiling, with ≥ 2 peptides assigned and ANOVA p ≤ 
0.05 between experimental groups. Based on differential protein expression levels, 
receptor activity was significantly enriched in NM compared to M (p: 0.0124).  
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Figure 14 shows proteins in PANTHER pathways that were upregulated in M 
and NM. A higher number of proteins involved in FAS signalling (2 vs. 0), glycolysis 
(5 vs. 0), nicotinic acetylcholine receptor signalling (2 vs. 0) and pyruvate 
metabolism (2 vs. 0), and lower number of proteins involved in gonadotropin 
releasing hormone receptor pathway (1 vs. 3), heterotrimeric Gi-α and Gs-α G-
protein signaling pathway (0 vs. 3) and integrin signalling pathway (1 vs. 3) were 
found in M compared to NM. Based on differential protein expression levels, 
nicotinic acetylcholine receptor signalling pathway was significantly enriched in M 
compared to NM (p: 0.0256) while the difference in other pathways were not 
significant. 
 
Figure 14: Graphical representation of proteins in PANTHER pathways that were 
upregulated in 8 primary UM tissue of patients that developed metastasis (M) and 8 
primary UM tissue of patients that did not develop metastatic disease (NM), 
respectively. A total of 94 differentially expressed proteins were identified by 
quantitative label-free LC-MS profiling, with ≥ 2 peptides assigned and ANOVA p ≤ 
0.05 between experimental groups. Based on differential protein expression levels, 
nicotinic acetylcholine receptor signalling pathway was significantly enriched in M 
compared to NM (p: 0.0256). Due to large number of pathways, only those that 
showed a difference of more than 1 protein between disease groups are shown. 
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Figure 15 shows protein classes that were upregulated in M and NM. A 
higher number of isomerases (7 vs. 0), nucleic acid binding proteins (7 vs. 3), 
phosphatases (2 vs. 0), transfer/carrier proteins (3 vs. 1) and transferases (6 vs. 3) 
were found in M compared to NM. In NM, cell adhesion molecules (3 vs. 0), 
chaperones (7 vs. 4), defence/immunity proteins (2 vs. 0), extracellular matrix 
proteins (5 vs. 0), membrane traffic proteins (5 vs. 1), oxireductases (5 vs. 3), 
proteases (2 vs. 0), and receptor proteins were found to be higher than in M. Based 
on differential protein expression levels, extracellular matrix and receptor proteins 
were significantly enriched in NM compared to M (p: 0.0113 and 0.0124 
respectively). A complete list of GO molecular function, GO biological process, 
PANTHER protein class and pathway can be found in supplementary data appendix I 
().    
 
 
Figure 15: Graphical representation of protein class of 49 vs. 45 proteins that were 
upregulated in 8 primary UM tissue of patients that developed metastasis (M) and 8 
primary UM tissue of patients that did not develop metastatic disease (NM), 
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respectively. A total of 94 differentially expressed proteins were identified by 
quantitative label-free LC-MS profiling, with ≥ 2 peptides assigned and ANOVA p ≤ 
0.05 between experimental groups. Based on differential protein expression levels, 
extracellular matrix and receptor proteins were significantly enriched in NM 
compared to M (p: 0.0113 and 0.0124 respectively). Due to large number of protein 
classes, only those that showed a difference of more than 1 protein between 
disease groups are shown.
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3.2. Bioinformatic reanalysis of gene expression 
microarray data 
 
To identify differentially expressed genes between primary UM tissue from 
patients who developed metastatic disease, versus primary UM tissue from patients 
who did not develop metastatic disease, bioinformatic reanalysis of publically 
available gene expression microarray datasets of monosomy 3 tumours that 
developed metastatic disease versus disomy 3 tumours that did not develop 
metastatic disease was performed. Laurent et al (29) compared 28 uveal 
melanomas from patients who developed liver metastases within three years of 
enucleation with 35 tumours from patients without metastases or who developed 
metastases more than 3 years after enucleation. However, it is not uncommon for 
UM patients to develop metastatic disease after 3 years. In order to eliminate this 
bias and obtain a more direct comparison, we studied monosomy 3 tumours that 
metastasised (M3M) versus disomy 3 tumours that did not metastasise (D3NM).  
3.2.1. Gene expression microarray analysis 
 
  Comparative genomic hybridization microarray data published by Laurent et 
al was obtained from GEO database (http://www.ncbi.nlm.nih.gov/geo/), under 
accession number GSE22138. This dataset was reanalysed to remove confounding 
clinical samples and samples with poor quality control (Padraig Doolan). From 63 
samples present in the original study, samples with chromosome 3 monosomy but 
without metastasis (n=10), and samples with chromosome 3 disomy with 
metastasis (n=4) were excluded. Tumours with partial monosomy 3 (n=5) and 
without chromosome 3 status (n= 8) were also excluded. Samples with other 
potential confounding factors were also excluded; tumours with extrascleral 
extension (n=2), no extrascleral extension information (n=2) and tumours anterior 
to the equator (e.g. ciliary body tumours, n=2). Quality control of the microarray 
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data was conducted using hierarchical cluster analysis and principal component 
analysis. Ten samples with poor quality control were excluded based on hierarchical 
cluster analysis (Figure 16, n=9) and principal component analysis (Figure 17, n=1). 
Figure 17 shows principal component analysis of 22 M3M and 14 D3NM tumours, 
and illustrates samples that were excluded from further analysis. In total, 43 
samples were excluded from further analysis (table 10).  
 
 
     Disomy 3 non-metastasised             Monosomy 3 metastasised 
Figure 16: Hierarchical cluster analysis (Pearson correlation coefficient) of 36 
samples following exclusion of monosomy 3 tumours that did not metastasise, 
disomy 3 tumours that metastasised and tumours with unknown or partial 
monosomy 3. Nine outlying samples were excluded from further analysis. 
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Figure 17: Principal component analysis showing distribution of 36 samples 
following exclusion of monosomy 3 tumours that did not metastasise, disomy 3 
tumours that metastasised and tumours with unknown or partial monosomy 3. 
Circled samples were excluded from further analysis for reasons illustrated above. 
 
Table 10: Samples that were excluded prior to transcriptomic analysis 
Exclusion criteria Number of samples 
Monosomy 3 non-metastasised 10 
Disomy 3 metastasised 4 
Partial monosomy 3 5 
Chromosome 3 status unknown 8 
Extrascleral extension 2 
Extrascleral extension unknown 2 
Tumours anterior to equator 2 
Poor quality control 10 
Total number of samples excluded 43 
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Eleven M3M and 9 D3NM samples were selected for transcriptomic analysis. 
Figure 18 and Figure 19 show hierarchical cluster analysis and principal component 
analysis of these samples, respectively.  
 
 
     Disomy 3 non-metastasised             Monosomy 3 metastasised 
Figure 18: Hierarchical cluster analysis (Spearman correlation coefficient) of 20 
samples following exclusion of monosomy 3 tumours that did not metastasise, 
disomy 3 tumours that metastasised, tumours with unknown chromosome 3 status 
or partial monosomy 3, tumours anterior to the equator of the globe and tumours 
with extrascleral extension or without extrascleral information. 
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Figure 19: Principal component analysis of 20 samples following exclusion of 
monosomy 3 tumours that did not metastasise, disomy 3 tumours that 
metastasised, tumours with unknown chromosome 3 status or partial monosomy 3, 
tumours anterior to the equator of the globe and tumours with extrascleral 
extension or without extrascleral information, showing good distribution within 
each disease group and good separation between both disease groups. 
 
Clinicopathologic details of samples that were analysed for differential gene 
expression are outlined in Table 11. In total, 449 genes were differentially 
expressed with a fold change ≥ 1.3 and P-value < 0.05. Of these, 246 genes were 
upregulated in the M3M group, while 203 were downregulated.  A full list of these 
genes can be found in supplementary data appendix II ( and ). Six upregulated and 6 
downregulated genes were considered for further follow-up based on p value, 
biological function and involvement in other diseases. SIPA1L2, CELF2, BCAT1, 
SDC2, WARS, and THBS2 are genes upregulated in M3M, while CNTN3, SORBS2, 
MEGF10, CHL1, DLC1, and PPP1R3C are downregulated genes that were considered 
(Table 12). Of these, SIPA1L2 (1.516 fold upregulated in M3M, p: 0.00107) and 
CNTN3 (3.068 fold downregulated in M3M, p: 0.000807) were chosen for further 
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validation by immunohistochemistry on FFPE UM sections. The former was selected 
for validation based on its novelty, as little is known about SIPA1L2, while CNTN3 
was chosen primarily due to its localisation to chromosome 3, which has significant 
prognostic implication in UM. Other genes that have been described by in other 
studies have also been found, validating our results. Onken et al (319) described a 
12-gene signature that accurately classifies patients to class 1 low-risk for 
metastasis and class 2 high-risk for metastasis. Of the 12 genes, 8 were identified in 
this study (HTR2B, FXR1, ID2, LMCD1, MTUS1, RAB31, ROBO1, and SATB1) with 
identical up/downregulation pattern. Mutations in BAP1 gene located in 
chromosome 3 occurs almost exclusively in metastasizing class 2 tumours (25), 
which was also found to be downregulated in M3M tumours in our study. 
Specifically, Laurent et al’s principal finding of high expression of PTP4A3 in 
metastasising tumours was also found, ensuring internal validation of our analysis. 
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Table 11: Clinicopathologic details of 20 tumours that were analysed for differential gene expression. Eleven monosomy three tumours that 
metastasised versus 9 disomy three tumours that did not metastasise were compared. M3: monosomy 3; D3: disomy 3; NA: not available. 
(29) 
Sample Ch 3 
status 
Meta-
stasis 
Age Gender Tumour 
location 
Diameter 
(mm) 
Tumour 
cell type 
Retinal 
detach-
ment 
Extrascleral 
extension 
Survival 
after 
diagnosis 
GSM550663 M3 Y 54.41 F on equator 10 epithelioid Y N 0.13 
GSM550671 M3 Y 56.33 M posterior to 
equator 
NA epithelioid Y N 7.33 
GSM550638 M3 Y 51.61 F on equator 12 epithelioid N N 21.78 
GSM550668 M3 Y 48.46 M on equator 12 NA Y N 14.95 
GSM550630 M3 Y 59.1 M on equator 20.9 epithelioid Y N 6.14 
GSM550662 M3 Y 62.88 M on equator NA epithelioid N N 12.88 
GSM550673 M3 Y 69.05 M posterior to 
equator 
NA epithelioid NA N 8.34 
GSM550679 M3 Y 50.17 M on equator 19.6 epithelioid Y N 17.61 
GSM550633 M3 Y 70.09 M on equator 13 mixed Y N 7.92 
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GSM550682 M3 Y 64.55 M on equator 10 mixed Y N 14.85 
GSM550670 M3 Y 62.12 M posterior to 
equator 
NA mixed Y N 18.89 
GSM550628 D3 N 50.64 F on equator NA mixed Y N  
GSM550674 D3 N 50.17 M on equator 10 epithelioid Y N  
GSM550644 D3 N 47.62 F on equator 17 mixed Y N  
GSM550629 D3 N 38.67 M on equator 11 NA Y N  
GSM550680 D3 N 66.26 M on equator 15 epithelioid NA N  
GSM550656 D3 N 57.69 M posterior to 
equator 
16 NA Y N  
GSM550675 D3 N 56.25 F on equator 15 epithelioid Y N  
GSM550654 D3 N 40.31 M on equator 18 NA Y N  
GSM550640 D3 N 51.95 F on equator 23 mixed N N  
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Table 12: Statistically significant genes that were considered for validation by 
immunohistochemistry. Elevan monosomy 3 tumours with metastasis (M3M) and 9 
disomy 3 tumours without metastasis (D3NM) were analysed for differential gene 
expression. A positive fold change represents upregulation while a negative fold 
change represents downregulation in M3M compared to D3NM. SIPA1L2 and 
CNTN3 were chosen for validation by immunohistochemistry. 
Gene ID Gene name 
Fold 
change 
P value 
Genes upregulated in monosomy 3 metastasised tumours 
CELF2 Elav-like family member 2 1.987 0.0000188 
WARS Tryptophanyl-tRNA synthetase 1.39 0.0001440 
SDC2 Syndecan 2 1.848 0.0003480 
THBS2 Thrombospondin 2 2.033 0.0008640 
SIPA1L2 
Signal-induced proliferation-associated 1 like 
2 
1.516 0.0010700 
BCAT1 Branched chain aminotransferase 1, cytosolic 1.674 0.0070600 
Genes downregulated in monosomy 3 metastasised tumours 
MEGF10 Multiple Epidermal Growth Factor 10 -3.472 0.0000084 
DLC1 Deleted in liver cancer 1 -2.137 0.0000142 
CHL1 
Cell adhesion molecule with homology to 
L1CAM 
-2.924 0.0000643 
PPP1R3C 
Protein phosphatase 1, regulatory (inhibitor) 
subunit 3C 
-1.376 0.0001640 
SORBS2 Arg/Abl-interacting protein ArgBP2 -2.545 0.0001810 
CNTN3 Contactin 3 (plasmacytoma associated) -3.067 0.0008070 
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3.2.2. Gene ontology analysis 
 
Gene ontology (GO) enrichment analysis of 449 differentially expressed 
genes with p ≤ 0.05 and fold change of ≥ 1.3 was conducted using the DAVID 
interface (313,314) to determine if any biological processes were overrepresented. 
Of these, 246 genes were upregulated and 203 genes were downregulated in 
monosomy 3 tumours that developed metastatic disease (M3M) compared to 
disomy 3 tumours that did not develop metastasis (D3NM). Table 13 shows the 
enriched GO biological processes for genes with a Benjamani Hochberg adjusted p 
of ≤ 0.05. A complete list of GO molecular function, GO biological process, PANTHER 
class and pathway can be found in supplementary data appendix II ()
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Table 13: List of Gene Ontology enriched biological processes of 449 differentially expressed genes with p ≤ 0.05 and fold change of ≥ 1.3 
between experimental groups of 11 monosomy 3 tumours that developed metastatic disease compared to 9 disomy 3 tumours that did not 
develop metastatic disease. Data presented in this table are those with Benjamani Hochberg adjusted p ≤ 0.05, in ascending order. 
Biological process Count % of genes p value 
 
Benjamini 
Hochberg 
adjusted p 
value 
 
Proteins 
GO:0042127~regulation of 
cell proliferation 
42 9.41704 8.45E-06 0.006136 DLC1, NBN, FGFR3, NDN, ERBB3, PPARG, PTGS1, PRRX1, 
BAP1, ZEB1, JAG1, CXADR, IL12RB2, WARS, AZGP1, EDNRB, 
ALDH1A2, CDCA7, ANG, RARB, IL13RA1, AKIRIN2, SYK, 
TCIRG1, PRKCA, PTPRC, ADAM10, LYN, STAT1, FOXP1, 
CLEC11A, KDR, CDC25B, CDKN1A, CTH, ID2, CCND2, JUN, 
GDF11, ADAMTS1, KLF4, NFIB 
 
GO:0010033~response to 
organic substance 
40 8.96861 5.88E-06 0.006398 ME1, ADCY1, ADCY2, DERL1, ERBB3, PPARG, PTGS1, PRKDC, 
C1S, TIMP3, B2M, IL12RB2, CD48, TNFRSF1A, FOS, ALDH1A2, 
GSTM3, PLIN2, BCHE, ANG, CASP8, FAS, DDAH2, AKIRIN2, 
PRKCA, ADAM10, LYN, SOCS2, PDE3A, STAT1, CDKN1A, ID2, 
CCND2, FYN, SQLE, JUN, RYR1, IGFBP2, TJP2, ABCC5 
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Biological process Count % of genes p value 
 
Benjamini 
Hochberg 
adjusted p 
value 
 
Proteins 
GO:0006955~immune 
response 
39 8.744395 5.14E-06 0.011171 NBN, CADM1, ENPP2, PPARG, TLR1, PRKDC, HFE, C1R, ZEB1, 
C1S, C1QC, B2M, RNF125, AZGP1, TNFRSF1A, TAP1, HLA-
DRB4, FAS, MR1, C2, HLA-DOA, SPON2, APLN, AKIRIN2, 
PTPRC, LYN, C4A, PTGER4, C4B, CTSS, GEM, PRKCD, TRIM22, 
FOXP1, CCL18, PSMB9, HLA-F, IGSF6, CD209 
 
GO:0002252~immune 
effector process 
14 3.139013 3.46E-05 0.014992 PTPRC, NBN, CADM1, LYN, C4A, C4B, PRKDC, C1R, C1S, C1QC, 
PRKCD, FOXP1, C2, FAS 
 
GO:0002449~lymphocyte 
mediated immunity 
10 2.242152 6.35E-05 0.017182 NBN, CADM1, C4A, C4B, C1R, C1S, FAS, C2, C1QC, PRKCD 
 
GO:0007507~heart 
development 
18 4.035874 3.32E-05 0.01795 DLC1, ERBB3, PDLIM3, PRKDC, CXADR, FOXP1, GJC1, 
ALDH1A2, CHD7, ID2, PLN, CASP8, FOXC1, ADAMTS1, RARB, 
BCOR, HTR2B, COL11A1 
 
GO:0019724~B cell 
mediated immunity 
9 2.017937 7.58E-05 0.018221 NBN, C4A, C4B, C1R, C1S, FAS, C2, C1QC, PRKCD 
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Biological process Count % of genes p value 
 
Benjamini 
Hochberg 
adjusted p 
value 
 
Proteins 
GO:0002443~leukocyte 
mediated immunity 
11 2.466368 6.02E-05 0.018603 NBN, CADM1, C4A, LYN, C4B, C1R, C1S, FAS, C2, C1QC, PRKCD 
 
GO:0048002~antigen 
processing and 
presentation of peptide 
antigen 
 
7 1.569507 5.88E-05 0.021173 CD209, HFE, MR1, HLA-DOA, TAPBPL, B2M, HLA-F 
GO:0002250~adaptive 
immune response 
10 2.242152 1.35E-04 0.029027 NBN, CADM1, C4A, C4B, C1R, C1S, FAS, C2, C1QC, PRKCD 
 
GO:0002460~adaptive 
immune response based 
on somatic recombination 
of immune receptors  
 
10 2.242152 1.35E-04 0.029027 NBN, CADM1, C4A, C4B, C1R, C1S, FAS, C2, C1QC, PRKCD 
GO:0019882~antigen 
processing and 
presentation 
10 2.242152 2.41E-04 0.046663 AZGP1, CD209, HLA-DRB4, HFE, MR1, HLA-DOA, TAPBPL, 
PSMB9, B2M, HLA-F 
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As shown in Figure 20, enrichment analysis identified 9.42% of the 
differentially regulated genes to be involved in regulation of cell proliferation, while 
biological processes involving immune response were also significantly enriched. 
 
 
Figure 20: Graphical representation of statistically significant (Benjamani Hochberg 
adjusted p ≤ 0.05) Gene Ontology enriched biological processes of 449 differentially 
expressed genes with p ≤ 0.05 and fold change of ≥ 1.3 between experimental 
groups of 11 monosomy 3 tumours that developed metastatic disease compared to 
9 disomy 3 tumours that did not develop metastatic disease. 
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Differentially expressed genes in each disease group of monosomy 3 
tumours that developed metastatic disease and disomy 3 tumours that did not 
develop metastatic disease were also analysed and compared directly using the 
PANTHER Database (http://www.pantherdb.org/) (315–317), for gene 
categorization according to biological process, molecular function, gene class and 
PANTHER pathway. Figure 21 shows the biological processes of genes that were 
upregulated in M3M and D3NM. A similar number of genes involved in apoptosis, 
biological regulation and cellular process and localisation were found in both 
groups. A higher number of genes involved in response to stimulus (15.4% vs. 9.4%) 
and immune system process (15.4% vs. 0%) were found in M3M compared to 
D3NM. Within these categories, statistically significant enrichment of processes 
involving complement activation (p: 0.003) and immune response (p: 0.044) were 
found based on the level of differential expression of genes in M3M compared to 
D3NM. Significant enrichment of phagocytosis was also found (p: 0.035). A lower 
number of genes involving metabolic process (45.4% vs. 51.3%), biological adhesion 
(7.9% vs. 11.1%) and developmental process (17.1% vs. 26.1%) were found M3M 
compared to D3NM. Within developmental process, significant enrichment of 
angiogenesis (p: 0.001), nervous system development (p: 0.001) and ectoderm 
development ( p: 0.024) were found based on the level of differential expression of 
these genes in D3NM compared to M3M. The difference in other categories was 
not significant.  
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Figure 21: Graphical representation of biologic processes of genes that were 
upregulated in 11 monosomy 3 tumours that developed metastatic disease (M3M, 
246 genes) and 9 in disomy 3 tumours that did not develop metastatic disease 
(D3NM, 203 genes). Based on differential gene expression level, processes involving 
immune system (p: 0.044) and response to stimulus (p: 0.031) were significantly 
enriched in M3M while developmental process (p: 0.001) was significantly enriched 
in D3NM. 
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Table 14 shows statistically significant biological process enrichment based 
on differential gene expression level in M3M compared to D3NM. Differential 
expression of genes in processes involving immune response and localisation were 
significantly higher in M3M while that of genes involved in angiogenesis, nervous 
system and ectoderm development were lower in M3M. 
 
Table 14: Statistically significant biological process enrichment based the level of 
differential expression of genes in 11 monosomy 3 tumours that that developed 
metastasis (M3M) compared to 9 disomy 3 tumours that did not develop 
metastasis (D3NM). ↑ and ↓ indicate increased and decreased expression in M3M. 
Biological Process 
Number of 
genes 
Expression 
in “M3M” 
P value 
Nervous system 
development 
32 ↓ 0.001 
Angiogenesis 12 
↓ 
0.001 
Complement activation 6 
↑ 
0.003 
Ectoderm development 32 ↓ 0.024 
Phagocytosis 4 ↑ 0.035 
Immune response 26 ↑ 0.044 
 
 
146 
 
Figure 22 shows the molecular function of genes that were upregulated in 
M3M and D3NM. Overall, a similar number of genes in each category were found. A 
higher number of genes with enzyme regulator (10% vs. 7.5%) and catalytic activity 
(34.3% vs. 31.7%) were found in M3M compared to D3NM. Lower number of genes 
with structural molecule (3.9% vs. 9%), receptor (10.4% vs. 12.6%) and binding 
activity (28.6% vs. 35.7%) were found M3M compared to D3NM. Based on the level 
of differential gene expression, only binding activity was significantly enriched in 
D3NM compared to M3M (n=3, p: 0.011). The difference in other categories was 
not significant.  
 
Figure 22: Graphical representation of molecular function of genes that were 
upregulated in 11 monosomy 3 tumours that developed metastatic disease (M3M, 
246 genes) and in 9 disomy 3 tumours that did not develop metastatic disease 
(D3NM, 203 genes). A higher number of genes with enzyme regulator and catalytic 
activity were found in M3M compared to D3NM while lower number of genes with 
structural molecule, receptor and binding activity were found M3M compared to 
D3NM. Based on the level of differential gene expression, binding activity was 
significantly enriched in D3NM compared to M3M (p: 0.011). 
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Figure 23 shows genes in PANTHER pathways that were upregulated in 
M3M and D3NM. A similar number of genes in both disease groups were found 
in most pathway categories. Compared to D3NM, higher number of genes 
involved in apoptosis signalling (1.8% vs. 1%), p53 pathway (1.1% vs. 0%), 
inflammation mediated by chemokine and cytokine  signalling pathway (2.1% vs. 
1%), heterotrimetric G-protein (2.5% vs. 0.5%) and PDGF signalling (2.5% vs. 
1.5%) pathways were found in M3M but these were not significantly enriched 
based on differential gene expression levels. A lower number of genes involved 
in Wnt signalling (1.4% vs. 2.5%) and cadherin signalling (0.4% vs. 3.5%) pathway 
was found in M3M compared to D3NM. Significant enrichment of the latter was 
found based on the level of differential gene expression (p: 0.014).  
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Figure 23 shown above: Graphical representation of genes in PANTHER pathways 
that were upregulated in 11 monosomy 3 tumours that developed metastatic 
disease (M3M, 246 genes) and in 9 disomy 3 tumours that did not develop 
metastatic disease (D3NM, 203 genes). Higher number of genes involved in 
apoptosis signalling, p53 pathway, inflammation mediated by chemokine and 
cytokine  signalling pathway, heterotrimetric G-protein and PDGF signalling 
pathways were found in M3M, while a lower number of genes involved in Wnt 
signalling (1.4% vs. 2.5%) and cadherin signalling (0.4% vs. 3.5%) pathway was 
found in M3M compared to D3NM. Based on differential gene expression level, 
significant enrichment of cadherin signalling pathway was found (p: 0.014). Due 
the high number of pathways identified with the total number of differentially 
expressed genes, those with less than 0.5% difference between M3M and D3NM 
are not shown. 
 
Figure 24 shows gene classes that were upregulated in M3M and D3NM. 
A higher number of genes associated with calcium binding proteins (3.2% vs. 
2.5%), chaperones (2.5% vs. 0%), defence/immunity protein (6.8% vs. 4%), 
enzyme modulator (10.7% vs. 9%), ligase (3.2% vs. 2.5%), and signalling 
molecules (6.4% vs. 5.5%) were found in M3M. Compared to D3NM, a lower 
number of cell adhesion molecules (2.5% vs. 6%), cytoskeletal protein (3.2% vs. 
6%), extracellular matrix protein (2.5% vs. 5%), hydrolase (10.7% vs. 12.6%), 
membrane traffic protein (0.7% vs. 2%), nucleic acid binding (9.3% vs. 13.1%), 
oxidoreductase (3.2% vs. 5%), phosphatase (2.1% vs. 4%), receptor (10.4% vs. 
12.6%), structural protein (0% vs. 2%), transcription factor (6.8% vs. 11.1%), and 
transfer/carrier protein (3.2% vs. 4.5%) were found in M3M. A similar number of 
genes in classes such as cell junction protein, isomerase, kinase, lyase, protease, 
surfactant, transferase, transmembrane receptor regulatory/adaptor protein and 
transporter proteins were found in both M3M and D3NM.  
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Figure 24: Graphical representation showing gene class that were upregulated in 
11 monosomy 3 tumours that developed metastatic disease (M3M, 246 genes) 
and in 9 disomy 3 tumours that did not develop metastatic disease (D3NM, 203 
genes). Based on differential gene expression level, significant enrichment of 
gene classes associated with cell adhesion molecule (p: 0.041), 
defence/immunity protein (p: 0.003), cytoskeletal protein (p: 0.03) and 
transcription factor (p: 0.01) were found. Due the high number of gene classes 
present within the total number of differentially expressed genes, those with less 
than 0.5% difference between M3M and D3NM are not shown.  
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Based on differential gene expression levels, significant enrichment in 
several gene classes were found. Compared to M3M, significant enrichment of 
cell adhesion molecule, cytoskeletal protein, membrane traffic protein, structural 
protein and transcription factor were found in D3NM. These are outlined in Table 
15. 
 
Table 15: Statistically significant gene class enrichment based the level of 
differential expression of genes in 11 monosomy 3 tumours that developed 
metastasis (M3M, 246 genes) compared to 9 disomy 3 tumours that did not 
develop metastasis (D3NM, 203 genes). ↑ and ↓ indicate increased and 
decreased expression in M3M. 
Gene class 
Number of 
genes 
Expression in 
“M3M” 
P value 
Cell adhesion molecule 19 ↓ 0.041 
Cytoskeletal protein 12 
↓ 
0.029 
Defence/immunity protein 6 
↑ 
0.029 
Membrane traffic protein 6 ↓ 0.023 
Structural protein 4 ↓ 0.037 
Transcription factor 11 ↓ 0.015 
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3.3. Validation of selected targets by 
immunohistochemistry 
 
In label-free LC-MS proteomic analysis of 8 primary UM tissue from 
patients who developed metastatic disease versus 8 from patients who did not 
develop metastatic disease, thioredoxin-dependant peroxidase reductase 
(PRDX3) was upregulated by 1.58 fold (p: 0.002) and cytosolic non-specific 
dipeptidase (CNDP2) was downregulated by 1.75 fold (p: 0.001) in primary UM 
tissues from patients that developed metastasis compared to those that did not. 
These targets demonstrated the most distinguishable difference of protein 
abundance in individual samples between the two disease groups (Figure 10).  
 
In the bioinformatic reanalysis of gene expression microarray data of 
monosomy 3 tumours with metastasis versus disomy 3 tumours that did not 
develop metastatic disease, signal-induced proliferation-associated 1-like protein 
2 (SIPA1L2) was upregulated by 1.516 fold (p: 0.00107) and contactin 3 (CNTN3) 
was downregulated by 3.068 fold (p: 0.000807) in monosomy 3 tumours that 
developed metastasis compared to disomy 3 tumours that did not metastasise. 
These targets were selected based on high statistical significance of differential 
expression, fold change and biological function.  
 
To determine the expression of these proteins in UM tissues, a total of 26 
full face UM tumour sections of 13 patients that developed metastasis (mUM) 
versus 13 that did not develop metastasis (nmUM) were used for 
immunohistochemistry for PRDX3, CNDP2, SIPA1L2 and CNTN3. Based on this 
pilot study, PRDX3 was selected for immunohistochemical validation in a larger 
cohort of 92 primary UM tissue microarray samples of 55 tumours that 
developed metastasis and 37 that did not develop metastasis. The 
immunohistochemical staining for the selected proteins were assessed by two 
observers who were blinded to all clinicopathologic and cytogenetic details 
including metastatic/non-metastatic information (Pathma Ramasamy, Anne-
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Marie Larkin). A scoring system similar to the one first described by Remmele 
and Stegner (318), and adapted by Coupland et al (243) was used. The full face 
UM section slides were scored based on intensity of staining (A) and percentage 
of tumour cells that stained (B). Intensity was graded as 0 for no staining, 1+ for 
weak, 2+ for moderate and 3+ for strong staining. A percentage score was 
assigned as follows: 1 (0-49%), 2 (50-74%), 3 (75-89%) and 4 (90-100%). A total 
score was obtained by multiplying (A) and (B). Thus, a minimum score of 0 and a 
maximum score of 12 was obtained. 
 
3.3.1. Demographics and clinicopathologic details of  
primary uveal melanoma tissues  
 
The demographics, clinicopathologic and cytogenetic details of 26 full 
face tumour sections of 13 patients that developed metastasis (mUM) versus 13 
that did not develop metastasis (nmUM) are outlined in Table 17. Patients who 
metastasised were diagnosed with UM between 1994-2010. Patients without 
metastasis were diagnosed with UM between 1994-2006 and were metastasis-
free for a period of 7-19 years (up to 2013). There were 11 males and 15 females. 
The mean age of diagnosis is 59.04 years (range: 35-88, SD: 13.75). Nine patients 
(69.2%) developed metastases to the liver, 2 to the lung, 1 to the kidney and 1 to 
both liver and skin. The mean survival for patients who developed metastases is 
41 months (range: 4-142, SD: 41.35). In total, 6 (23.1%) patients also had ciliary 
body involvement. Of those, 5 patients developed metastatic disease (4 
developed liver metastasis and 1 developed lung metastasis). In total, 10 patients 
(38.5%) had epithelioid cell type; 7 of those (70%) had metastatic disease. There 
were ten patients (38.5%) with mixed (spindle and epithelioid cell types) cell 
type; 4 developed metastasis and 6 did not. Six patients (23%) had spindle cell 
type tumours; 2 developed metastasis and 4 did not. The majority of tumours (16 
patients, 61.5%) did not exhibit extrascleral extension, one tumour that 
developed metastasis demonstrated extrascleral extension while this 
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information was unavailable for 9 tumours. Twenty tumours had largest tumour 
dimension (LTD) information available. The mean LTD was 13.5 mm (range: 8-20, 
SD: 4.55). There was no tumour size information available for 6 tumours. Five 
tumours (25%) were classified as small (<10mm), 9 (45%) were medium (10-
15mm), and 6 (30%) were large (>15mm). One out of 5 small tumours, 5 out of 9 
medium tumours and 4 out of 6 large tumours developed metastasis. All 13 UM 
tumours of patients that developed metastasis demonstrated chromosome 3 
monosomy. There were no monosomy 3 tumours in the non-metastasised group. 
Of the 13 UM tumours of patients that did not develop metastasis, 7 (53.8%) 
were disomy 3 tumours, 2 (15.4%) were trisomy 3 while chromosome 3 
information was not available for 4 (30.8%) tumours. A summary of 
demographics, clinical, histopathologic and cytogenetic details of 26 patient 
tumours analysed are outlined in table 16. 
 
 
 
 
Table 16: Demographics, clinical, histopathologic and cytogenetic details of 26 
uveal melanoma patient tumours analysed for immunohistochemical expression 
of thioredoxin-dependant peroxidase reductase 3 (PRDX3), cytosolic non-specific 
dipeptidase (CNDP2), contactin 3 (CNTN3) and signal-induced proliferation-
associated 1-like protein 2 (SIPA1L2). NA: not available 
 
Metastasis (mUM) 
No metastasis 
(nmUM) Total 
Mean age of 
diagnosis 
(years) 
60.46 (SD: 15.04)    
Range: 36 - 88 
57.62 (SD: 12.78)    
Range: 35 - 77 
59.04 (SD 13.75)     
Range 35 - 88 
Dead 13 (100%) 0 13/26 (50%) 
Mean survival 
(months) 
41.0 (SD: 41.35)     
Range: 4 - 142   
Male 3 (23.1%) 8 (61.5%) 11 (42%) 
Female 10 (76.9%) 5 (38.5%) 15 (57.7%) 
Metastasis/No 
metastasis 
13 (50%) 13 (50%) 26 (100%) 
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Metastasis (mUM) 
No metastasis 
(nmUM) Total 
Liver 9 (69.2%) - - 
Lung 2 (15.4%) - - 
Kidney 1 (7.7%) - - 
Kidney and 
skin 
1 (7.7%) - - 
Ciliary body 
involvement 
5 (38.4%) 1 (7.7%) 6/26 (23.1%) 
Extrascleral extension 26 
No 9 (69.2%) 7 (53.9%) 16 (61.5%) 
Yes 1 (7.7%) 0 1 (3.8%) 
NA 3 (23.1%) 6 (46.1%) 9 (34.6%) 
Cell types 26 
Spindle 2 (15.3%) 4 (30.8%) 6 (23.1%) 
Epithelioid 7 (53.9%) 3 (23.1%) 10 (38.5%) 
Mixed 4 (30.8%) 6 (46.1%) 10 (38.5%) 
Tumour size 26 
Small (< 
10mm) 
1 (7.7%) 4 (30.8%) 5 (19.2%) 
Medium  
(10-15mm) 
5 (38.4%) 4 (30.8%) 9 (34.6%) 
Large (> 
15mm) 
4 (30.8%) 2 (15.3%) 6 (23.1%) 
NA 3 (23.1%) 3 (23.1%) 6 (23.1%) 
Chromosome 3 status 17/92 (18.5%) 
Monosomy 3 13 (100%) 0 13 (50%) 
Disomy 3 0 7 (53.8%) 7 (26.9%) 
Trisomy 0 2 (15.4%) 2 (7.7%) 
NA 0 4 (30.8%) 4 (15.4%) 
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Table 17: Clinical, histopathologic and cytogenetic details of full uveal melanoma sections used for immunohistochemistry 
Sample Sex Age at 
diagnosis 
(years) 
Metastatic 
sites 
Survival 
after 
diagnosis 
(months) 
Ciliary body 
involvement 
Extrascleral 
extension 
Cell type LTD Chr. 3 
1 F 58 Liver 62 Y NA M NA Monosomy 
2 F 39 Kidney 142 N N S Medium Monosomy 
3 F 88 Liver 5 N N M NA Monosomy 
4 M 71 Lung 26 N N M Medium Monosomy 
5 F 50 Liver, skin 64 N NA S Small Monosomy 
6 M 54 Liver 18 Y N M Large Monosomy 
7 F 58 Liver 52 N N E Large Monosomy 
8 F 51 Liver 8 N N E Medium Monosomy 
9 F 73 Liver 4 Y N E Medium Monosomy 
10 M 72 Liver 92 N Y E Large Monosomy 
11 F 76 Liver 10 Y NA E NA Monosomy 
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Sample Sex Age at 
diagnosis 
(years) 
Metastatic 
sites 
Survival 
after 
diagnosis 
(months) 
Ciliary body 
involvement 
Extrascleral 
extension 
Cell type LTD Chr. 3 
12 F 36 Lung 7 Y N E Large Monosomy 
13 F 60 Liver 43 N N E Medium Monosomy 
14 M 51 None NA N N S Small NA 
15 F 43 None NA N N S Small Normal 
16 M 68 None NA N N E Medium Trisomy 
17 F 64 None NA N N E Medium Normal 
18 M 69 None NA Y N S Large Normal 
19 F 77 None NA N NA M NA Normal 
20 F 53 None NA N NA M NA Normal 
21 F 56 None NA N N E Large Normal 
22 M 74 None NA N NA M Small NA 
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Sample Sex Age at 
diagnosis 
(years) 
Metastatic 
sites 
Survival 
after 
diagnosis 
(months) 
Ciliary body 
involvement 
Extrascleral 
extension 
Cell type LTD Chr. 3 
23 M 54 None NA N NA M Medium Trisomy 
24 M 43 None NA N NA M NA NA 
25 M 35 None NA N N M Medium Normal 
26 M 62 None NA N NA S Small NA 
N, no; Y, yes; S, spindle cells; E, epithelioid cells; M, mixed cells; LTD, largest tumour diameter; NA, not available. 
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For the larger tissue microarray study, 92 tumour samples were used for PRDX3 
immunohistochemistry. Each UM tumour sample was represented by 4 tissue 
cores in the TMA slides. The full demographics, clinicopathologic and cytogenetic 
details of these patients are outlined in supplementary data appendix III (). There 
were 55 tumours (59.8%) from patients that developed metastatic disease, while 
37 (40.2%) were from patients that did not develop metastasis. Patients who 
metastasised were diagnosed with UM between 1994-2010. The majority of 
patients without metastasis (31/37, 83.8%) were diagnosed with UM between 
1994-2006 and were metastasis-free for a period of 7-19 years (up to 2013). 
There were 2 patients diagnosed in 2007 with monosomy 3 tumours that are 
metastasis-free for at least 6 years, and one patient diagnosed in 2009 with 
monosomy 3 tumour is metastasis-free for at least 4 years. A further 3 patients 
with disomy 3 tumours that are metastasis-free for at least 4 years were also 
included. Forty-nine (53.3%) were males and 43 (46.7%) were females. The mean 
age of diagnosis is 59.77 years (SD 14.82, range 24.75-93.75). Twenty-nine 
patients developed metastasis to the liver (52.7%), 3 to the lung (5.5%), 2 to the 
brain (3.6%), 2 to the spine (3.6%) while 6 patients developed multiple 
metastases including the liver (10.9%). Metastatic site information was not 
available for 13 patients (23.6%). Fifty-four patients have died from metastasis (1 
patient still alive with liver metastasis diagnosed in 2013). Twenty three (62.2%) 
patients without metastasis are still alive while 14 (37.8%) have died of causes 
unrelated to UM. Fourteen tumours (15.2%) also involved the ciliary body and 11 
(78.7%) of these developed metastasis. Forty-seven tumours were of mixed cell 
type (51.1%), 31 were spindle (33.8%) and 13 (14.1%) were epithelioid. The 
majority of tumours (n=78, 84.8%) did not exhibit extrascleral extension, 7 
tumours (7.6%) had extrascleral extension and this information was not available 
for 7 cases. Twelve tumours (13%) were classified as small (<10mm), 23 (25%) 
were medium (10-15mm), 46 (50%) were large (>15mm) while this information 
was unavailable for 11 cases (12%). Chromosome 3 information was available for 
17 tumours; 10 were monosomy 3 and 7 were disomy 3 (58.8% and 41.2% 
respectively). In patients with monosomy 3 tumours, 6 (60%) developed 
metastasis. The remaining 4 patients with monosomy 3 tumours, diagnosed 
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between 2005 and 2009, are metastasis-free while all 7 patients with disomy 3 
tumours did not develop metastasis. The demographics, clinical, histopathologic 
and cytogenetic details of 92 patient tumours analysed are outlined in Table 18. 
 
 
Table 18: Demographics, clinical, histopathologic and cytogenetic details of 92 
uveal melanoma patient tumours analysed for immunohistochemical expression 
of thioredoxin-dependant peroxidase reductase 3 (PRDX3) using tissue 
microarray. NA: not available 
 
Metastasis No metastasis Total 
Mean age of 
diagnosis 
(years) 
61.81 (SD: 14.6)      
Range: 31.25 - 93.75 
56.76 (SD: 14.84)   
Range: 24.75 - 85.0 
59.77 (SD 14.82)    
Range: 24.75-93.75 
Dead 54/55 (98.2%) 14/37 (37.8%)* 68/92 (73.9%) 
Mean survival 
(months) 
64.04 (SD: 77.84)   
Range: 3 - 427 
189.07 (SD: 53.73) 
Range: 96 - 328 
89.78 (SD: 89.15)   
Range: 3 - 427 
Male 30 (61.2%) 19 (38.8) 49 (53.3%) 
Female 25 (58.1%) 18 (41.9%) 43 (46.7%) 
Metastasis/No 
metastasis 
55 (59.8%) 37 (40.2%) 92 (100%) 
Liver 29 (52.7%) - - 
Lung 3 (5.5%) - - 
Brain 2 (3.6%) - - 
Spine 2 (3.6%) - - 
Multiple 6 (10.9%) - - 
Site NA 13 (23.6%) - - 
Ciliary body 
involvement 
11 (78.7%) 3 (21.3%) 14 (15.2%) 
Extrascleral extension 92 
No 45 (57.7%) 33 (42.3%) 78 (84.8%) 
Yes 6 (85.7%) 1 (14.3%) 7 (7.6%) 
NA 4 (57.1%) 3 (42.9%) 7 (7.6%) 
Cell types 92 
Spindle 16 (51.6%) 15 (48.4%) 31 (33.7%) 
Epithelioid 10 (76.9%) 3 (23.1%) 13 (14.1%) 
Mixed 28 (59.6%) 19 (40.4%) 47 (51.1%) 
NA 1 (100%) 0 1 (0.1%) 
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Metastasis No metastasis Total 
Tumour size 92 
Small (< 
10mm) 
3 (33.3%) 9 (66.7%) 12 (13%) 
Medium  
(10-15mm) 
13 (56.5%) 10 (43.5%) 23 (25%) 
Large (> 
15mm) 
32 (69.6%) 14 (30.4%) 46 (50%) 
NA 7 (63.6%) 4 (36.4%) 11 (12%) 
Chromosome 3 status 17/92 (18.5%) 
Monosomy 3 6 (60%) 4 (40%) 10 (58.8%) 
Disomy 3 0 7 (100%) 7 (41.2%) 
NA 49 (65.3%) 26 (34.7%) 75 (81.5%) 
*Cause of death unrelated to uveal melanoma 
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3.3.2. Pilot immunohistochemistry study in full face uveal 
melanoma tissue sections 
 
To determine the expression of selected target proteins in UM tissues, a 
total of 26 full face UM tumour sections of 13 patients that developed metastasis 
(mUM) versus 13 that did not develop metastasis (nmUM) were used for 
immunohistochemistry for PRDX3, CNDP2, SIPA1L2 and CNTN3. Based on this, 
further validation of the most promising target was carried out in a larger cohort 
of 147 UM tissue microarray samples. 
 
3.3.2.1. Thioredoxin-dependent peroxidase reductase 
(PRDX3) 
 
In LC-MS/MS label-free analysis, PRDX3 was upregulated by 1.58 fold (p: 
0.002) in primary UM tissues from patients that developed metastasis compared 
to those that did not. To determine the expression of PRDX3 in primary UM 
tissues, immunohistochemical staining of PRDX3 was performed on 13 primary 
UM tumours of patients that developed metastatic disease (mUM) and 13 
primary UM tumours of patients that did not develop metastasis (nmUM). The 
demographics and clinicopathologic details of these samples are outlined in 
Table 17. Staining of PRDX3 in UM tissues was cytoplasmic with no nuclear 
staining.  
 
In mUM, the mean score was 8.3 (median: 8, range: 4-12, SD: 2.43). There 
were no tumours that showed negative (0) or weak staining (1+). Ten (76.9%) 
tumours showed moderate (2+) staining that ranged from 50-100% and 3 
tumours (23.1%) showed strong staining (3+) throughout the tumour. Tumours 
that showed strong staining in mUM were from patients that developed 
metastasis and died within 10 months of diagnosis.  
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In nmUM, the mean score was 5.85 (median: 4, range: 2-12, SD 3.6). 
There were no tumours that showed negative staining. Four (30.8%) tumours 
showed weak staining ranging between 40-80%, 5 (38.4%) showed moderate 
staining ranging between 40-100% and 4 showed strong staining ranging 
between 50-100% staining of tissues. Representative immunohistochemical 
expression of PRDX3 in UM tissues are shown in Figure 25. 
 
A trend towards higher expression score in mUM compared to nmUM 
was observed, but it was not statistically significant (Mann-Whitney U test, p: 
0.061). No significant difference was seen when comparing the intensity of 
staining between mUM and nmUM (p: 0.435, Mann-Whitney U test). However, a 
significant difference between percentage of tumour cells staining was seen (p: 
0.011, Mann-Whitney U test). A summary of the expression of PRDX3 in all 26 
UM tissues are shown in Table 19. 
 
 
 
 
 
 
  
164 
 
 
Figure 25: Representative immunohistochemical slides of thioredoxin-dependant 
peroxidase reductase 3 (PRDX3) expression in uveal melanoma tissues, showing 
different intensities of cytoplasmic staining. (i) Strong staining in sample 9 mUM; 
(ii) Moderate staining in areas (white arrow) and scattered areas of melanin 
(black arrow) in sample 18 nmUM; (iii) Weak staining and scattered areas of 
dense melanin in sample 15 nmUM; (iv) Negative control showing no staining. 
LC-MS proteomic profiling of primary UM tissues identified upregulation of 
PRDX3 in tissues of patients who developed metastasis compared to those who 
did not develop metastasis. Immunohistochemical expression in 13 primary UM 
tissues of patients who developed metastasis (mUM) and 13 patients who did 
not develop metastasis (nmUM) showed a trend toward higher expression score 
in mUM (p: 0.061, Mann-Whitney U test). Magnification X 400, scale bar=100µm  
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Table 19: Summary of results of thioredoxin-dependant peroxidase reductase 3 
(PRDX3) immunohistochemistry in 13 primary UM tissues of patients who 
developed metastasis (mUM) and 13 patients who did not develop metastasis 
(nmUM). LC-MS proteomic profiling of 16 primary UM tissues identified 
upregulation of PRDX3 (1.58 fold, p: 0.002) in tissues of patients who developed 
metastasis (n=8) compared to those who did not develop metastasis (n=8). 
*Significant difference in percentage of tumour cells staining 
 
Metastasis (n=13) 
No metastasis 
(n=13) 
Overall staining score (0-12) 
Mean: 8.3, SD: 2.43 
Median: 8, Range: 4-
12 
Mean: 5.85, SD: 3.6 
Median: 4, Range: 2-
12 
Difference in scores,  p 0.061† 
Staining 
Weak intensity  
Percentage staining 
range 
0 
- 
4 
60-80% 
Moderate intensity 
Percentage staining 
range 
10 
50-100% 
5 
40-100% 
Strong intensity 
Percentage staining 
range 
3 
100% 
4 
50-100% 
Difference in staining intensity, p 0.435† 
Difference in staining percentage, 
p 
0.011†* 
†Mann Whitney U 
  
166 
 
No significant correlation between PRDX3 score and survival in patients 
with metastatic disease was found (p: 0.502, Spearman correlation). Higher 
expression of PRDX3 significantly correlated with monosomy 3 tumours 
compared to disomy/trisomy 3 (p: 0.014, Spearman correlation). No significant 
correlation between PRDX3 score and cell type was found (p: 0.693, Spearman 
correlation). Furthermore, no significant correlation between PRDX3 score and 
tumour size was identified (p: 0.462, Spearman Correlation). Higher PRDX3 score 
was seen in tumours with ciliary body involvement, but this was not statistically 
significant (p: 0.059, Spearman correlation). No significance between PRDX3 
score and extrascleral extension was found (p: 0.684, Spearman correlation). 
These results are summarised in table 20. 
 
Table 20: Correlation between thioredoxin-dependant peroxidase reductase 3 
(PRDX3) immunohistochemistry score in 13 primary UM tissues of patients who 
developed metastasis (mUM) and 13 patients who did not develop metastasis 
(nmUM), and clinicopathological parameters. All p values were derived from 
Spearman correlation. *Statistically significant correlation between higher PRDX3 
score and aggressive monosomy 3 tumours was found. 
 
PRDX3 expression score (p value) 
Survival 0.502 
Chromosome 3 status 0.014* 
Cell type 0.693 
Tumour size 0.462 
Ciliary body involvement 0.059 
Extrascleral extension 0.684 
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3.3.2.2. Cytosolic non-specific dipeptidase 2 (CNDP2) 
 
In LC-MS/MS label-free analysis, CNDP2 was downregulated by 1.75 fold 
(p: 0.001) in primary UM tissues from patients that developed metastasis 
compared to those that did not. Immunohistochemical staining of CNDP2 was 
performed on 13 primary UM tumours of patients that developed metastatic 
disease (mUM) and 13 primary UM tumours of patients that did not develop 
metastasis (nmUM). The demographics and clinicopathologic details of these 
samples are outlined in Table 17. Despite using a higher concentration of CNDP2 
antibody, the overall staining intensity in UM tissues was less than that of PRDX3, 
and was cytoplasmic with no nuclear staining.  
 
In mUM, the mean score was 5.31 (median: 4, range: 0-12, SD: 3.04). One 
tumour showed negative staining while 4 tumours (30.8%) showed weak (1+) 
staining that ranged between 90-100% of the tumours. Six tumours (46.2%) 
showed moderate (2+) staining that ranged from 50-100% while 2 tumours 
(15.4%) showed strong staining (3+) between 40-100% of tumour tissue. 
 
In nmUM, the mean score was 6.08 (median: 4, range: 2-12, SD 3.73). 
There were no tumours that showed negative staining. Five tumours (38.5%) 
showed weak staining ranging between 50-90%, 2 (15.4%) showed moderate 
staining ranging between 60-90% and 6 showed strong staining ranging between 
30-90% staining of tumour tissues. Representative immunohistochemical 
expression of CNDP2 in UM tissues are shown in Figure 26. 
 
No clear trend towards lower expression score in mUM compared to nmUM was 
observed (p: 0.752, Mann-Whitney U test). No significant difference was seen 
when comparing the intensity or percentage of staining between mUM and 
nmUM (p: 0.318 and p: 0.113 respectively, Mann-Whitney U). Summary of the 
expression of CNDP2 in 26 UM tissues are shown in Table 21. 
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Figure 26: Representative immunohistochemical slides of cytosolic non-specific 
dipeptidase (CNDP2) expression in uveal melanoma tissues, showing different 
intensities of cytoplasmic staining. Relative to other targets, the overall staining 
intensity of CNDP2 was less, and was graded accordingly. (i) Strong staining in 
sample 21 nmUM; (ii) Moderate staining in sample 3 mUM; (iii) Weak staining 
and scattered areas of melanin in sample 11 mUM; (iv) Negative control showing 
no staining. LC-MS proteomic profiling of primary UM tissues identified 
downregulation of CNDP2 in tissues of patients who developed metastasis 
compared to those who did not develop metastasis. Immunohistochemical 
expression in 13 primary UM tissues of patients who developed metastasis 
(mUM) and 13 patients who did not develop metastasis (nmUM) did not show a 
significant difference in expression score between the two groups (p: 0.752, 
Mann-Whitney U test). Magnification X 400, scale bar =100 µm  
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Table 21: Summary of results of cytosolic nonspecific dipeptidase reductase 
(CNDP2) immunohistochemistry in 13 primary UM tissues of patients who 
developed metastasis (mUM) and 13 patients who did not develop metastasis 
(nmUM). LC-MS proteomic profiling of 16 primary UM tissues identified 
downregulation of CNDP2 (1.75 fold, p: 0.001) in tissues of patients who 
developed metastasis (n=8) compared to those who did not (n=8). 
 
Metastasis (n=13) 
No metastasis 
(n=13) 
Overall staining score (0-12) 
Mean: 5.31, SD: 3.04 
Median: 4, Range: 0-
12 
Mean: 6.08, SD: 3.73 
Median: 4, Range: 2-
12 
Difference in scores,  p 0.752† 
Staining 
Negative 
Percentage staining 
range 
1 
100% 
- 
- 
Weak intensity  
Percentage staining 
range 
4 
90-100% 
5 
50-90% 
Moderate intensity 
Percentage staining 
range 
6 
50-100% 
2 
60-90% 
Strong intensity 
Percentage staining 
range 
2 
40-100% 
6 
30-90% 
Difference in staining intensity, p 0.318† 
Difference in staining percentage, 
p 
0.113† 
†Mann Whitney U  
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No significant correlation between CNDP2 score and survival in patients 
with metastatic disease was found (p: 0.323, Spearman correlation). Higher 
expression of CNDP2 significantly correlated with disomy/trisomy 3 tumours 
compared to monosomy 3 (p: 0.045, Spearman correlation). No significant 
correlation between CNDP2 score and cell type was found (p: 0.563, Spearman 
correlation). Furthermore, no significant correlation between CNDP2 score and 
tumour size, ciliary body involvement or extrascleral extension was identified (p: 
0.831, p: 0.336 and p: 0.753 respectively, Spearman Correlation). These results 
are summarised in table 22. 
 
 
Table 22: Correlation between cytosolic nonspecific dipeptidase reductase 
(CNDP2) immunohistochemistry score in 13 primary UM tissues of patients who 
developed metastasis (mUM) and 13 patients who did not develop metastasis 
(nmUM), and clinicopathological parameters. All p values were derived from 
Spearman correlation.. *Statistically significant correlation between higher 
CNDP2 score and non-aggressive disomy/trisomy 3 tumours was found. 
 
 CNDP2 expression score, p value 
Survival 0.323 
Chromosome 3 status 0.045* 
Cell type 0.563 
Tumour size 0.831 
Ciliary body involvement 0.336 
Extrascleral extension 0.753 
 
  
171 
 
3.3.2.3. Contactin 3 (CNTN3) 
 
In the bioinformatic reanalysis of gene expression microarray data of 
monosomy 3 tumours with metastasis (M3M) versus disomy 3 tumours without 
metastasis (D3NM), CNTN3 was downregulated by 3.07 fold (p: 0.0008) in M3M 
compared to D3NM. Immunohistochemical staining of CNTN3 was performed on 
13 primary UM tumours of patients that developed metastatic disease (mUM) 
and 13 primary UM tumours of patients that did not develop metastasis 
(nmUM). The demographics and clinicopathologic details of these samples are 
outlined in Table 17. Staining of CNTN3 in UM tissues was cytoplasmic with no 
nuclear staining.  
 
In mUM, the mean score was 2.54 (median: 1, range: 0-12, SD: 3.71). Six 
tumours (46.2%) showed negative staining while 3 tumours (23.1%) showed 
weak (1+) staining that ranged between 30-100% of the tumours. Three tumours 
(23.1%) showed moderate (2+) staining that ranged from 20-100% while 1 
tumours (7.7%) showed strong staining (3+) between 40-100% of tumour tissue. 
 
In nmUM, the mean score was 3.31 (median: 4, range: 1-8, SD: 2.10). 
There were no tumours that showed negative staining. Eight tumours (61.5%) 
showed weak staining ranging between 20-90% and 5 (38.5%) showed moderate 
staining ranging between 20-90%. No tumours demonstrated strong staining. 
Representative immunohistochemical expression of CNTN3 in UM tissues are 
shown in Figure 27. 
 
A trend towards lower expression score in mUM compared to nmUM was 
observed but it was not statistically significant (p: 0.099, Mann-Whitney U test). 
No significant difference was seen when comparing the intensity or percentage 
of staining between mUM and nmUM (p: 0.127 and p: 0.154 respectively, Mann-
Whitney U test). A summary of the expression of CNTN3 in all 26 UM tissues are 
shown in table 23. 
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Figure 27: Representative immunohistochemical slides of contactin 3 (CNTN3) 
expression in uveal melanoma tissues, showing different intensities of 
cytoplasmic staining. (i) Strong staining in sample 12 mUM; (ii) Moderate staining 
in sample 23 nmUM; (iii) Weak staining in sample 25 nmUM; (iv) no staining in 
sample 1 mUM. Similarly, negative controls showed no staining. Bioinformatic 
reanalysis of gene expression microarray data showed downregulation of CNTN3 
in 11 monosomy 3 tumours that developed metastasis compared to 9 disomy 3 
tumours without metastasis. Immunohistochemical expression in 13 primary UM 
tissues of patients who developed metastasis (mUM) and 13 patients who did 
not develop metastasis (nmUM) showed a trend towards lower expression score 
in mUM compared to nmUM (p: 0.099, Mann-Whitney U test). 
i: magnification X 200, scale bar = 200 µm  
ii-iv: magnification X 400, scale bar  = 100 µm  
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Table 23: Summary of results of contactin 3 (CNTN3) immunohistochemistry in 
13 primary UM tissues of patients who developed metastasis (mUM) and 13 
patients who did not develop metastasis (nmUM). Bioinformatic reanalysis of 
gene expression microarray data showed downregulation of CNTN3 (3.07 fold, p: 
0.0008) in 11 monosomy 3 tumours that developed metastasis compared to 9 
disomy 3 tumours without metastasis. 
 
Metastasis (n=13) 
No metastasis 
(n=13) 
Overall staining score (0-12) 
Mean: 2.54, SD: 3.71 
Median: 1, Range: 0-
12 
Mean: 3.31, SD: 2.10 
Median: 4, Range: 1-
8 
Difference in scores,  p 0.099† 
Staining 
Negative 
Percentage staining 
range 
6 
100% 
- 
- 
Weak intensity  
Percentage staining 
range 
3 
30-100% 
8 
20-100% 
Moderate intensity 
Percentage staining 
range 
3 
20-100% 
5 
20-90% 
Strong intensity 
Percentage staining 
range 
1 
100% 
- 
- 
Difference in staining intensity, p 0.127† 
Difference in staining percentage, 
p 
0.154† 
†Mann Whitney U  
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No significant correlation between CNTN3 score and survival in patients 
with metastatic disease was found (p: 0.728, Spearman correlation). CNTN3 
score showed no significant correlation with chromosome 3 status or cell type (p: 
0.157 and p: 0.176 respectively, Spearman correlation). Furthermore, no 
significant correlation between CNTN3 score and tumour size, ciliary body 
involvement or extrascleral extension was identified (p: 0.133, p: 0.856 and p: 
0.218 respectively, Spearman Correlation). These results are summarised in table 
24. 
 
Table 24: Correlation between contaction 3 (CNTN3) immunohistochemistry 
score in 13 primary UM tissues of patients who developed metastasis (mUM) and 
13 patients who did not develop metastasis (nmUM), and clinicopathological 
parameters. All p values were derived from Spearman correlation. 
 
 CNTN3 expression score, p value 
Survival 0.728 
Chromosome 3 status 0.157 
Cell type 0.176 
Tumour size 0.133 
Ciliary body involvement 0.856 
Extrascleral extension 0.218 
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3.3.2.4. Signal-induced proliferation-associated 1 like 2 
(SIPA1L2) 
 
In the bioinformatic reanalysis of gene expression microarray data of 
monosomy 3 tumours with metastasis versus disomy 3 tumours without 
metastasis, SIPA1L2 was upregulated by 1.52 fold (p: 0.001) in M3M compared to 
D3NM. Immunohistochemical staining of SIPA1L2 was performed on 13 primary 
UM tumours of patients that developed metastatic disease (mUM) and 13 
primary UM tumours of patients that did not develop metastasis (nmUM). The 
demographics and clinicopathologic details of these samples are outlined in 
Table 17. Staining of SIPA1L2 in UM tissues was cytoplasmic with no nuclear 
staining. Overall, the staining intensity was relatively weak compared to other 
targets, with no sample demonstrating strong staining intensity. 
 
  In mUM, the mean score was 2.85 (median: 4, range: 0-4, SD: 1.72). Three 
tumours (23.1%) showed negative staining while 8 tumours (61.5%) showed 
weak (1+) staining that ranged between 75-100% of the tumours. Two tumours 
(15.4%) showed moderate (2+) staining that ranged from 20-50% while no 
tumours showed strong staining (3+). 
 
In nmUM, the mean score was 1.62 (median: 1, range: 0-6, SD: 1.98). Six 
tumours (46.2%) showed negative staining and 6 tumours (46.2%) showed weak 
staining ranging between 40-100%. One showed moderate staining in 75% of 
tumour tissue. No tumours showed strong staining. Representative SIPA1L2 
immunohistochemical expression in UM tissues are shown in Figure 28. 
 
A trend towards higher expression score in mUM compared to nmUM 
was observed but it was not statistically significant (p: 0.094, Mann-Whitney U 
test). No significant difference was seen when comparing the intensity or 
percentage of staining between mUM and nmUM (p: 0.218 and p: 0.055 
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respectively, Mann-Whitney U test). A summary of the expression of SIPA1L2 in 
all 26 UM tissues are shown in table 25.  
 
Table 25: Summary of results of signal-induced proliferation-associated 1-like 
protein 2 (SIPA1L2) immunohistochemistry in 13 primary UM tissues of patients 
who developed metastasis (mUM) and 13 patients who did not develop 
metastasis (nmUM). Bioinformatic reanalysis of gene expression microarray data 
showed upregulation of SIPA1L2 (1.52 fold p: 0.001) in 11 monosomy 3 tumours 
that developed metastasis compared to 9 disomy 3 tumours without metastasis. 
 
 
Metastasis (n=13) 
No metastasis 
(n=13) 
Overall staining score (0-12) 
Mean: 2.85, SD: 1.72 
Median: 4, Range: 0-
4 
Mean: 1.62, SD: 1.98 
Median: 1, Range: 0-
6 
Difference in scores,  p 0.094† 
Staining 
Negative 
Percentage staining 
range 
3 
100% 
6 
100% 
Weak intensity  
Percentage staining 
range 
8 
75-100% 
6 
40-100% 
Moderate intensity 
Percentage staining 
range 
2 
20-50% 
1 
75% 
Strong intensity 
Percentage staining 
range 
- 
- 
- 
- 
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Difference in staining intensity, p 0.218† 
Difference in staining percentage, 
p 
0.055† 
†Mann Whitney U  
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Figure 28: Representative immunohistochemical slides of signal-induced 
proliferation-associated 1 like 2 (SIPA1L2) expression in uveal melanoma tissues, 
showing different intensities of cytoplasmic staining. (i) Moderate staining and 
scattered areas of melanin (black arrow) in sample 4 mUM; (ii) Moderate staining 
in sample 10 mUM; (iii) Weak staining in sample 19 nmUM; (iv) No staining in 
sample 14 mUM. Similarly, negative control showed no staining. Bioinformatic 
reanalysis of gene expression microarray data showed upregulation of SIPA1L2 in 
patients with 11 monosomy 3 tumours that developed metastasis compared to 9 
disomy 3 tumours without metastasis. Immunohistochemical expression in 13 
primary UM tissues of patients who developed metastasis (mUM) and 13 
patients who did not develop metastasis (nmUM) showed a trend towards higher 
expression score in mUM compared to nmUM (p: 0.094, Mann-Whitney U test). 
i: magnification X 200, scale bar = 200 µm  
ii-iv: magnification X 400, scale bar  = 100 µm  
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No significant correlation between SIPA1L2 score and survival in patients 
with metastatic disease was found (p: 0.055, Spearman correlation). SIPA1L2 
score showed no significant correlation with chromosome 3 status or cell type (p: 
0.202 and p: 0.071 respectively, Spearman correlation). Furthermore, no 
significant correlation between SIPA1L2 score and tumour size, ciliary body 
involvement or extrascleral extension was identified (p: 0.249, p: 0.779 and p: 
0.678 respectively, Spearman Correlation). These results are summarised in table 
26. 
 
Table 26: Correlation between signal-induced proliferation-associated 1-like 
protein 2 (SIPA1L2) immunohistochemistry score in 13 primary UM tissues of 
patients who developed metastasis (mUM) and 13 patients who did not develop 
metastasis (nmUM), and clinicopathological parameters. All p values were 
derived from Spearman correlation. 
 
SIPA1L2 score, p 
Survival 0.055 
Chromosome 3 status 0.202 
Cell type 0.071 
Tumour size 0.249 
Ciliary body involvement 0.779 
Extrascleral extension 0.678 
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3.3.3. Immunohistochemical validation of thioredoxin-
dependant peroxidase reductase (PRDX3) in larger 
tissue microarray study 
 
In the pilot immunohistochemical study of 26 samples, a trend toward 
higher expression of PRDX3 in primary UM samples that developed metastasis 
was found. Compared to all other targets, PRDX3 also demonstrated the most 
significant difference in expression in primary UM tissues of patients that 
developed metastasis versus those that did not (p: 0.061). Thus, PRDX3 was 
chosen for further validation in a larger cohort of 92 primary UM tissue 
microarray samples of 55 tumours that developed metastasis and 37 that did not 
develop metastasis. 
 
The TMA slides were scored based on staining only, as all tumours 
demonstrated homogenous staining given the small core size. The staining 
intensities observed in TMA tumours were either negative, weak or strong. Each 
tumour had 4 representative cores, and each core was assigned a score of 0-2. 
No staining was scored as 0, weak staining as 1 and strong staining as 2. A total 
score for each patient was obtained by adding the scores of all 4 cores. Thus, a 
minimum score of 0 and a maximum score of 8 was obtained. The total score 
was divided into 2 categories: 0-3 as low expression and 4-8 as high expression. 
In order for a patient to be categorised as “low expression”, a minimum of at 
least 1 core per patient would be required to demonstrate negative staining. The 
minimum staining for a patient to be categorised as “high expression” requires 
all 4 cores to demonstrate weak staining, 1 strong with 2 weak staining or 2 
strong with 2 negative staining tumour cores. Thus, tumours with heterogenous 
PRDX3 staining in 4 cores would be classified as low or high based on the 
presence or absence of negative staining. Using this method, 4 weak staining 
cores, with a total score of 4 would be appropriately categorised as a positive 
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result. Figure 29 and 30 demonstrates representative strong positive, weak 
positive and negative staining in TMA tumour tissues. 
 
 
 
Figure 29: Representative immunohistochemical slides of thioredoxin-dependant 
peroxidase reductase 3 (PRDX3) expression in uveal melanoma tissue microarray 
samples showing (i) strong positive cytoplasmic staining (ii) weak positive 
cytoplasmic staining and (iii) no staining. Quantitative label-free LC-MS 
proteomic profiling identified upregulation of PRDX3 (1.58 fold, p: 0.00218) in 8 
fresh frozen primary UM tissue specimens from patients who developed 
metastasis compared to 8 fresh frozen primary UM tissue specimens from 
patients who did not develop metastasis. Magnification X 200, scale bar=200 µm  
182 
 
 
Figure 30: Representative immunohistochemical slides of thioredoxin-dependant 
peroxidase reductase 3 (PRDX3) expression in uveal melanoma tissue microarray 
samples, showing (i) strong positive cytoplasmic staining (ii) weak positive 
cytoplasmic staining and (iii) no staining. Quantitative label-free LC-MS 
proteomic profiling identified upregulation of PRDX3 (1.58 fold, p: 0.00218) in 8 
fresh frozen primary UM tissue specimens from patients who developed 
metastasis compared to 8 fresh frozen primary UM tissue specimens from 
patients who did not develop metastasis.  
Magnification X 400, scale bar  = 100 µm   
183 
 
The majority of tumours demonstrated the same intensity of staining 
across all 4 cores of tissue [26/37 (70.3%) of tumours without metastasis and 
47/55 (85.5%) in tumours with metastasis]. There were a number of tumours 
that demonstrated different staining intensities in the 4 cores of tissue. In 
patients without metastasis, 11/37 (29.7%) tumours demonstrated varied 
staining in the 4 representative cores. Of these, 10 tumours had 3 cores with the 
same intensity of staining while 1 tumour had 2 cores that stained differently to 
the other 2. In patients with metastasis, 8/55 (14.5%) tumours demonstrated 
varied staining in the 4 representative cores. Of these, 6 tumours had 3 cores 
with the same intensity of staining while 2 tumours had 2 cores that stained 
differently to the other 2. These are outlined in Table 27. The mean score in the 
metastasised patients is 6.18 (SD: 2.66, 95% CI: 5.46 – 6.90). The mean score in 
patient tumours with no metastasis is 4.54 (SD: 3.56, 95% CI: 3.36 – 5.73). 
 
 
Table 27: Each tumour was represented by 4 tumour cores. The figures show the 
majority of tumours demonstrated the same intensity of staining in all 4 tumour 
cores. 
 
Number of cores staining with the same intensity 
4 3 2 
No metastasis 26/37 (70.3%) 10/37 (27%) 1/37 (2.7%) 
Metastasis 47/55 (85.5%) 6/55 (10.9%) 2/55 (3.6%) 
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There were 23 and 69 number of patient tumours with a score of 0-3 
(categorised as low expression) and 4-8 (categorised as high expression) 
respectively. Seven and 48 patients who developed metastasis demonstrated 
low and high expression respectively. Sixteen and 21 patients who did not 
develop metastasis demonstrated low and high expression respectively (table 
28). In the non-metastasised group, 4 of the 21 patient tumours that 
demonstrated high expression of PRDX3 are monosomy 3 tumours that were 
diagnosed between 2005-2009 (when chromosome 3 monosomy test was 
commenced as part of routine clinical practice). Although at the time of this 
study these patients are metastasis-free, it is highly likely that these patients will 
develop metastasis based on their cytogenetic risk factor of monosomy 3. 
 
 
Table 28: Distribution or PRDX3 expression score in primary uveal melanoma 
tumours with metastasis and without metastasis. Low expression is defined as a 
combined score of 0-3 and high expression is defined as a combined score of 4-8 
for all 4 cores of tumour tissues per patient. Quantitative label-free LC-MS 
proteomic profiling identified upregulation of PRDX3 (1.58 fold, p: 0.00218) in 8 
fresh frozen primary UM tissue specimens from patients who developed 
metastasis compared to 8 fresh frozen primary UM tissue specimens from 
patients who did not develop metastasis.  
 
PRDX3 
expression 
Metastasised 
tumours (n=55) 
Non-metastasised 
tumours (n=37) 
Total 
(n=92) 
Low Expression 7 (12.7%) 16 (43.2%) 23 
(25%) 
High expression 48 (87.3%) 21 (56.8%) 69 
(75%) 
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Multivariate studies have demonstrated that tumours consisting of 
epithelioid and mixed cell types are associated with high risk for metastasis. This 
was assessed in our population of patients to determine if a similar relationship 
may be found. Although figure and table 31 demonstrates a shorter survival time 
in patients with tumours of epithelioid and mixed cell type compared to spindle, 
there was no significant correlation identified (p: 0.074; n: 65, Pearson 
Correlation). Furthermore, no correlation was identified between cell type and 
metastasis (p: 0.561; n: 91, Pearson Correlation). This was further analysed to 
determine if patients with epithelioid and mixed cell type demonstrated higher 
rate of metastasis. After grouping these two cell types together, no significant 
difference in the rate of metastasis was identified compared to spindle cell type 
(p: 0.368, Fisher’s Exact). No significant correlation was found between PRDX3 
expression and cell type (p: 0.797, n: 91, Spearman Correlation). Conventionally, 
large tumour size is associated with high risk for metastasis. A positive 
correlation was identified between tumour size and the presence of metastasis 
(p: 0.01, n: 81, Spearman Correlation). However, no significant correlation was 
found between PRDX3 expression and tumour size (p: 0.313, n: 81, Spearman 
Correlation). No significant correlation was found between tumour size and cell 
type (p: 0.159, n: 80, Spearman Correlation). Furthermore, no significant 
difference between the frequency of metastasis and extrascleral extension was 
found (p: 0.147, Pearson Chi-square; p: 0.234, Fisher’s Exact). 
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Figure and table 31: Box plot 
demonstrating relationship 
between cell type and 
survival. There was no 
significant correlation 
between cell type and 
survival (p: 0.074, Pearson 
Correlation). All data in the 
table are represented as 
months. 
 
   
  
 Cell type 
Spindle Epithelioid Mixed 
Mean 116.15 38.2 74.11 
Median 104 32.5 37 
Standard 
deviation 
69.8 28.78 78.32 
95% CI 83.48 - 
148.82 
17.61 - 
58.79 
47.21 - 
101.02 
Minimum 11 6 3 
Maximum 228 100 328 
Interquartile 
range 
112.5 39.5 115 
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Currently, chromosome 3 monosomy is one of the most widely used 
prognostic markers for metastatic risk. In this study, a significant correlation was 
demonstrated between chromosome 3 status and the presence of metastasis (p: 
0.008, n: 17, Spearman Correlation). A significant difference in the frequency of 
metastasis was identified based on chromosome 3 status (p: 0.034, n: 17 Fishers 
Exact). However, no association between cell type, tumour size and chromosome 
3 status was found (p: 0.339 n: 17, and p: 0.549, n: 16 respectively, Spearman 
Correlation). As only 5/17 patients with chromosome 3 status available (all 
monosomy 3 tumours) have died, survival analysis for chromosome 3 was not 
possible. It was not possible to determine if PRDX3 expression was associated 
with chromosome 3 status, as all 17 tumours with chromosome 3 information 
available (10 monosomy and 7 disomy 3 tumours) demonstrated high expression 
of PRDX3. 
 
A statistically significant difference of PRDX3 expression was observed in patients 
that did and did not develop metastasis (p: 0.001, Mann-Whitney U,  
Table 29). A significant positive correlation between high PRDX3 expression and 
metastasis was also observed (p: 0.001, correlation coefficient: 0.346, n: 92 
Spearman correlation). Furthermore, a significant negative correlation between 
PRDX3 staining score and expression with survival was found (p: 0.005, 
correlation coefficient: -0.343, n: 66 and p: 0.017, correlation coefficient: -0.294, 
n: 66 respectively, Spearman correlation).  
 
Table 29: Test statistics showing the statistically significant difference of PRDX3 
expression in patients that did or did not develop metastasis. A total of 92 
patients were studied; 55 with metastasis and 37 without metastasis. *p < 0.05 
Test statistics PRDX3 expression 
Mann-Whitney U 707 
Wilcoxon W 1410 
Z -3.296 
Asymp. Sig. (2-tailed) 0.001* 
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Kaplan-Meier survival analysis was performed to demonstrate the 
significant impact of metastasis on patient survival. In patients with metastasis, 2 
samples were excluded from analysis (sample 60 and 65). These patients lived for 
35.6 and 27.75 years after enucleation, respectively. Information such as date of 
metastasis and location were unavailable for these patients. As described by 
Harbour et al, low-risk class 1 patients can be further subdivided to 1a and 1b 
(315–317). Class Ib is associated with a low risk of late onset metastasis. These 2 
patients were significant outliers and were excluded from subsequent survival 
analyses.  
 
The details and distribution of survival rates in patients with and without 
metastasis are outlined in figure 32. The mean survival for patients who 
developed metastases is 51.88 months (SD: 46.32, 95% CI: 38.99 – 64.78). The 
mean survival for patients who did not develop metastasis is 189.07 months (SE: 
53.73, 95% CI: 158.05 – 220.09). Figure 33 shows the Kaplan-Meier survival 
analysis for patients with and without metastasis (p: 0.000).  
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Figure 32: Box plot demonstrating the 
distribution of survival months in 
patients with and without metastasis. 
The table shows the details of survival 
of these patients. The data are 
presented in months. 
 
 
 Metastasis 
Yes 
n=52 
No 
n=14 
Mean 51.89 189.07 
Median 37 179 
Standard 
deviation 
46.32 53.73 
95% CI 38.99 – 
64.78 
158.05 – 
220.09 
Minimum 3 96 
Maximum 226 328 
Interquartile 
range 
54.25 67.25 
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Figure 33: Kaplan-Meier survival analysis showing significant correlation between 
metastasis and death in 52 patients that developed metastasis compared to 14 
patients that did not develop metastasis. The mean survival for patients with and 
without metastasis is 51.89 and 189.07 months respectively. 
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Survival analysis was performed to determine if PRDX expression was 
significantly associated with overall survival. In the 66 patients that have died, 14 
demonstrated low expression while 52 demonstrated high expression (21.2% 
and 78.8% respectively). The mean, standard error and 95% confidence interval 
for survival time for low and high expression of PRDX3 is outlined in table 30. A 
statistically significant difference in overall survival was observed between 
tumours that demonstrated low and high expression of PRDX3 (p: 0.013, Mantel-
Cox log-rank; p: 0.026, Wilcoxon-Breslow; p: 0.017, Tarone-Ware). Kaplan-Meier 
analysis demonstrated a significant negative correlation between PRDX3 
expression and survival (Figure 34). 
 
Table 30: Survival rates of patients with tumours that demonstrated low and high 
expression of PRDX3. A statistically significant difference in survival rate was 
observed between tumours that demonstrated low and high expression (p: 
0.013, Mantel-Cox log-rank; p: 0.026, Wilcoxon-Breslow; p: 0.017, Tarone-Ware) 
PRDX3 
expression 
Survival (months) 
Mean Standard error 
95% confidence 
interval 
Low (n=14) 130.64 24.77 82.14 – 179.14 
High (n=52) 67.61 8.67 50.63 – 84.61 
Overall (n=66) 80.99 9.09 63.17-98.80 
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Figure 34: Kaplan-Meier survival analysis showing a significant negative 
correlation between PRDX3 expression and survival in 52 patients that 
demonstrated high expression compared to 14 patients that demonstrated low 
expression. The mean survival for patients with low and high PRDX3 expression is 
130.64 and 67.61 months respectively. (p: 0.013, Mantel-Cox log-rank; p: 0.026, 
Wilcoxon-Breslow; p: 0.017, Tarone-Ware) 
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Table 31: Summary of association between PRDX3 expression and 
clinicopathological parameters. 
 PRDX3 expression score, p value 
Metastasis 0.001†, 0.001* 
Survival 0.017*, 0.013§ 
Cell type 0.797* 
Tumour size 0.313* 
†Mann Whitney U  
*Spearman Correlation 
§ 
Mantel-Cox 
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4. Discussion 
 
  Uveal melanoma is the most common primary intraocular malignancy in 
adults. It is associated with the development of metastatic disease in about 50% 
of patients, and 40% of patients with UM die of metastatic disease despite 
successful treatment of the primary tumour (5,6). Progress made in molecular 
genetics has led to significant improvement in prognostic stratification of 
patients into low-risk and high-risk for developing metastatic disease (21,22). 
This has enabled closer surveillance of patients at-risk for metastasis, and earlier 
detection and treatment of metastatic disease. It has also increased the 
understanding of the events that trigger the development of UM. However, very 
little is known about the molecular biology of the development of metastatic 
disease. Effective treatment strategies for metastatic disease remain elusive and 
survival rates are poor. Only a few proteomic studies of uveal melanoma have 
been carried out to date. Most of these studies have been performed using cell 
lines, with only 2 studies using primary UM tissue. Using recent advances in 
proteomic technologies, quantitative label-free LC-MS proteomic profiling was 
performed to identify differentially expressed proteins between primary UM 
tissue from patients who developed metastatic disease, versus primary UM 
tissue from patients who did not develop metastasis. Furthermore, bioinformatic 
reanalysis of publically available gene expression microarray datasets of 
monosomy 3 tumours that developed metastatic disease versus disomy 3 
tumours that did not develop metastatic disease was also carried out to identify 
differentially expressed genes. 
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4.1. Quantitative label-free LC-MS proteomic analysis 
 
To identify differentially expressed proteins, 8 fresh-frozen primary UM 
tissues from patients that developed metastatic disease (M) and 8 from patients 
that did not develop metastasis (NM), with a minimum follow-up of 7 years, 
were subjected to quantitative label-free LC-MS proteomic analysis.  
 
Gene ontology (GO) enrichment analysis of 94 proteins with p ≤ 0.05 and 
≥ 2 peptides matched using the DAVID interface showed significant enrichment 
of proteins involved in negative regulation of apoptosis and in carbohydrate 
metabolic and catabolic processes. Furthermore, in primary UM tissues that 
developed metastasis (M), processes involving metabolism, mitosis and 
biological regulation were higher than that in primary UM tissues that did not 
metastasise (NM) while processes involving cell-to-cell and biological adhesion 
were lower in M compared to NM. PANTHER pathway categorisation showed a 
higher number of proteins involved in glycolysis and pyruvate metabolism in M 
compared to NM. Lower number of proteins involved in gonadotropin releasing 
hormone receptor pathway, heterotrimeric Gi-α and Gs-α G-protein signalling 
pathway and integrin signalling pathway were found in M compared to NM. 
4.1.1. Proteins associated with apoptosis and proliferation 
 
In 2000, Hanahan and Weinberg defined resistance to apoptosis as one of 
the hallmarks of cancer (320). This concept has been established by several 
studies over the last two decades, where suppression of apoptosis has been 
shown to enable progression to high-grade malignancy and resistance to therapy 
(321–323). Tumour cells evolve various strategies to circumvent apoptosis. In 
UM, alterations in p53, BCL-2 and PTEN downregulation have been shown to 
enhance resistance to apoptosis (324). In this study, PRDX3, HSP27 and KIT, along 
with proteins HSP71, HSPD1, NDKA, ANXA5, SYUA, APOH, ALBU, CRYAB, APOE 
and GRP78 were associated with negative regulation of apoptosis. PRDX3 and its 
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involvement in apoptosis will be discussed later. Heat shock protein-27 (HSP27) 
was found to be upregulated by 1.56 fold (p: 0.05) in M compared to NM. This is 
in agreement with another UM tissue proteomic study by Coupland et al (243) 
where higher HSP27 expression was associated with a favourable prognosis. 
Monosomy 3 tumours were found to have a significantly lower HSP-27 
expression compared to disomy 3 tumours, demonstrating a significant negative 
correlation between reduced HSP-27 expression and a predicted survival of < 8 
years (289).  
 
HSP-27 is a cytoplasmic protein involved in the inhibition of cell 
proteolysis and protein conformation stabilisation (290,291). It is overexpressed 
in a variety of cancer cells and is associated with a poor prognosis in gastric, 
prostate, and node-negative breast carcinoma (292–294). In contrast, high levels 
of HSP-27 expression indicate a good prognosis in non–small-cell lung 
carcinomas and ovarian carcinomas (295,296). This suggests that HSP-27 may 
play different roles in different tissues or that there are other elements present 
in some malignancies that can override or bypass any effects HSP-27 may have 
(297). Of interest, HSP-27 overexpression has been shown to inhibit cell 
proliferation and reduce cell invasiveness in one human cutaneous melanoma 
cell line (298). From this, it was postulated that underexpression of HSP-27 in 
melanoma cells results in increased tumour cell motility and invasiveness. HSP27 
was also identified in another proteomic study by Wang et al (240). A UM cell 
line was analysed 15 and 48 hours post X-ray radiation to identify proteins 
associated with cell cycle arrest. It was found to be nearly 3 fold higher 48 hours 
post radiation, suggesting a role in growth arrest and cellular senescence. 
 
Mast/stem cell growth factor receptor (KIT) was also identified in this 
study, where it was 4.85 fold upregulated (p: 0.008) in M compared to NM. KIT, a 
member of the PDGFR family of kinases, is a receptor tyrosine kinase that is 
activated by binding of stem cell-derived factor (SCF) and plays an essential role 
in the regulation of various cellular processes including cell survival and 
proliferation, stem cell maintenance, and in melanogenesis (56). KIT activates the 
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AKT signalling pathway by phosphorylating PI3K and also transmits signals via 
GRB2 and activation of RAS, RAF1 and the MAPK pathway (56). Mouriaux et al 
showed KIT expression in normal choroidal melanocytes and activation by SCF 
stimulated proliferation (57). In normal uveal melanocytes, stimulation with SCF 
resulted in activation of both ERK1/2 and AKT but in a KIT-expressing UM cell 
line, stimulation led to MAPK pathway activation only (58). 
Immunohistochemical expression of KIT was positive in 62.7-78.2% of primary 
UM tissue and treatment with KIT inhibitor led to significant decrease in 
proliferation, invasion and cell death in UM cell lines (58,59). An in vitro study 
found constitutive ERK1/2 activation that enabled UM cell proliferation and 
transformation in a KIT dependant manner. Inhibition of UM proliferation was 
observed when depleted of SCF/KIT, but not AKT, suggesting that the 
proliferative effects of the SCF/KIT autocrine loop in uveal melanoma likely 
funnel primarily through the MAPK pathway (60). However, activation-related 
mutations of KIT have not been found (57,61).  
 
DJ-1, an oncogene identified by Pardo et al (239) in the first proteomic 
study of uveal melanoma, was found to be upregulated by 2.15 fold (p: 0.009) in 
M compared to NM. It was expressed in vitro and found in the culture media but 
was absent in normal melanocyte cell line or culture media (239). Importantly, 
DJ-1 functions as a redox-sensitive chaperone and as a sensor against oxidative 
stress (325). It may act as an atypical peroxiredoxin-like peroxidase that 
scavenges H2O2 and protect cells against H2O2-mediated cell death (325). 
Furthermore, it is required for correct mitochondrial morphology and for 
autophagy of dysfunctional mitochondria(325). Malignant cells have been 
described to secrete DJ-1 and it plays a role in tumourigenesis in breast cancer, 
non-small cell lung carcinoma and prostate cancer (247,248). Kim et al identified 
DJ-1 as a negative regulator of the tumour suppressor PTEN, promoting cell 
survival in primary breast and lung cancer patients (249). A recent study 
suggested serum DJ-1 level as a potential biomarker for the diagnosis and 
prognosis prediction of patients with pancreatic cancer (250). Recently, it was 
shown that elevated DJ-1 was found to be significantly associated with risk 
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factors for malignant transformation of choroidal naevus, namely nevus 
thickness greater than 1.5 mm, diameter larger than 8 mm, and presence of 
acoustic hollowness on ultrasonography (251). This interesting finding, coupled 
with the identification of DJ-1 in UM tissue in this label-free proteomic study, 
warrants further investigation into the potential role serum DJ-1 may play in 
tumourigenesis and monitoring of patients at risk for malignancy. 
 
In PANTHER analysis, lower number of proteins involved in gonadotropin 
releasing hormone (GnRH) receptor pathway (GnRHR) were found in M 
compared to NM. Four proteins were associated with this pathway; integrin β1 
(ITGB1, downregulated in M), heat shock 70 kDa protein 1A (HSPA1A, 
downregulated in M), guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit 
beta-2 (GNB2, downregulated in M) and Annexin A5 (ANXA5, upregulated in M). 
In primary ovarian cultures of ovarian carcinomas and tumour biopsies, 
widespread presence (>80%) of GnRH receptor has been reported, suggesting 
that alterations of GnRH receptor may be one of the most common 
abnormalities in human ovarian cancer (326,327). It has been implicated in 
proliferation, tumour progression and metastatic spread, suggesting a regulatory 
role in ovarian cancer (328–330). Following silencing of GnRH receptors, Cheung 
et al  recently showed inhibition of adhesion to peritoneal mesothelium of highly 
malignant ovarian cancer cells in vitro (331). In vivo, GnRH receptor inhibition 
decreased the expression of integrin β1, α2 and α5 and P-cadherin, leading to 
significant attenuation of tumour growth and peritoneal metastasis (331). 
However, upregulation of proteins involved in the GnRH receptor pathway in UM 
tissues appear to inhibit metastatic formation, suggesting that this pathway is 
involved in an alternative manner than that reported by Cheung et al. This is 
supported by the contrasting findings of other studies that have shown that 
GnRH and its agonists are effective in controlling tumour growth and 
invasiveness in endometrial, ovarian and prostate cancer (332–334). 
GnRH/GnRHR mediated inhibition of tumour invasion and metastatic potential 
were associated with upregulation of actin cytoskeleton remodelling, mainly 
through the activation of Rac1 (335,336), as well as by influencing the activity of 
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cell-cell adhesion molecules and/or the regulation of cell substrate attachment-
associated proteins (337,338). In breast cancer, GnRH and its agonists inhibited 
growth and metastatic capacity both in vitro and in vivo (332,339–341). 
Furthermore, its inhibitory effects on breast cancer cell migration has also been 
established (333,334). The activation of GnRH receptor in a highly invasive breast 
cancer cell line increased RhoA-GTP levels and stimulated actin remodelling, 
resulting in increased cell adhesion and loss of migration capacity, suggesting 
that GnRH may act to reduce the metastatic potential and invasiveness of 
malignant breast tumour cells (342). GnRH receptor pathway has not been 
implicated in UM, but the finding of downregulation of this pathway in primary 
UM that developed metastasis needs to be investigated further. 
 
In PANTHER analysis, lower number of proteins involved in the 
heterotrimeric Gi-α and Gs-α G-protein signalling pathway were found in M 
compared to NM. GNB2, PYGL and PYBG were all found to be differentially 
expressed in NM. Gs and Gi are guanine nucleotide-binding, heterotrimer 
proteins that regulate the activity of adenylate cyclase, and are responsible for 
transferring stimulatory and inhibitory signals, respectively, from cell surface 
receptors to the enzyme catalytic unit (343). Gs-α protein stimulates adenylyl 
cyclase to produce the second messenger molecule cyclic AMP (cAMP), and the 
Gi-α proteins have an antagonistic inhibitory function. Thus, these proteins act to 
regulate and mediate intracellular signal transduction. The Gs-α protein (GNAS) 
gene has been found to play an important role in promoting tumour cells 
apoptosis in squamous cell cancer cells (344). In UM, activating mutation of 
GNAQ or GNA11 mutations are found in about 85-91% of cases and represents 
the most common oncogenic mutation (23,24,35). The mutations are mutually 
exclusive and occur in exon 4 (R183) or exon 5 (Q209) in GNAQ or GNA11. It is 
not associated with tumour class, stage or clinicopathological parameters and 
therefore, indicates an early event in the disease pathogenesis (23). It has been 
shown that mutations in the Gqα subunits GNAQ or GNA11 are responsible or 
the constitutive activation of the MAPK pathway in the development of UM. 
Mutant GNAQ/GNA11 are affected at the intrinsic GTPase domain where 
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hydrolysis of GTP to GDP and the Gα-GDP re-association with Gβγ subunits is 
defective. Thus, this leads to the constitutive Gα activation and downstream 
signalling of the MAPK pathway. However, mutations in GNAI or GNAS (encoding 
Gi-α and Gs-α G-protein respectively), or the expression of these G-protein 
coupled receptors have not been investigated in UM. Interestingly, GnRH 
antagonists were shown to promote proapoptotic signalling in reproductive 
tumour cells by activating a Gi-α-coupling state of the GnRH receptor (345). This 
antiproliferative action occurs through a Gi-α -mediated activation of stress-
activated protein kinase pathways, resulting in caspase activation and 
transmembrane transfer of phosphatidlyserine to the outer membrane 
envelope. In ovarian and endometrial cancer cells, antiproliferative signal 
transduction by luteinizing hormone-releasing hormone was found to be 
mediated by Gi-α, resulting in down-regulation of mitogenic signal transduction 
and cell proliferation (346). Gs-α mutations have also been shown to be 
associated with endocrine adenomas (343). More recently, a high throughput 
analysis found Gs-α R201 mutations in a small subset of pancreatic and ovarian 
cancers and a significant percentage of breast cancers (347). Furthermore, 
numerous studies have shown amplification or polymorphisms of GNAS to be 
associated with increased survival and a predictor of response to treatment in 
ovarian, bladder, renal, colorectal, breast, oesophageal and non-small cell lung 
cancer (344,348–352). These studies support the findings of higher expression of 
proteins involved in the Gi-α and Gs-α G-protein signalling pathway in UM 
samples of patients who did not develop metastasis. Further investigation of the 
role of these G-protein coupled receptors in UM may improve insights into the 
development of metastatic disease, and therapeutic targets. 
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4.1.2. Proteins associated with energy metabolism 
 
A decade later, Hanahan and Weinberg added to the hallmarks of cancer, 
the ability of neoplastic cells to reprogram and upregulate energy metabolism to 
sustain cell growth and uncontrolled proliferation (353). In fact, the enhanced 
metabolism of cancer cells can be visualised in many malignancies using positron 
emission tomography (PET) with a radiolabeled analog of glucose (18F-
fluorodeoxyglucose, FDG) as a reporter. In this study, TPI, PKM2, CRYAB, 3HIDH, 
PPP1CB, PGAM1, PGM2, ENOA, G6PI, PYGL and HEXB were associated with 
carbohydrate metabolic and catabolic processes. Triosephosphate isomerase 
(TPI) was upregulated by 1.79 fold (p: 0.006) in primary UM tissues of patients 
that developed metastatic disease compared to those that did not. This protein 
was also identified by a previous 2D-DIGE study by our group, where it was 
associated with invasion and migration (244). TPI is an enzyme that's critical in 
glycolysis and gluconeogenesis (305). In cervical cancer cells, functional 
inactivation of TPI induced apoptosis (307). It has also been shown to be involved 
in the aggressiveness of breast cancer (308). Other proteomic studies found it to 
be significantly increased in lung cancer tissue (309), cell lines and patients' 
plasma (310), and in prostate cancer (311), suggesting its use as a serum 
biomarker. Interestingly, TPI was also shown to be expressed in uveal melanoma 
primary cell cultures by Pardo et al (239) in the first proteomic study in UM. 
Cancer cells use intermediates of carbohydrate metabolism for various 
biosynthetic pathways, such as those generating nucleosides and amino acids 
(353,354). Pyruvate kinase isozymes M2 (PKM2) was upregulated by 1.84 fold (p: 
0.05) in M compared to NM. PKM2 provides the metabolic advantage that the 
phosphometabolites upstream of pyruvate accumulate and are then available as 
precursors for the synthesis of amino acids, nucleic acids, and lipids (355). In 
proliferating cancer cells, pyruvate metabolism and its intermediates also 
becomes available for the synthesis of fatty acids, cholesterol, and isoprenoids 
(33). Thus, the entire metabolism of cancer cells is reprogrammed in a manner 
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that drives biosynthetic reactions and energy production that are necessary to 
support tumour growth and proliferation. 
 
Fatty acid binding protein 3 (FABP3) was identified to be upregulated by 
2.46 fold (p: 0.04) in M compared to NM. Similar to TPI, this protein was also 
identified by a previous 2D-DIGE study by our group and was shown to be 
associated with UM cell invasion and migration (244). FABPs are expressed in a 
variety of tissues, playing a role in fatty acid metabolism (299) and are suggested 
to be involved in a number of biological processes such as cell differentiation, cell 
growth, and apoptosis (300). One proteomics study showed a heterogeneous but 
unique FABP expression pattern in the different subtypes of renal cell carcinoma, 
suggesting its use for classification of this disease (299). Expression of FABP was 
significantly high in an aggressive small cell lung cancer cell line, suggesting that 
it may influence mitosis and cell growth (301). Another proteomic study 
identified FABP as a biomarker to predict gefininib treatment response in 
patients with lung adenocarcinoma (302). FABP was also shown to be expressed 
in human gastric carcinoma, and was associated with disease progression, 
tumour aggressiveness and poor patient survival (303). In contrast, ectopic 
expression of FABP3 in breast cancer cells was shown to reduce tumourigenicity 
in nude mice (304). This suggests a complex relationship between FABP and 
cancer. 
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4.1.3. Proteins associated with adhesion and cellular 
organisation 
 
Neoplastic cells also demonstrate evasion of contact-inhibition that 
normally supress further proliferation in cells. In vitro studies have shown that 
cell-cell contact in dense populations of normal cells propagated in two-
dimensional culture operate to suppress further cell proliferation, yielding 
confluent cell monolayers (353). This is abolished in various types of cancer cells 
in culture, suggesting that contact inhibition is an in vitro surrogate of a 
mechanism that operates in vivo to ensure normal tissue homeostasis, one that 
is abrogated during the course of tumourigenesis (353). Adhesion proteins 
ITGB1, PRELP, TLN1, APOH, COL1A1 and DCN were all downregulated in primary 
UM tissues that developed metastasis. In PANTHER analysis, a lower number of 
proteins involved in integrin signalling pathways were found in M compared to 
NM. Specifically, integrin β1 (ITGB1) was upregulated by 1.68 fold (p: 0.04) in 
NM. Integrins and its role in tumour cell proliferation, migration, and invasion 
has been the subject of intense research. Conventionally, increased expression of 
integrins have been implicated in tumour growth and metastasis (356,357). 
However, recent studies suggest a crucial, contradictory role of integrins in the 
regulation of tumour cell survival. Integrins are able to either enhance cell 
survival or initiate apoptosis depending on environmental cues. While ligated 
integrins promote cell survival, it is now emerging that unligated integrins 
promote pro-apoptotic cascades (358,359). In a process called integrin-mediated 
death (IMD), unligated integrins on adherent cells recruit and activate caspase 8, 
resulting in apoptotic cell death (358). It was also shown that integrin-mediated 
metastatic dissemination is achieved by the loss of caspase 8, thereby avoiding 
IMD (360). This may explain the findings of several studies that showed that the 
pro-tumourigenic integrin αvβ3 could inhibit tumour progression in mouse 
models of glioblastoma (361) and cutaneous melanoma (362). Decreased 
expression of integrin α2β1 was shown to increase tumour dissemination but re-
expression reversed some of the malignant properties of breast cancer cells, 
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suggesting that α2β1 could function as a tumour suppressor (363). In a mouse 
model of spontaneous pancreatic islet cancer, integrin β1 inhibited tumour cell 
motility (364). Other studies have shown the ability of integrin α5β1 to inhibit 
oncogene-induced transformation (365,366). Thus, it is likely that the higher 
expression of integrin β1 in non-metastatic primary UM tissues represents a pro-
apoptotic effect, thereby limiting tumour growth and metastatic dissemination. 
 
EF1G was upregulated by 2.02 fold in M disease group (p: 0.000387). 
Elongation factor-1 is a GTP-binding protein that plays a role in translation and 
protein biosynthesis by mediating the transport of aminoacyl-tRNA to 80S 
ribosome (367,368). It has 4 subunits: α, β, γ, and δ. The γ and β subunit 
demonstrates strong affinity to leucyl- and histidyl-tRNA synthetases, while glu-
proly-, glutaminyl-, alanyl-, aspartyl-, lysyl-, phenylalanyl-, glycyl-, and 
tryptophanyl-tRNA synthetases show moderate interactions with the α and δ 
subunits (369). It is a major substrate for phosphorylation by maturation-
promoting factor, which regulates entry into the M-phase of the cell cycle (370). 
Maturation-promoting factor is a protein kinase that consists a cdc2 and cyclin B 
complex, and its levels peak just before anaphase and then decline rapidly (371). 
Overexpression of EF1G has been demonstrated in 7 out of 9 pancreatic cancer 
tissues compared to matched normal tissues from the same patients (372). In 
oesophageal carcinoma, Mimori et al identified a significant association between 
overexpression of EF1G mRNA and severe lymph node metastases, suggesting its 
use as a preoperative biomarker to identify high-risk patients (373). The authors 
also reported similar overexpression in gastric carcinoma, where EF1G was 
overexpressed in 22 of 30 tumours compared to normal tissue (374). 
Furthermore, the expression of EF1G was also observed in gastric, hepatic, 
ileocecal, duodenal, and colon carcinoma cell lines (374). Frazier and colleagues 
also demonstrated overexpression of EF1G-hybridizing RNA in 25 of 29 colorectal 
carcinomas relative to normal adjacent tissue, and in 14 of 25 adenomas 
(375,376). This is further supported by another study that reported over 2 fold 
expression of EF1G in colorectal adenocarcinomas compared to normal-
appearing more distal mucosa (377).  
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Vimentin was upregulated by 1.98 fold in M disease group (p: 0.02). It is 
an intermediate filament  protein that plays an important role in maintenance of 
cell structure and organelle positioning, including mitochondrial morphology 
(378,379). It is also important for cellular cytoskeleton flexibility and motility 
(380,381). In prostate cancer, vimentin expression is associated with 
invasiveness, and contributes to metastatic disease (382–385). Furthermore, 
vimentin has been shown to be associated with metastatic gastric cancer 
(386,387), lymph node metastases in oesophageal cancer (388) and metastatic 
hepatocellular carcinoma (389). In a 2-DE proteomic study, differential 
upregulation of vimentin was observed in colorectal cancer tissue compared to 
surrounding normal tissue (390). Similarly, overexpression increased invasion 
and migration of breast cancer cell lines (391,392). In cutaneous melanoma, a 
proteomic study demonstrated vimentin overexpression may serve as a 
diagnostic marker in primary tumours, and as a predictor of hematogenous 
metastases (393), while other studies also support its overexpression in 
metastatic melanoma (394–397).  
 
In a recent study by Corbi et al, EF1G was shown to bind to promoter 
region of the vimentin gene (398). In HeLa cells, EF1G depletion led to mis-
localisation of vimentin protein, resulting in a severe compromise of cellular 
shape and mitochondria localisation (398). EF1G also co-localised in 
mitochondria and following knockdown, mitochondrial fragmentation and 
increased cellular superoxide was observed (398). Interestingly, vimentin was 
identified in the 50 statistically significant proteins in our study (1.98 fold 
upregulated in M, p: 0.017).  Thus, it is likely that upregulation of EF1G in UM 
upregulates vimentin expression. This, supported by other studies, and may lead 
to the development of metastases and poor survival. The relationship between 
EF1G and mitochondrial localisation and maintenance demonstrated by Corbi et 
al is also an interesting finding. In our study, PRDX3 was upregulated by 1.58 fold 
in the M group (p: 0.002). PRDX3 is a protein that exclusively localises in 
mitochondria. It reduces cellular reactive oxidative species such as H2O2, and 
may be upregulated as part of the mitochondrial anti-oxidant defence response 
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in order to protect organelles from oxidative damage and prevent cell death 
(399). Furthermore, PRDX3 overexpression in prostate cancer confers resistance 
to H2O2-induced apoptosis through a failure to activate pro-apoptotic pathways 
(400). Taken together, EF1G, vimentin and PRDX3 may interact in a synergistic 
manner to increase UM cell protein synthesis, metabolism, cellular organisation, 
proliferation and ultimately, metastatic dissemination. 
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4.2. Bioinformatic reanalysis of gene expression 
microarray data 
   
  To identify differentially expressed genes between primary UM tissue 
from patients who developed metastatic disease, versus primary UM tissue from 
patients who did not develop metastatic disease, bioinformatic reanalysis of 
publically available gene expression microarray datasets of monosomy 3 tumours 
that developed metastatic disease versus disomy 3 tumours that did not develop 
metastatic disease was performed. Laurent et al (29) compared 28 uveal 
melanomas from patients who developed liver metastases within three years of 
enucleation with 35 tumours from patients without metastases or who 
developed metastases more than 3 years after enucleation. However, it is not 
uncommon for UM patients to develop metastatic disease after 3 years. In order 
to eliminate this bias and obtain a more direct comparison, we studied 
monosomy 3 tumours that metastasised (M3M) versus disomy 3 tumours that 
did not metastasise (D3NM). After exclusion of 43 samples, 11 M3M and 9 D3NM 
samples were analysed. In total, 449 genes were differentially expressed with a 
fold change ≥ 1.3 and P-value < 0.05. Of these, 246 genes were upregulated in 
the M3M group, while 203 were downregulated. Six upregulated and 6 
downregulated genes were considered for further follow-up based on p value, 
biological function and involvement in other diseases. SIPA1L2, CELF2, WARS, 
SDC2, THBS2 and BCAT1 are genes upregulated in M3M, while CNTN3, MEGF10, 
DLC1, CHL1, PPP1R3C, and SORBS2 are downregulated genes that were 
considered (Table 12). Of these, SIPA1L2 (1.516 fold upregulated in M3M, p: 
0.00107) and CNTN3 (3.068 fold downregulated in M3M, p: 0.000807) were 
chosen for further validation by immunohistochemistry on FFPE UM sections. 
The former was selected for validation based on its novelty, as little is known 
about SIPA1L2, while CNTN3 was chosen primarily due to its localisation to 
chromosome 3, which has significant prognostic implication in UM. Other genes 
that have been described by in other studies have also been found, validating 
our results. Onken et al (319) described a 12-gene signature that accurately 
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classifies patients to class 1 low-risk for metastasis and class 2 high-risk for 
metastasis. Of the 12 genes, 8 were identified in this study (HTR2B, FXR1, ID2, 
LMCD1, MTUS1, RAB31, ROBO1, and SATB1) with identical differential expression 
pattern. Mutations in BAP1 gene located in chromosome 3 occurs almost 
exclusively in metastasizing class 2 tumours (25), which was also found to be 
downregulated in M3M tumours in our study. Specifically, Laurent et al’s 
principal finding of high expression of PTP4A3 in metastasising tumours was also 
found, ensuring internal validation of our analysis. 
 
Gene ontology (GO) enrichment analysis of 449 differentially expressed 
genes with p ≤ 0.05 and fold change of ≥ 1.3 using the DAVID interface showed 
significant enrichment of genes involved in regulation of proliferation and 
immune response. These includes BAP1, JUN, DLC1, ADAM10 and WARS. 
Compared to disomy 3 tumours without metastasis (D3NM), processes involving 
immune system and response to stimulus were significantly enriched in 
monosomy 3 tumours that developed metastatic disease (M3M) based on 
differential gene expression level. Based on molecular function of genes 
identified, binding activity was also significantly enriched in M3M compared to 
D3NM. PANTHER pathway categorisation showed significant enrichment of 
cadherin signalling pathway in D3NM compared to M3M with genes involved in 
GO biological processes such as cell signalling, proliferation, apoptosis and 
adhesion. Similarly, significant enrichment of cell adhesion molecules, such as 
CNTN3, CHL1 and SDC2 were found in D3NM compared to M3M.  
 
  Elav-like family member 2 (CELF2) was upregulated by 1.987 fold in M3M 
(p: 0.0000188). It is located at cytoband 10p13 and encodes for a member of a 
protein family that regulate pre-mRNA alternative splicing and may also be 
involved in mRNA editing, and translation (401). In breast cancer cells, CELF2 
protein was found to be elevated in response to irradiation and promoted 
apoptosis. Knockdown of CELF2 expression in irradiated cells inhibited apoptosis, 
suggesting that CELF2 is a critical regulator of the apoptotic response to 
genotoxic injury in breast cancer cells (402). A similar relationship was identified 
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in colon cancer cells and suggests the use of CELF2 as a chemotherapeutic agent, 
where CELF2 overexpression induced apoptosis by inhibition of prostaglandin E2 
via the COX-2 pathway, which is frequently overexpressed in neoplasms. 
Furthermore, downregulation inhibited radiation-induced apoptosis of colon 
cancer cells (403). CELF2 expression was also found to be reduced during 
neoplastic transformation in colon cancer, suggesting that it might play a crucial 
role in tumour initiation and progression (404). In pancreatic cancer, curcumin 
was found to inhibit tumour growth through mitotic catastrophe by increasing 
the expression of CELF2, thereby inhibiting the translation of COX-2 and VEGF 
mRNA (405). These studies suggest that overexpression of CELF2 has tumour-
suppressive properties, and enhances apoptosis of tumour cells. In our study, an 
opposite relationship was found, where CELF2 was upregulated in aggressive 
tumours. Burgess and McCannel et al recently performed gene-expression 
analysis of 3 primary UM cell lines derived from patients who developed liver 
metastases within 1.5 years (406,407). In agreement to our findings, they 
identified CELF2 to be significantly upregulated in monosomy 3 tumours. 
Furthermore, van Gils et al also support this finding, with CELF2 upregulation 
identified as a classifier gene associated with poor prognosis (408). This suggests 
that CELF2 may play a role in UM via an alternative, unknown mechanism. 
 
  Protein phosphatase 1, regulatory subunit 3C (PPP1R3C) was 
downregulated by 1.376 fold in M3M (p: 0.000164). It is located at cytoband 
10q23 and encodes a regulatory subunit of protein phosphatase-1 (PP1). It 
interacts with PPP1CC catalytic subunit of PP1 and associates with glycogen by 
forming complexes with glycogen phosphorylase, glycogen synthase and 
phosphorylase kinase which is necessary for its regulation of PP1 activity 
(409,410). PPP1R3C is predominantly involved in glycogen metabolism by 
activating glycogen synthase, reducing glycogen phosphorylase activity and 
limiting glycogen breakdown (410). PPP1R3C has been shown to be induced by 
hypoxia (411,412) and in breast cancer cells, hypoxia-inducible factor was shown 
to induce PPP1R3C expression to promote glycogen accumulation (413). 
PPP1R3C mRNA was reduced in a number of cutaneous melanoma cell lines 
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compared to melanocytes and was correlated with high proportion of promoter 
methylation (414). PPP1R3C was also found to be methylated in 25% of 
cutaneous melanoma tumours and in colon cancer cell lines, suggesting its role 
as a tumour suppressor gene (414). PPP1R3C was also identified as one of top 20 
differentially methylated region in prostate cancer (415). Mutation and promoter 
hypermethylation of this gene with downregulation of expression was also 
identified in colorectal adenocarcinoma, but this was not observed in normal 
colonic mucosa (416,417). Although these studies have identified PPP1R3C in 
cancer, its role has not been studied extensively, and little is known about its 
functions. 
4.2.1. Genes associated with apoptosis and proliferation 
 
 BRCA1-associated protein 1 (BAP 1) gene was downregulated by 1.34 fold 
in M3M compared to D3NM (p: 0.026). As monosomy 3 tumours are associated 
with metastasis and poor prognosis, the remaining chromosome 3 genes likely 
contain mutations on potential tumour suppressor genes that can lead to an 
aggressive phenotype. Harbour et al conducted exome sequencing of monosomy 
3 UM samples and found that BAP1 had mutations on 3p21.1 in 85% of class 2 
aggressive UM and almost never in class 1 tumours (25). Microarray gene 
expression profiling of 92.1 UM cells transfected with control versus BAP1 siRNA 
showed a shift in the expression profile towards a class 2 signature in BAP1 
depleted cells compared to control cells (25). Interestingly, BAP1 depletion 
caused an increase in mRNA levels for the proto-oncogene KIT, which is highly 
expressed in class 2 tumours. Furthermore, RNAi-mediated knock down of BAP1 
in 92.1 UM cells, which did not contain a detectable BAP1 mutation, 
recapitulated many characteristics of the de-differentiated class 2 UM phenotype 
(80). Either BAP1 mutation or loss of chromosome 3 can occur first, but both 
events appear to be necessary for the tumour to metastasise (26). It is localised 
to chromosome 3p21.31-p21.2, a region previously noted by Trolet et al to be 
deleted in UM (81). It encodes a deubiquitinating enzyme that interacts with the 
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breast cancer susceptibility gene (BRCA1) and BRCA1-associated RING domain 
protein 1 (BARD1) to form a tumour suppressor heterodimeric complex (29). It 
possesses a large C-terminal domain which is predicted to coordinate the 
selective association with potential substrates or regulatory components (82). 
Functionally, BAP1 enzyme removes ubiquitin molecules from specific proteins to 
regulate their function. For example, BAP1 removes ubiquitin molecules from 
histone H2A, which causes changes in the expression of specific genes that are 
regulated by this histone (83). It also modulates the assembly of multiprotein 
complexes containing numerous transcription factors and cofactors, and 
activates transcription in an enzymatic-activity–dependent manner, thereby 
regulating the expression of a variety of genes involved in various cellular 
processes (84). BAP1 has been implicated in several types of cancer such as lung, 
breast, and renal cell carcinoma (85–90). Germline BAP1 mutations have been 
described in families with a high risk for hereditary cancer and a novel ‘BAP1 
cancer syndrome’ that includes UM, cutaneous melanoma and melanocytic 
neoplasm, lung adenocarcinoma, meningioma and malignant mesothelioma, has 
been described (91–95). In HeLa and other cell lines, BAP1 depletion altered the 
expression of genes that were key mediators of cell-cycle progression, DNA 
replication and repair, cell metabolism, survival, and apoptosis (84). In vivo, 
expression of wild-type BAP1 was shown to significantly decrease 
tumourigenicity of a human non-small cell lung cancer cell line in nude mice. 
Conversely, expression of mutant BAP1 that lacks either deubiquitinating activity 
or nuclear localization did not suppress tumourigenicity, implying that both 
deubiquinating activity and nuclear localization are necessary for the tumour-
suppressive activity (96). Depsipeptide, a histone deacetylase HDAC inhibitor was 
shown to inhibit proliferation and growth by increasing expression of Fas and 
FasL in 3 UM cell lines derived from primary tumour and 2 cell lines derived from 
liver metastasis. Depsipeptide induced gene upregulation of both Fas and FasL in 
these cells, and an increase in activated caspase-3, apoptosis and cell-cycle arrest 
was observed in treated cells compared to non-treated cells (97). Landreville et 
al showed that HDAC inhibitors induced morphologic differentiation, cell-cycle 
exit, and a shift to a differentiated, melanocytic gene expression profile in 
212 
 
cultured UM cells. Furthermore, it was also shown to inhibit growth of UM 
tumours in vivo (98). Although BAP1 may function as a tumour suppressor in UM, 
the manner in which mutations/loss of this gene plays a role in the development 
of metastatic disease is not yet understood. 
 
 v-jun sarcoma virus 17 oncogene homolog (JUN) was differentially 
downregulated in M3M by 1.32 fold (p: 0.023). It is located in cytoband 1p32 and 
interacts directly with specific target DNA sequences to regulate gene 
expression. It is involved in a number of cell responses, such as cell proliferation 
and cell death (418). C-Jun and Jun kinase have been implicated in both pro- and 
antiapoptotic responses in different cells types (419). The most common known 
oncogenic mutations occur in GNAQ or GNA11, found in about 85% of all primary 
UM irrespective of tumour class or stage (23,24). Constitutive activation of the 
RAS/RAF/MEK/ERK pathway plays a crucial role in UM development, likely as a 
consequence of active mutations in the G-proteins GNAQ and GNA11 
(24,34,36,37). In a recent study, microarray analysis of UM cell lines with GNAQ 
mutations treated with the MEK inhibitor selumetinib was performed to identify 
gene targets of activated GNAQ (38). The expression of JUN was shown to be 
induced upon treatment of UM cells with selumetinib while knockdown of c-Jun 
expression significantly increased the antiproliferative effects in these cell lines, 
suggesting that c-Jun induction may be involved in mechanisms of resistance to 
MEK inhibition. In another study, combined inhibition of MEK/MAPK and 
PI3K/AKT pathways in GNAQ-mutant cells showed significant increase of 
phosphorylated c-jun (54). Similarly, knockdown of c-jun significantly enhanced 
the growth-inhibitory effect of MEK and PI3K inhibitors. These studies coupled 
with our finding of downregulation of JUN in monosomy 3 tumours with 
metastasis suggest that JUN may play a metastasis-suppressor role in UM. 
 
 Deleted in liver cancer, DLC1 was downregulated by 2.137 fold in M3M 
(p: 0.0000142). It is located in cytoband 8p22 and encodes a GTPase-activating 
protein (GAP) that acts as a negative regulator of small RhoGTP-binding proteins 
(420). Aberrant upregulation of Rho proteins plays an important role in 
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tumourigenesis, progression and metastasis (421). DLC1 has been established as 
a genuine tumour suppressor gene and is increasingly considered a metastasis 
suppressor gene (422). It has been shown to regulate and inhibit cell motility, 
migration (423) and angiogenesis (424). Downregulation of DLC1 has been shown 
to be critically involved in hepatocellular carcinoma (425–429), breast carcinoma 
(430–434), lung carcinoma (431,435–437), prostate carcinoma (438–440) and 
various other malignancies (430,431,441–444) where it has been shown to 
promote neoplastic transformation, proliferation, invasion, migration, and 
metastatic dissemination. DLC1 also mediates its tumour suppressive effects via 
GAP-independent mechanisms. In lung carcinoma cells, Yang et al reported that 
DLC1 displaced Annexin 2 binding from the pro-inflammatory protein S100A10 
(435). The latter is a critical surface receptor for plasminogen, which facilitates 
tumour invasion. Increased expression of DLC1 inactivated plasminogen and 
resulted in inhibition of in vitro cell migration, invasion, colony formation, and 
anchorage-independent growth of aggressive lung cancer cells (435). The Rho-
GTPase activity is dependent on tensin-1, -2 and -3 binding, which is required to 
activate and mediate the antioncogenic effects of DLC1 (445,446). Dysregulation 
of epidermal growth factor receptor (EGFR) plays a critical role in cell growth and 
migration, and is associated with metastatic formation (447). Tensin-3 was 
shown regulate DLC1 Rho-GAP activity and inhibit EGFR-mediated cell migration 
and transformation, suggesting a combined therapeutic approach to target 
aberrant EGFR expression in cancer (445). Onken et al demonstrated that 
deletion of 8p12-22 was associated with more rapid onset of metastasis within 
high-risk class 2 tumours. They identified Leucine zipper tumour suppressor-1 
(LZTS1) within this region as a metastasis suppressor gene in functional studies 
(448). In another study of 86 UM tumours and 66 liver metastases, loss of 8p has 
also been observed in 46% of primary UM tumours that metastasised, and in 
only one of the 15 non-metastasising tumours (449). Further, 45% of UM liver 
metastases also showed deletion of this region. Apart from chromosome 3 
status, 8p loss and 8q gain were the main differences between metastasising and 
non-metastasising tumours. A recent large study of 320 UM tumours by Shields 
and colleagues showed that even in the presence monosomy 3, 8p loss 
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significantly increased the risk of metastasis and was found to be an independent 
predictor or poor metastatic outcome (450). Van Gils et al also identified DLC1 
downregulation to be associated with 4-year disease free survival (408). 
However, DLC1 was not found to be a classifier gene in UM. Although DLC1 has 
never been studied in UM, our study provides compelling evidence to warrant 
further investigation into its role in the development of metastatic disease, 
which may yield novel biomarkers and targets for therapeutic intervention. 
  
A disintegrin and metalloproteinase domain 10 (ADAM10) was found to 
be differentially upregulated in M3M by 1.72 fold (p: 0.008). This gene is located 
in cytoband 15q22 and is a cell surface protein with a unique structure 
possessing both potential adhesion and protease domains. ADAM10 is the 
principle sheddase for several other molecules associated with cancer 
proliferation, differentiation, adhesion and migration such as MET, Notch, E-
cadherin, CD44 and L1 adhesion molecule (451). In agreement with our findings, 
the first and only study implicating ADAM10 in promoting UM metastasis and 
invasiveness was recently reported. Gangemi et al showed high ADAM10 
mRNAexpression correlated with metastatic progression where only 37% of 
patients with high ADAM10 expression were metastasis-free after 6 years, 
compared to 70% of patients with low ADAM10 expression (452). In vitro, UM 
cells express the active form of ADAM10 which cleave m-Met and promote 
soluble MET release. As expected, siRNA knockdown of ADAM10 led to reduction 
of soluble MET levels and significantly inhibited cell invasion (452). Given the 
preferential dissemination of UM cells to the liver, HGF and MET have been 
investigated in several studies. High immunohistochemical expression of HGF 
and MET in primary UM tissues have been reported (66–68). Mallikarjuna et al 
found a significant association between high MET expression and death due to 
uveal melanoma. Interestingly, the 6 tumours with liver metastasis showed 
higher expression of MET and were negative for HGF, suggesting a possible 
mechanism of ligand-independent MET activation (69). The activation of 
PI3K/AKT pathway induced by the HGF/MET was shown to attenuate cell-cell 
adhesion by downregulation of cell adhesion molecules E-cadherin and beta-
215 
 
catenin, promoting the enhanced motility and migration of uveal melanoma cells 
(70,71). On HGF stimulation, receptor MET translocated to the nucleus in a 
ligand-dependent manner, suggesting that MET may modulate the expression of 
genes involved in UM cell migration (70). Conversely, downregulation of MET 
expression decreased proliferation and migration by inhibiting AKT 
phosphorylation (67,72). Taken together, the correlation between ADAM10 
expression and MET at mRNA and protein level shown by Gangemi et al, and our 
findings of differential upregulation of ADAM10 expression in monosomy 3 
tumours with metastasis, suggests that both molecules contribute to the 
development of metastatic disease in UM. 
 
Inhibition of Notch signalling has been shown to inhibit several cancer 
types, such as lung (453) , pancreatic (454,455) and gastrointestinal cancers 
(456,457). In UM cells, Asnaghi et al demonstrated suppression of tumour spread 
and hypoxia-induced invasion by inhibition of Notch signalling in vitro (458). 
Transfection of the Notch ligand Jag2 into UM cells led to a 3 fold increase in 
growth, motility and invasion, suggesting the involvement of Notch pathway in 
promoting growth and metastasis (459). Furthermore, direct knockdown and 
suppression of Notch1 expression in UM cells resulted in significant inhibition of 
growth (460). When combined with recombinant oncolytic adenovirus H101, 
which replicates specifically in p53-depleted tumour cells, remarkable tumour 
growth inhibition and prolonged mouse survival in xenograft mice model was 
successfully demonstrated, suggesting Notch pathway deregulation in UM (460). 
Indeed, the expression of Notch receptors, ligands and targets were found in 5 
UM cell lines and 30 primary UM tissue samples (461). Constitutively active 
forms of Notch1 and Notch2 promoted growth of UM cells but pharmacologic 
blockade using the γ-secretase inhibitor MRK003 suppressed growth and 
invasion in vitro and in vivo (461). TIMP3 is an endogenous inhibitor of ADAM, 
and the activity of ADAM is thought to be upregulated in cancers due to the loss 
of TIMP3, possibly through its promoter hypermethylation (462). In our analysis, 
TIMP3 was found to be differentially downregulated by 1.41 fold in monosomy 3 
tumours with metastasis (M3M) compared to disomy 3 tumours without 
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metastasis (D3NM). This is an interesting finding, as van der Velden et al also 
demonstrated differential downregulation of TIMP3, due to promoter 
methylation, in metastatic cell lines (derived from liver metastases) compared to 
primary UM cell lines from the same patient (463).  
 
 Tryptophanyl-tRNA synthetase (WARS) was upregulated by 1.39 fold in 
M3M (p: 0.000144). It is located at cytoband 14q32 and regulates ERK, AKT, and 
eNOS activation pathways that are associated with angiogenesis, cytoskeletal 
reorganization and shear stress-responsive gene expression (464,465). Elevated 
WARS has been shown to be induced by TNF- α, interferon-α and γ, resulting in 
inhibition of angiogenesis and  cell growth (466–469). Specifically in the eye, it is 
a potent antagonist of VEGF-induced retinal angiogenesis and has been 
suggested as a potential treatment of neovascular ocular diseases (470). Low 
immunohistochemical expression of WARS in colorectal carcinoma tissue 
correlated with increased risk for recurrence and worse survival, likely secondary 
to its antiangiogenic properties (471). In pancreatic carcinoma cell lines, low 
expression of WARS with concomitant increase in metastatic potential was 
shown to be induced by hypoxia (472). Anti-VEGF agents have been shown to 
suppress in vitro growth and in vivo hepatic micrometastases in UM (473,474). In 
our study, WARS was upregulated in aggressive UM by a modest 1.39 fold. 
Nevertheless, it is likely that the molecular characteristics of upregulated WARS 
in aggressive UM is independent of its anti-angiogenic properties. 
 
 Branched chain aminotransferase 1, cytosolic (BCAT1) is located at 
cytoband 12p12 and was upregulated by 1.674 fold in M3M (p: 0.0071). It was 
also identified to be upregulated by McCannel et al in their study of 3 aggressive 
primary UM cell lines with monosomy 3 loss (407). It is involved in amino acid 
metabolism and is essential for cell growth (475). BCAT1 is suggested to be 
involved in proliferation and tumour formation (476). In colorectal cancer, BCAT1 
protein expression was significantly higher in advanced primary tumours that 
metastasised, compared to those that did not. Positive immunohistochemical 
expression predicted distant metastases and was associated with poor 5 year 
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survival compared to negative tumours, suggesting its use as a biomarker and 
therapeutic target (477). BCAT1 gene expression is regulated by MYC (478) and has 
been shown to be directly targeted by MYC during tumourigenesis (479,480). 
MYC induced overexpression of BCAT1 gene in nasopharyngeal carcinoma and in 
vitro inhibition of proliferation was observed when BCAT1 expression was 
suppressed (481,482). It is likely that BCAT1 upregulation in M3M is secondary to 
MYC expression. The MYC gene is located on chromosome 8q24.21. In UM, 
amplification of chromosome 8q is strongly associated with metastatic death 
(483). In our proteomic study, PRDX3 was upregulated in aggressive UM. MYC 
also directly induces PRDX3 expression which is required for MYC-mediated 
transformation and maintenance of mitochondrial function (484). The potential 
significance of MYC in UM is discussed in section 4.3.2, page 230. 
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4.2.2. Genes associated with adhesion and cellular 
organisation 
 
  Syndecan 2 (SDC2) was upregulated by 1.848 fold in M3M (p: 0.000348). 
It is located at cytoband 8q22.1 and functions as an integral membrane protein 
and participates in cell proliferation, cell migration and cell-matrix interactions 
via its receptor for extracellular matrix proteins (485). SDC2 also mediates cell 
binding and  signalling (485). It has been shown to interact with syntenin-1, 
which functions as a cytosolic signal effector downstream from SDC2 to regulate 
the surface availability of a number of cell adhesion and signalling molecules 
(486–488). Syntenin-1 was identified by Pardo et al (489) in a proteomic study of 
5 UM cell lines’ secretome. SDC2 was also identified by van Gils et al as a 
classifier gene (408). In another study, high levels of syntenin protein expression 
in primary UM tumour was found to be significantly associated with earlier 
metastatic progression and correlated with metastatic risk as strongly as 
monosomy 3 (490). Furthermore, UM liver metastases also showed higher 
syntenin expression compared to primary tumours (490). The authors also 
demonstrated that inhibition of syntenin expression reduces the activation of 
FAK, Src and AKT. Src has been shown to be an upstream tyrosine kinase for 
ERK1/2 activation in primary UM (264). Similarly, MAPK pathway has been 
implicated in uveal melanoma (33,34,154).Dasatinib, a Src family kinase inhibitor, 
was recently shown to inhibit MAPK and induce growth arrest in monosomy 3 
UM cell cultures (265). Thus, syndecan 2 and its intrinsic interaction with 
syntenin-1 may be critical in metastatic formation and dissemination in UM, and 
warrants further investigation as a therapeutic target. 
 
  Cell adhesion molecule with homology to L1CAM, CHL1 was 
downregulated by 2.924 fold in M3M (p: 0.0000643). It is located in cytoband 
3p26 and encodes a member of the L1 gene family of neural cell adhesion 
molecules (L1CAM). Deregulated expression of L1CAM has been implicated in 
various cancers such as cutaneous melanoma (491), ovarian (492), prostate (493) 
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and colon cancer (494). Deletions of chromosome 3p is one of the most common 
alterations in oesophageal squamous cell carcinoma, and CHL1 deletion was 
associated with poor prognosis and identified as a putative tumour suppressor 
gene (495,496). Similarly, CHL1 was also suggested as a tumour suppressor gene 
in nasopharyngeal carcinoma (497). In breast cancer tissues, CHL1 
downregulation was associated with high-grade phenotype while in vitro studies 
showed that overexpression suppressed proliferation and invasion (498). 
Likewise, knockdown of CHL1 expression increased proliferation and invasion in 
breast cancer cells (498). In neural progenitor cells (NPCs), CHL1 deficiency 
enhanced activation of ERK1/2 mitogen-activated protein kinase (MAPK) and 
stimulated proliferation and differentiation of these cells (499). Downregulation 
of CHL1 was also observed in several types of cancer (breast, kidney, rectum, 
colon, thyroid, stomach, skin, small intestine, bladder, vulva and pancreatic 
cancer), and suggested to act as a tumour suppressor gene (500). However, 
upregulation of CHL1 was associated with metastatic growth in ovarian, colon 
and breast cancer (500). This suggests that CHL1 may function as a tumour 
suppressor gene in several cancers and as an oncogene in others. In cervical 
cancer cells, Long et al demonstrated that miR-10a regulated CHL1 expression 
(501). Overexpression of miR-10a negatively regulated CHL1 expression and 
promoted colony formation, migration and invasion, suggesting that miR-
10a/CHL1 mediated metastatic formation. Cell adhesion molecules in UM have 
been investigated in several studies. Burgess and McCannel et al have also 
identified CHL1 downregulation in primary UM cell lines derived from aggressive 
tumours (406,407). Analysis of activated leukocyte cell adhesion molecule 
(ALCAM) located in chromosome 3q13 did not reveal methylation-mediated 
silencing of this gene in UM tumour tissues (502). In a more recent study, 
silencing ALCAM expression reduced invasiveness of a UM cell line in vitro. 
However, ALCAM overexpression did not increase motility or invasion, 
suggesting that ALCAM’s regulation of adherens junctions may differentially 
enhance or decrease invasiveness, depending on the type of cadherin adhesion 
complexes present in the primary tumour, and on the cadherin status of the 
tumour cells themselves (503). Immunohistochemical expression of melanoma 
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adhesion molecule (MCAM) in primary UM tumours was shown to be associated 
with metastatic death (504). In another study, intercellular cell adhesion 
molecule 1 (ICAM1) was an independent risk factor for metastasis within 5 years 
of diagnosis, while expression of neural cell adhesion molecule (NCAM) and 
vascular cell adhesion molecule 1 (VCAM1) was not related to metastasis 
formation (505). Mooy et al, however, demonstrated that NCAM was 
significantly more expressed in aggressive, rapidly metastasising tumours and in 
metastatic tissues (506). Interestingly, complete loss of CHL1 expression was 
shown in monosomy 3 tumours, but not due to allele loss, mutations or 
epigenetic alteration, suggesting that CHL1 downregulation was mediated by 
other mechanisms (507). However, functional studies of CHL1 in UM are lacking 
and its role as a potential tumour suppressor gene in UM needs to be 
investigated further. 
 
Arg/Abl-interacting protein ArgBP2 (SORBS2) was downregulated by 
2.545 fold in M3M (p: 0.000181). It is located in cytoband 4q35 and encodes an 
adapter protein that plays a role in the assembling of signalling complexes, being 
a link between ABL kinases and actin cytoskeleton (508). SORBS2, also known as 
Sorbin and SH3 domain-containing protein 2, has several well-defined structural 
motifs comprising three Scr homology 3 domains (SH3), a sorbin homology 
domain (SoHo), proline-rich ligand-binding sites and several serine/threonine 
phosphorylation sites (509). It also functions as a scaffold protein that regulates 
the balance between adhesion and motility by coordinating the function of 
multiple signalling pathways converging on the actin cytoskeleton (509). SORBS2 
protein can form complex with ABL1 and CBL, thus promoting ubiquitination and 
degradation of ABL1 (508). SORBS2γ also functions as an adaptor protein for 
AKT1 and PAK1 to promote cell survival via AKT1/PAK1 pathway (510). An 
immunohistochemical study has demonstrated that phosphorylated AKT 
correlates with poor prognosis in UM (49). Increased PAK1 expression was 
identified in invasive UM cell lines and knockdown led to a 5-fold decrease in 
invasive potential, suggesting that it is associated with tumour progression and 
metastasis (511). Suppression of AKT activation and MET (also implicated in UM) 
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by natural withanolide withaferin A inhibited cell proliferation, and induced 
apoptosis in multiple UM cell lines in vitro (512). However, whether the 
AKT/PAK1 pathway plays a role in UM is unknown. In our study, SORBS2 was 
downregulated in aggressive UM. This suggests that SORBS2 plays a protective 
role in a manner that is independent of γ-isoform’s AKT/PAK binding properties. 
Interestingly, McCannel et al also identified decreased SORBS2 expression in 
monosomy 3 tumours (407). Furthermore, van Gils et al identified SORBS2 as a 
classifier gene in UM, with decreased expression associated with poor prognosis 
(408). SORBS2 was identified as a tumour suppressor gene in cervical carcinoma. 
Inducing its expression in cell lines led to significant reduction in proliferation, 
colony formation and anchorage-dependant growth (513). A truncation in the 
SORBS2 gene has also been identified in a Burkitt lymphoma cell line (514). 
SORBS2 expression in the pancreas, which is high in normal tissue, was lost 
during oncogenic transformation, and its expression was decreased in malignant 
tumours (515). In vitro, expression of SORBS2 inhibited adhesion and migration 
of cancer cells. When its expression in a highly invasive cell line was restored and 
injected into mice, the ability to form tumours was reduced, demonstrating anti-
tumoural properties. As SORBS2 is involved in the organisation and stabilisation 
of the actin cytoskeleton, Taieb et al postulated that decreased expression leads 
to actin disorganization, cell dedifferentiation, and eventually, to abnormal cell 
migration and invasion (515). Taken together, these findings suggest that 
downregulation of SORBS2 may increase its metastatic capabilities while its 
expression may inhibit metastatic formation in UM. 
 
Thrombospondin 2 (THBS2) was upregulated by 2 fold in M3M (p: 
0.000864). It is located at cytoband 6q27 and encodes the thrombospondin 
family of matricellular proteins that mediates cell-to-cell and cell-to-matrix 
interactions (516). It interacts with matrix metalloproteinase-2 (MMP2) where 
high expression of THBS2 led to increased cell adhesion and migration (517). In 
ovarian and colorectal carcinoma, THBS2 was one of 2 genes suggested as a 
“core metastasis-associated” gene expression signature (518). In lung carcinoma, 
THBS2 and MMP9 was suggested to play an important role in metastatic 
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formation (519). Gene expression profiling of prostate cancer versus normal 
prostate tissue identified THBS2 as one of 28 transcripts significantly associated 
with recurrence after radical prostatectomy (520). Tumour-derived pancreatic 
stellate cells are essential cellular components of the pancreatic tumour 
microenvironment that releases growth factors, proteases, and extracellular 
matrix proteins to stimulate the spread of pancreatic cancer (521). These cells 
were shown to express high levels of THBS2 protein to promote and enhance 
invasion of pancreatic cancer cell lines while the opposite held true, where 
knockdown of THBS2 expression suppressed invasion of cancer cells (521). In 
epithelial ovarian tumours, higher expression of THBS2 was shown to correlate 
with an aggressive phenotype, while its expression was not detected in 
borderline epithelial tumours (522). In cutaneous melanoma, THBS2 was strongly 
expressed in melanoma metastases but not in primary tumours (523). Another 
study however suggests the opposite, where THBS2 was suggested to suppress 
haematogenous metastasis (524). THBS2 protein has also been shown to inhibit 
angiogenesis (525,526) and tumour growth in vivo (526). It has been shown to be 
protective in multistep carcinogenesis where THBS2 deficient mice demonstrated 
dramatically enhanced susceptibility to skin carcinogenesis, accelerated tumour 
formation and growth (527).  In an immunohistochemical study, variable THBS2 
expression was detected in UM tumour tissues in approximately 40% of 
specimens, but was not associated with survival, tumour vascularity or any other 
histopathological parameters of survival (528). In another UM study, another 
member of the thrombospondin family, THBS1 was effective in attenuation of 
tumour growth while THBS1 was decreased in response to the angiogenic switch 
during progression of uveal melanoma (529). Based on current evidence, high 
expression of the matricellular THBS2 may be associated with 
aggressive/metastatic disease in some malignancies, likely by facilitating 
adhesion and activating cell signalling pathways that regulate motility. 
Conversely, its protective effect in other tumours may be secondary to its 
antiangiogenic properties. 
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Multiple Epidermal Growth Factor 10, MEGF10 was downregulated by 
3.47 fold in M3M (p: 0.0000084). It is located at cytoband 5q23 and encodes for 
membrane receptors that are critical in phagocytosis of apoptotic cells by 
macrophages (530). It also plays a role in cell adhesion by facilitating mosaic-like 
adhesion patterns such as those found in retinal neuronal arrangement 
(531,532). It is essential in the regulation of myogenesis and has been described 
in a variety of disorders such as congenital myopathy (533), and early onset 
myopathy, areflexia, respiratory distress and dysphagia (EMARDD) (534,535). 
MEGF10 has also been shown to suppress proliferation by inhibiting cell motility 
necessary for cell division (532). MEGF10 was 1 of 25 genes identified in 12 
different paediatric cancer tissues compared to normal, suggesting that it may 
play a significant role in tumourigenesis (536). In acute myeloid leukaemia, 
MEGF10 it was identified as a marker of favourable outcome (537). Interestingly, 
MEGF10 was also significantly downregulated in fine-needle aspiration biopsy 
samples of monosomy 3 UM tumours (407) and in 3 UM cell lines derived from 
primary UM tumours that metastasised within 1.5 years (406). Our results are in 
keeping with these studies, and suggests that downregulation of MEGF10 may 
promote UM metastases by promoting tumour cell motility and proliferation 
with a concomitant inhibition of apoptosis. 
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4.3. Thioredoxin-dependant peroxidase reductase 
(PRDX3) 
 
Quantitative LC-MS proteomic analysis of UM tissues identified 
differential upregulation of PRDX3 by 1.58 fold (p: 0.002) in primary UM tissues 
from patients that developed metastasis compared to those that did not. 
Although not statistically significant, immunohistochemical staining of PRDX3 on 
13 primary UM tumours of patients that developed metastatic disease (mUM) 
and 13 primary UM tumours of patients that did not develop metastasis (nmUM) 
showed a trend towards higher expression in mUM compared to nmUM. All of 
the tumours in the mUM group demonstrated either moderate or strong staining 
(76.9% and 23.1%). Interestingly, 3 samples in mUM that showed strong staining 
throughout the tumour were from patients that died within 10 months after 
enucleation; 2 with liver metastases died between 4-10 months after enucleation 
and 1 with lung metastasis died 7 months after enucleation. However, there 
were also 4 tumours in nmUM that demonstrated strong staining varying from 
50% to 100% of tumour tissue. A significant difference between percentage of 
tumour cells staining in mUM compared to nmUM was observed, but not for 
intensity of staining. There was a significant correlation between high PRDX3 
expression and monosomy 3 tumours. No other significant correlation was found 
between PRDX3 expression and other histopathologic factors. The lack of 
meaningful statistically significant results of PRDX3 expression may be explained 
by the relatively small sample size of 26 tumours. 
 
No significant correlation was found between PRDX3 expression and cell 
type or tumour size. It was not possible to determine if PRDX3 expression was 
associated with chromosome 3 status, as all 17 tumours with chromosome 3 
information available (10 monosomy and 7 disomy 3 tumours) demonstrated 
high expression of PRDX3. A statistically significant difference of PRDX3 
expression was observed in patients that did and did not develop metastasis. A 
significant positive correlation between high PRDX3 expression and metastasis 
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was observed. Likewise, a significant correlation between high PRDX3 expression 
and shorter survival was found. The difference in overall survival between 
tumours that demonstrated low and high expression of PRDX, demonstrated by 
Kaplan-Meier survival curve, was also significant. Incorporation of PRDX3 
expression in logistic regression analysis increased the probability of predicting 
metastasis by 9.8%. Using PRDX3 expression score of low/high, 43.2% of patients 
with no metastasis and 87.3% of patients with metastasis would be successfully 
predicted, giving an overall positive predictive percentage of 69.6%. Based on 
this study population, a patient with high expression of PRDX3 would be 5.22 
times more likely to develop metastasis compared to one with low expression.  
 
In this study, 2 members of the PRDX family were identified that were 
statistically significant; PRDX3 and PRDX4 (1.58 and 2.19 fold upregulated in 
metastatic primary UM respectively. The PRDX family (I–VI) is critically involved 
in redox regulation of the cell and protect radical-sensitive enzymes from 
oxidative damage by a radical-generating system. These isoenzymes are widely 
distributed subcellularly, in contrast to the most other antioxidant enzymes. 
PRDXs exert their protective antioxidant role in cells through their peroxidase, 
whereby hydrogen peroxide, peroxynitrite and a wide range of organic 
hydroperoxides are reduced and detoxified (538–540). In addition, these 
proteins are also involved in a range of other cellular roles, including the 
modulation of cytokine-induced hydrogen peroxide levels, which have been 
shown to mediate signalling cascades leading to gene expression, cell 
proliferation, differentiation and apoptosis (538,541,542).  
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4.3.1. PRDX3 inhibits apoptosis via the intrinsic pathway 
 
Normal cellular processes that involve oxygen result in the production of 
reactive oxygen species (ROS) such as superoxide (O2˙
ˉ ), hydrogen peroxide 
(H2O2), and hydroxyl radical (OH˙). Each of these species has the potential to 
oxidize macromolecules and thereby to induce mutation of DNA, impairment of 
protein function, and lipid peroxidation. O2˙
ˉ does not readily cross the 
mitochondrial membrane, given its charged nature. O2- is catalysed by Mn2+ 
dependent superoxide dismutase (MnSOD) present in mitochondrial matrix 
(543). This protects mitochondrial function from O2- mediated damage of various 
enzymes. Although MnSOD relieves mitochondrial oxidative stress caused by 
O2˙
ˉ, it generates H2O2 causing a different type of oxidative stress. Furthermore, 
H2O2 is readily converted to the more powerful oxidant OH˙ via the Fenton 
reaction. Intracellular H2O2 is removed mostly by catalase, glutathione 
peroxidase (GPx), and peroxiredoxin (PRDX). However, the vast majority of 
mitochondrial H2O2 is catalysed by PRDX3, with mitochondrial GPx1 accounting 
for removal of only 15% of H2O2 (544).  Furthermore, PRDX3 is much more 
abundant in mitochondria than GPx and is therefore a critical regulator of 
mitochondrial H2O2 concentration (545). On reaction with H2O2, the redox-
sensitive Cysteine residue of each subunit of the PRDX homodimer is oxidized to 
Cys-SOH, which then reacts with a neighboring Cys-SH of the other subunit to 
form an intermolecular disulphide (546). This disulfide is reduced specifically by 
thioredoxin, not by glutathione or glutaredoxin (546). The reduced form of 
thioredoxin is then regenerated by thioredoxin reductase at the expense of 
NADPH .(547–549).  
 
Apoptosis is a genetically determined process of cell self-destruction to 
eliminate DNA-damaged, superfluous, or unwanted cells. Dysregulation of this 
normal physiological process may result in uncontrolled cell growth and 
ultimately, tumour formation and progression. Resistance to apoptosis can also 
augment the escape of tumour cells from surveillance by the immune system 
227 
 
(550). Apoptosis occurs via two alternative pathways: either through “death 
receptors” on the cell surface (extrinsic pathway) or through intracellular 
mitochondria (intrinsic pathway). Mitochondria play a central role in this process 
by releasing cytochrome c and other proapoptotic proteins that ultimately leads 
to the formation of an apoptosome and subsequently apoptosis. The 
mitochondrial production of ROS is also thought to be associated with the 
activation and propagation of apoptosis (551,552). Indeed, generation of ROS by 
mitochondria appears to be an early event in apoptotic signalling initiated by 
TNF-α, ceramide, or glutamate (553–555). Various studies have demonstrated 
the role of H2O2 as a second messenger in both extrinsic and intrinsic apoptotic 
pathway (556–558).  
 
Chang et al recently identified PRDX3, via its effects on H2O2, to be a 
critical regulator of apoptotic signalling (545). Depletion of PRDX3 resulted in 
increased intracellular H2O2, cytochrome c and other proapoptotic molecules 
such as caspase 3, sensitising cells to induction of apoptosis by staurosporine or 
TNF-α (545). Although many proapoptotic stimuli induce the intracellular 
accumulation of H2O2, a causal relationship between the mitochondrial 
generation of H2O2 and its active participation in apoptosis was shown (545). 
Therefore, cells that express PRDX, or indeed increased PRDX expression may 
catalyse the production of TNF/staurosporine-mediated mitochondrial H2O2 
necessary for apoptosis. The increased expression of PRDX3 in primary UM 
tissues from patients who developed metastasis found in this study indicates its 
potential role as a suppressor of mitochondria-mediated apoptosis by 
eliminating H2O2. Via this mechanism, UM cells expressing high levels of PRDX3 
may evade apoptosis, leading to uncontrolled cell proliferation. PRDX3 also 
protects the mitochondria against H2O2 and OH˙ mediated mitochondrial RNA 
damage. This supports the well-established knowledge that tumour cells exhibit 
a high metabolic rate to support rapid proliferation and growth.  
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Overexpression of PRDX3 protects thymoma cells from apoptosis induced 
by hypoxia, a bolus of peroxide or the anticancer agent imexon (559). In prostate 
cancer cells, increased mitochondrial ROS was observed secondary to high 
metabolism (560). In these cells, PRDX3 and PRDX4 may be upregulated as part 
of their anti-oxidant defence response in order to protect organelles from 
oxidative damage and prevent cell death (399). Another study also identified 
PRDX3 overexpression in prostate cancer, where these cells demonstrated 
resistance to H2O2-induced apoptosis through a failure to activate pro-apoptotic 
pathways (400). High expression of PRDX3 in prostate cancer tissues was also 
shown to be associated with aggressive disease and poor patient outcome (561). 
PRDX3, along with PRDX4, was also identified in a prostate cancer tissue 
proteomic study where these proteins were overexpressed and increased 
proliferation of prostate cancer cell lines (562). An immunohistochemical study 
identified a positive correlation between PRDX3 expression and proliferation in 
breast cancer tissues. Silencing PRDX3 gene in breast cancer cell lines also 
decreased proliferation and induced cell cycle arrest at the S and G2/M phase 
(563). Another study observed that the overexpression of PRDX I–III in breast 
cancer could be explained by the antiapoptotic and proliferative effects that 
these proteins exert (564). Karihtala et al found high expression of PRDX I, III, IV 
and V in breast carcinoma, suggesting that PRDXs are able to inhibit H2O2-
mediated physiological apoptosis, cause abnormal proliferation, and thereby 
may lead to tumourigenesis (565). Specifically, they found a correlation between 
strong PRDX3 expression and poorly differentiated tumours. In lung squamous 
and adenocarcinoma, upregulation of PRDX1, PRDX3 and TRX was observed and 
suggested to represent an attempt by tumour cells to adjust to the 
microenvironment in a manner that is advantageous to survival and proliferation 
(566). In hepatoma cells, overexpression of PRDX6 conferred resistance to 
peroxide-induced apoptosis, suggesting that its up-regulation may be a tumour-
supportive adaptation in cancerous states (567). Neuroblastoma cells that were 
depleted of PRDX3, along with PRDX5 were more prone to oxidative damage and 
apoptosis (568). Taken together, high PRDX3 expression found in aggressive UM 
may be necessary to inhibit apoptosis, upregulate cell proliferation to provide 
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growth advantage to the tumours cells. In addition to that, high PRDX3 
expression would sustain and support the high metabolic demand of these cells, 
facilitating propagation and dissemination, ultimately leading to metastasis.  
 
Dioscin is a glucoside saponin which has been shown to possess anti-
proliferative properties against a number of human cancer cells such as 
leukaemia, lung adenocarcinoma and HeLA cells (569–571). A recent study by 
Wang et al demonstrated that the pro-apoptotic activity of dioscin in 
oesophageal cancer cell lines was mediated by PRDX1 and PRDX6, via the 
intrinsic mitochondrial pathway (572). Dioscin led to a decrease in PRDX1 and 
PRDX6 levels, thereby causing an increase in ROS levels leading to apoptosis. 
However, overexpression of PRDXs significantly blocked the elevated ROS levels 
and apoptosis induced by dioscin, suggesting the central importance of PRDXs in 
the mechanism of action of dioscin in inducing cancer cell apoptosis. The authors 
suggest that agents which either increase ROS generation or decrease the 
expression of antioxidant enzymes have the potentiality to target cancer cells 
with little or no effect on normal cells. This may have significant therapeutic 
implications in UM. While PRDX3 wasn’t identified by Wang et al, the use of this 
agent to determine its effects in UM cells in vitro should be investigated. To 
support this, Wang et al identified PRDX1 and PRDX6 by comparing dioscin-
treated and non-treated cancer cells, to identify differential expression of 
proteins that may be central to its apoptotic effects. As shown in numerous 
other studies, a variety of PRDXs have been implicated in different human 
cancers. As dioscin has been shown to initiate apoptosis via the mitochondrial 
pathway, the exclusive localisation of PRDX3 within the mitochondria provides 
further justification to study its effects in UM. 
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4.3.2. MYC activates PRDX3 expression and stimulates 
proliferation 
 
Deregulated overexpression of MYC, which mimics conditions found in 
cancer cells, directly induces PRDX3 expression that is required for MYC-
mediated transformation and maintenance of mitochondrial function (484). The 
MYC gene is located on chromosome 8q24.21. In UM, amplification of 
chromosome 8q is strongly associated with metastatic death (483). Several 
studies have determined the expression of MYC in UM. MYC was amplified in 5 
of 8 hepatic metastatic lesions analysed by FISH (573). Larger tumour size and 
tumours with monosomy 3 were significantly associated with amplification of 
MYC (574). High expression of MYC was associated with high proliferative index 
in UM tissues (575), and high MYC expression, MIB-1 index and large tumour 
diameter were independent prognostic parameters for poor outcome (576). 
Conversely, Chana et al demonstrated improved survival in MYC positive 
tumours (577,578). The authors did however identify a link between MYC 
overexpression and UM resistance to interferon-α, supporting the concept that 
MYC downregulation is associated with the cell growth inhibition produced by 
interferon-α and that resistance is associated with tumour MYC overexpression 
(579). Recently, gene microarray study of high-grade tumours overexpressing 
chromosome 8q showed upregulation of Development And Differentiation-
Enhancing Factor (DDEF1) also located on chromosome 8q24.21, but not MYC 
(580). However, the specific functional effects of MYC in UM are yet to be 
determined. Given that it directly activates PRDX3, future studies to investigate 
this may yield further insights into the tumour biology and potential therapeutic 
targets. 
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Experimental models of MYC-mediated tumourigenesis suggest that 
established tumours are addicted to MYC and that deregulated expression of 
MYC result in an addiction not only to MYC but also to nutrients (581). MYC 
regulates energy metabolism through its direct activation of genes involved in 
glycolysis, glutamine metabolism and mitochondrial biogenesis (582,583). MYC is 
also known to induce the production of ROS, possibly through its induction of 
mitochondrial biogenesis and increased metabolism,  causing genomic instability 
(584–586). In UM, overexpression of MYC may induce sustained oxidative insult 
on the genome of tumour cells, causing specific chromosomal alterations found 
in UM, such as loss of heterozygosity/monosomy 3 that ultimately leads to the 
metastatic phenotype. It may also be hypothesised that once the level of MYC-
induced ROS reaches this threshold level, the expression of PRDX3 increases in 
response to the increased oxidative stress. This would further inhibit apoptosis 
and protect mitochondria from oxidative damage, enabling normal physiological 
function to meet the high-energy requirement of UM tumour cells.  
 
This potential MYC-induced changes in aggressive UM provides an 
opportunity to develop therapeutic targets. In fact, knock-down of MYC in 
established cancer cell lines inhibited cell proliferation at various stages of the 
cell cycle,  and in some instances induced apoptosis (587–589). Furthermore, 
expression of a dominant negative inhibitor of MYC heterodimerization in vivo 
resulted in rapid regression of incipient and established lung tumours, suggesting 
that inhibiting MYC function could be a potential therapeutic strategy (590). 
Strategies have emerged to inhibit MYC expression, to interrupt MYC-MAX 
dimerization, to inhibit MYC-MAX DNA binding, and to interfere with key MYC 
target genes (581). BET bromodomain regulatory proteins recently emerged as 
potent regulators of MYC expression in different tumour types (581). BRD4, a 
transcriptional regulator in the BET domain, was shown to bind to the MYC 
promoter region and play a critical role in MYC expression in human cancer cells. 
Inhibition of BET BRD4 protein could inhibit in vivo tumourigenesis, suggesting 
that targeting MYC expression is feasible in selected cancers (591,592). Targeting 
MYC-induced repression of miR-26a in liver cancer  animal models resulted in a 
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remarkable response, suggesting that interfering with MYC regulated microRNAs 
could be therapeutically feasible (593). Phosphofructokinase, PFKM is another 
target gene of MYC (594) that may have implications in UM. Although not 
statistically significant (p=0.06), PFKM was upregulated by 2 fold in metastatic 
primary UM tissue. Furthermore, a recent proteomic study found 
downregulation of PFKM in irradiated 92.1 cells, suggesting its role in cell-cycle 
arrest and tumour senescence (241). Activation of PFK is regulated by the 
bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 
(PFKFB), which in turn is regulated by protein kinases such as AKT and MAPK 
(287). It has been shown that the MEK/MAPK and PI3K/AKT pathways are highly 
activated in UM (33,34,154,155). In a phase II study, the MEK inhibitor 
selumetinib extended progression-free survival by nearly 9 weeks and reduced 
tumour size by 50% in patients with UM (288). This downregulation of PFKM may 
reflect a shift in the energy demand of tumour cells post radiation, possibly via 
the inhibition of MAPK and AKT pathways. Taken together, the direct inhibition 
of MYC may be a feasible therapeutic target in UM, and warrants further 
investigation. 
 
In this study, the significance of high PRDX3 expression in primary UM 
tissues that developed metastasis and its association with shorter survival may 
represent a potential involvement of this protein in tumour growth and 
dissemination. Its role in inhibiting apoptosis and interaction with the MYC and 
MAPK pathway likely promotes tumour cell survival, proliferation and eventually 
metastatic formation. Further analysis of the expression, activity level, and 
function of PRDX3 in UM would be essential for defining the potential role of 
these proteins as novel biomarkers and therapeutic targets. Such studies could 
also provide new insights into the role of PRDX3 as a potential biological 
determinant contributing to the development of metastatic disease. 
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4.4. Cytosolic non-specific dipeptidase (CNDP2) 
 
Quantitative LC-MS proteomic analysis of UM tissues identified CNDP2 as 
being was downregulated by 1.75 fold (p: 0.001) in primary UM tissues from 
patients that developed metastasis compared to those that did not. 
Immunohistochemical staining of CNDP2 on 13 primary UM tumours of patients 
that developed metastatic disease (mUM) and 13 primary UM tumours of 
patients that did not develop metastasis (nmUM) did not show any statistically 
significant difference of expression between the two groups. A trend towards 
lower expression in mUM was found, with 46% of mUM tumours demonstrating 
no CNDP2 expression (no staining) while all nmUM tumours showed positive 
staining for CNDP2. However, no significant difference was seen when comparing 
the intensity or percentage of staining between mUM and nmUM. No significant 
correlation between CNDP2 score and survival in patients with metastatic 
disease was found, but higher expression significantly correlated with 
disomy/trisomy 3 tumours compared to monosomy 3. No other significant 
correlation between CNDP2 score and clinicopathological factors were found. 
Apart from correlation with chromosome 3 status, the lack of significant results 
of CNDP2 expression may be explained by the relatively small sample size of 26 
tumours. Due to a relatively weak staining in both mUM and nmUM tissues, 
CNDP2 was not evaluated further in the larger cohort of UM microarray samples.  
 
CNDP2 is a nonspecific dipeptidase that is widely distributed in central 
and peripheral human tissues of adults (595). It is predominantly involved in 
amino acid metabolism and hydrolyses a variety of dipeptides including L-
carnosine, but has a strong preference for Cys-Gly and hydrophobic dipeptides 
including prolyl amino acids. It exists in 2 isoforms; isoform 1 and isoform 2.  
CNDP2 is mainly implicated in the susceptibility of developing diabetic 
nephropathy with conflicting results (596–598), and in Parkinsons disease, where 
it was found to be elevated (599). Only 2 published reports directly implicate low 
expression of CNDP2 with malignancies, suggesting that it may exert tumour-
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suppressive effects (600,601). However, CNDP2 has also been identified in 
various genomic and proteomic studies in cancer, though it has never directly 
implicated in cancer development or progression (602–607). 
 
Deletion of CNDP2 gene was observed in 27.2% cancer specimens from 
an aCGH study containing more than 3,000 cancer specimens where high 
frequency of copy number loss was observed in oesophageal squamous cell 
carcinoma (63.6%) and colorectal cancer (50.9%), suggesting that deletion of this 
gene is common in several gastrointestinal cancer types (602). CNDP2 was 
identified as one of 95 genes that were differentially upregulated in a study 
comparing secondary metastatic oral squamous carcinoma to primary tumours 
(603). This gene signature was also found to be strongly associated with poor 
patient outcome in an independent cohort of patients. A recent microarray study 
compared gene expression profiles of normal CD34+ bone marrow cells to those 
from patients with myelodysplastic syndrome (MDS) to identify gene signatures 
for classification of different subtypes of the disease (607). Different gene 
signatures were found to distinguish MDS from normal, aggressive MDS from 
normal, stable MDS from normal and del(5q) MDS from normal. The del(5q) 
subtype is classified as low-risk category and is treated with lenalidomide as 
standard practice (608). Of the 4 categories studied, overexpression of CNDP2 
was one of 33 member gene signature identified that distinguished between 
del(5q) MDS and normal subjects. Since CNDP2 wasn’t identified in the gene 
signature of more aggressive subtypes, its overexpression in low-risk MDS may 
correlate with our findings of higher expression in primary UM that did not 
metastasise. 
 
In cutaneous melanoma, a GEP study comparing invasive vs. non-invasive 
mouse xenograft models identified CNDP2 to be upregulated in the invasive 
model (606). However, this opposite relationship to our results may not be of 
any significance, since the molecular characteristics between cutaneous 
melanoma and UM differ significantly. It is known that these are 2 separate 
disease entities, with almost exclusive cytogenetic and molecular characteristics. 
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Genetic mutations associated with cutaneous melanoma such as BRAF and NRAS 
are rare in UM, while mutations in GNAQ and BAP1 are absent in cutaneous 
melanoma (609,610). Clinically, uveal melanoma spreads haematogenously, 
while cutaneous melanoma also spread via the lymphatic system. Therefore, it is 
likely that CNDP2 may play different roles in different cancer types. 
 
In order to derive an objective method to grading of clear cell renal 
carcinoma, LC-MS/MS study of 50 cancer samples equally distributed among 
normal tissues and Fuhrman grades 1–4 was performed by Perroud et al (605). 
Grade 1 tumours have the most favorable prognosis with lowest risk for 
metastasis while grade 4 is associated with high-metastatic risk (611). CNDP2 
was identified as the most statistically significant protein to be overexpressed in 
grade 1 and 2, while the abundance of this protein was uniformly low across 
normal, grade 3 and 4 samples. However, the authors did not further investigate 
the specific properties of CNDP2 in this disease. A recent 2D-DIGE proteomic 
analysis identified CNDP2 as one of 68 proteins that were underexpressed in 
cholangiocarcinoma compared to paired non-tumoral liver tissue from the same 
patients (604). Parallel significance in UM may be inferred from these proteomic 
studies. The higher expression of CNDP2 in UM that did not metastasize may 
represent less aggressive disease with low metastatic potential. 
 
A large-scale cDNA transfection study on human hepatoma cells showed 
that CNDP2 isoform-2 gene underexpression was significantly associated with 
tumor microsatellite formation and venous invasion, which are features of 
metastasis in hepatocellular carcinoma (HCC) (600). HCC cell line transfected 
with this gene was found to suppress invasion, suggesting that it may play a role 
as a metastasis-suppressor. Furthermore, significant induction of G1 arrest, 
sensitization to cell apoptosis, inhibition of cell growth, and tumour formation 
was observed in nude mice transfected with the CNDP2 isoform-2 gene. 
Significant downregulation of other proteins associated with invasion and 
metastasis formation, such as CXCR3, MMP11, and CD44s was also observed in 
transfected HCC cells. The authors conclude that CNDP2 isoform-2 plays a 
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significant inhibitory role in the formation, growth and metastasis in HCC. While 
these associations were found in HCC, this may have implications in UM given 
that 90% of UM preferentially metastasises to the liver. Thus, it is tempting to 
postulate that CNDP2 may exert a protective role in the development of liver 
metastasis in UM. However, the downregulation of CNDP2 in primary UM 
samples that metastasised to the liver were variable in our study. Half of the 
samples metastasised to the liver (4/8), while another metastasised to both the 
liver and lung. The mean raw abundance of CNDP2 in samples that developed 
hepatic metastases was higher than that of samples that developed extrahepatic 
metastases (357600 SIV vs. 231385 SIV). Nevertheless, the expression levels of 
CNDP2 in hepatic metastases, and it potential effects on cell lines derived from 
hepatic metastasis should be investigated. This may provide further insights into 
targeted therapy for patients with hepatic metastases. 
 
An array CGH study identified deletion of CNDP2 gene in pancreatic 
carcinoma tissues (601). Deletion of this gene was an independent poor 
prognostic marker for overall survival after adjusting for other factors associated 
with patient outcome. The median overall survival of patients without deletion 
of CNDP2 gene was significantly longer compared to those with deletion of this 
gene (30.3 months vs. 16.0 month).  Furthermore, a significant association 
between deletion of the CNDP2 gene and high grade of tumours was also 
observed. In vitro studies of the effect of CNDP2 demonstrated that cells 
expressing CNDP2 had significantly lower proliferation rate than CNDP2-
knockdown cells. Furthermore, a significant increase of G0/G1 cell cycle phase 
and attenuated cell migration was also observed. Based on these findings, the 
authors suggest that CNDP2 may function as a growth suppressor, which may not 
be related to its enzymatic activity.  
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Elevated levels of CNDP2 may indicate the absence of metastases, and 
may be useful as a biomarker to monitor patients at high risk for metastasis. 
However, the validity of CNDP2 as a biomarker needs to be investigated in 
patients by comparing class 1 low risk patients and class 2 high risk/patients that 
have developed metastatic disease. The use of CNDP as a biomarker to 
determine the response to currently used chemotherapeutic agents for the 
treatment of metastatic disease should also be investigated. Its role to guide 
selection of patients for adjuvant treatment is also necessary. CNDP2 was  found 
in an unpublished qualitative proteomic study of human normal vitreous humour 
(612). Its presence in normal vitreous raises the possibility of the use of CNDP2 
as a vitreous biomarker in UM patients treated with modalities other than 
enucleation. Aspiration of vitreous fluid is an invasive but relatively safe and 
simple technique. Serial measurement of CNDP2 in vitreous may be used to 
monitor response to treatment, disease progression, and more importantly the 
onset and development of distant metastasis. The presence, expression and 
variations of CNDP2 in vitreous fluid of enucleated UM specimens of different 
disease stages needs to be determined to explore its use as a biomarker. 
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4.5. Signal-induced proliferation-associated 1-like 
protein 2 (SIPA1L2) 
 
Bioinformatic reanalysis of gene expression microarray data of 
monosomy 3 tumours with metastasis (M3M) versus disomy 3 tumours without 
metastasis (D3NM) identified differential upregulation of signal-induced 
proliferation-associated 1-like protein 2 (SIPA1L2) in M3M. It had the fifth most 
significant p value (p: 0.001) where it was 1.516 fold differentially upregulated in 
M3M compared to D3NM. It is located in cytoband 1q42 and positively regulates 
GTPase activity and small GTPase-mediated signal transduction (613). Otherwise, 
very little is known about SIPA1L2. However, immunohistochemical staining of 
SIPA1L2 on 13 primary UM tumours of patients that developed metastatic 
disease (mUM) and 13 primary UM tumours of patients that did not develop 
metastasis (nmUM) did not show any statistically significant difference of 
expression between the two groups. No identifiable trend of expression was 
seen in either group, which may reflect the modest fold change that was found in 
the microarray analysis. No significant difference was seen when comparing the 
intensity or percentage of staining between mUM and nmUM. SIPA1L2 
expression did not correlate with clinicopathological factors such as survival, 
chromosome 3 status, cell type or tumour size. Similar to the other selected 
targets, the lack of significant results of SIPA1L2 expression may be explained by 
the relatively small sample size of 26 tumours. Thus, SIPA1L2 was not evaluated 
further in the larger cohort of UM microarray samples.   
 
SIPA1L2 was identified to be upregulated by McCannel et al in their study 
of 3 aggressive primary UM cell lines with monosomy 3 loss (407), while van Gils 
et al also reported upregulated SIPA1L2 as a classifier gene associated with poor 
prognosis in UM (408). Gene expression profiling of prostate cancer versus 
normal prostate tissue identified SIPA1L2 as one of 28 transcripts significantly 
associated with recurrence after radical prostatectomy (520). Interestingly, this 
study also identified THBS2 among the 28 transcripts. However, neither of these 
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were followed-up. Significant and consistent over expression of SIPA1L2 and 
many other genes was shown in astrocytic cancer cells (614). SIPA1L2 was also 
identified as one of top 50 genes that were overexpressed in aggressive, therapy-
resistant prostate cancer cells that were initially androgen-dependent but 
eventually survived and resumed growth under androgen-deprived conditions 
(615). Fibroblasts constitute the majority of tumour stroma and have been 
suggested to be prominent modifiers of cancer progression, with a specific 
subpopulation designated as cancer-associated fibroblasts (CAFs) that play a key 
role in promoting tumor initiation and progression. Compared to normal 
prostate tissue fibroblast, gene expression profiling identified upregulation of 
SIPA1L2 and 72 other genes in prostate carcinoma fibroblast (616).  
 
Signal transducer and activator of transcription 3 (STAT3) is a latent 
cytoplasmic transcription factor that it regulates transcription of target genes, 
induced by a variety of upstream signals, including growth factors, cytokines and 
non-receptor tyrosine kinases (617–620). Constitutive STAT3 activation has been 
demonstrated in a variety of cancers such as cutaneous melanoma (621), 
lymphoma (622), myeloma (623), squamous cell (624), prostate (625) and breast 
carcinoma (626). In order to identify genes regulated by STAT3, fibroblast cells 
constitutively expressing STAT3 were shown to downregulate SIPA1L2 expression 
amongst numerous other genes (627). It is likely that our finding of upregulated 
SIPA1L2 in aggressive UM plays a role that is independent of STAT3 regulation. In 
support of this, only one study that sought to determine whether UM cells 
require Notch activity for growth, reported STAT3 expression in UM (461). Notch 
blockade using the γ-secretase inhibitor (GSI) MRK003 was shown to inhibit UM 
cell growth and invasion by inhibiting AKT, Erk, and STAT3. Both AKT and Erk 
pathways are known to be involved in UM (33,34,154,155), but the significance 
of STAT3 is unknown.  
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4.5.1. SIPA1L2 may inhibit apoptosis via the extrinsic 
pathway 
 
Expression of RAS oncogene occurs in about 30% of human tumours, 
including cutaneous melanoma (628–630). SIPA1L2, along with 27 other genes 
was shown to be involved in a complex pathway in RAS-mediated epigenetic 
silencing of Fas (631). In the extrinsic apoptotic pathway, activation of one of the 
death receptors signalling pathways such as Fas triggers upstream signalling 
caspases that leads to apoptosis (632). Fas interacts with Fas ligand (FasL) and 
recruits the adaptor molecule Fas-associated death domain (FADD) (633). FADD 
also has another domain called the death effector domain, which in turn recruits 
pro-caspase-8 and/or pro-caspase-10 to the receptor (633). The resulting protein 
complex activates these initiator caspases and triggers further increased caspase 
activity that leads to the activation of effector caspases such as caspase-3, -6 and 
-7. Effector caspases selectively cleave a restricted set of target proteins that 
ultimately leads to apoptosis. Tumour cells have been shown to be resistant to 
Fas-mediated apoptosis, with molecular defects being identified at several levels 
of the apoptotic signalling pathway (634). Indeed, tumours demonstrate 
resistance to apoptosis in a manner that evades surveillance by the host immune 
system and leads to uncontrolled growth (550). As an anti-tumour immune 
response, infiltrating T cells and NK cells express FasL as a cytotoxic mediator 
(635). However, resistance to Fas-mediated apoptosis protects cancer cells 
against the anti-tumour response (635). In colorectal tumours, decreased Fas 
expression was only observed in a small number of adenomas, while carcinomas 
demonstrated reduced Fas expression and was associated with tumour 
progression (636). Furthermore, complete loss of Fas expression was observed 
more frequently in tumours that had already metastasised (636). Recently, 
mesenchymal stem cells were shown to induce apoptosis, inhibit growth and 
metastasis of multiple myeloma in mice via the Fas/FasL mechanism (637). Decoy 
receptor 3 (DcR3) protects cells from a wide range of apoptotic stimuli and was 
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shown to be expressed in pancreatic carcinoma cells (638). These cells 
demonstrated resistance to FasL-mediated apoptosis and silencing of DcR3 
expression enhanced the inhibitory effects of FasL, reduced proliferation and 
colony formation in vitro (638). Further, the downregulation of DcR3 induced 
FADD, caspase‑3 and caspase‑8, thus triggering cell apoptosis in these cells (638). 
Several studies have implicated reduced Fas levels with lymph node involvement, 
bone metastases, recurrences and poor prognosis in breast cancer (639–643). 
Low Fas expression in osteosarcoma was shown to correlate with increased 
metastatic propensity (644). Interestingly, Fas -negative tumour cells gained the 
ability to evade the host defence mechanism and form lung metastases (644). In 
mice with lung metastases, aerosol treatment with chemotherapeutic agents 
known to upregulate Fas expression, such as liposomal 9-Nitrocamptothecin and 
Gemcitabine induced tumor regression in wild type mice. However, lung 
metastases in FasL-deficient mice did not respond to the treatment. 
Chemotherapeutic drugs can upregulate Fas and FasL expression in tumour cells 
and induce Fas-mediated apoptosis and lead to tumour regression (645). 
Cytotoxic drug-induced activation of the Fas/FasL pathway has been shown in 
leukaemia cells, hepatoblastoma, neuroblastoma and brain tumours (646,647). 
Chemotherapeutic agents such as etoposide and cisplatin has been shown to 
upregulate FasL expression at therapeutic concentrations and are capable of 
inducing tumour cell death in a Fas-dependent manner (648,649). In 
medulloblastoma and glioblastoma, γ-irradiation was shown to cause cell death 
by a Fas/FasL-dependent mechanism (650). Kallikrein-binding protein (KBP), a 
serine proteinase inhibitor, decreased cell viability and induced apoptosis of 
colorectal carcinoma cells by increasing expression of FasL and activated 
caspase-8 (651). 
 
Although mutations of the RAS family of oncogenes in UM are rare (652–
656), an immunohistochemical study showed that both Fas and FasL was 
expressed in UM tumours (657). It was also demonstrated that low expression of 
FasL was associated with an increased risk for metastasis. In another study, 
depsipeptide, a HDAC inhibitor was shown to inhibit proliferation and growth by 
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increasing expression of Fas and FasL in 3 UM cell lines derived from primary 
tumour and 2 cell lines derived from liver metastasis. Depsipeptide induced gene 
upregulation of both Fas and FasL in these cells, and an increase in activated 
caspase-3, apoptosis and cell-cycle arrest was observed in treated cells 
compared to non-treated cells (97). Given the current evidence of Fas in cancer, 
it may be hypothesised that increased SIPA1L2 expression in aggressive UM may 
inhibit apoptosis, promote tumour growth and metastatic formation via this 
mechanism. While it has been shown that SIPA1L2 is involved in RAS-mediated 
epigenetic silencing of Fas (631), whether it silences Fas via RAS-independent 
manner needs further investigation to test this hypothesis. 
 
4.5.2. Upregulation of SIPA1L2 due to loss of pRB and 
TFAP2A may cause deregulation of cellular homeostasis 
 
Recently, SIPA1L2 was identified as one of 21 target genes for the 
transcription factor activator protein-2 gamma (TFAP2C) in a breast cancer cell 
line (658). Activator protein-2 (AP-2) regulates gene expression by binding to a 
GC-rich recognition sequence in the regulatory regions of many genes (659,660). 
AP-2 regulates various signaling pathways involved in development (including the 
eye), cell growth, differentiation and apoptosis (661–665) and plays a crucial role 
in cellular homeostasis between normal cell growth and neoplastic formation 
(666,667). Several studies have shown AP-2 to exert both positive and negative 
regulatory roles in breast cancer initiation, growth and metastatic progression 
(668–672). In acute myeloid leukemia, transcription factor activator protein-2 
alpha (TFAP2A) upregulated other target genes that stimulated cancer cell 
proliferation and survival (673). Conversely, reduced expression of TFAP2A was 
associated with poor prognosis in gastric adenocarcinoma (674), and glioma 
(675) while overexpression in pancreatic cancer could be exploited to decrease in 
vivo tumour growth and resistance to gemcitabine (676). In cutaneous 
melanoma, TFAP2A acts as a tumour-suppressor gene by inducing cell-cycle 
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arrest and apoptosis, with loss of expression of nuclear TFAP2A correlated to 
melanoma progression (677–680). Conversely, re-expression of TFAP2A in highly 
metastatic cutaneous melanoma cell lines significantly reduced tumor growth 
and decreased experimental lung metastasis in vivo (681). Penna et al 
demonstrated that miR-214 contributed to cutaneous melanoma progression 
and metastatic formation through suppression of the TFAP2C gene (682). 
Further, TFAP2C mRNA was downregulated in melanoma but expressed in skin as 
well as nevus samples. In a more recent study, Penna et al also identified indirect 
downregulation of TFAP2A by miR-214, which may be as a consequence of 
downregulated TFAP2C (683). Indeed, it is known that TFAP2C silencing reduces 
TFAP2A protein levels (683) and that TFAP2 family members regulate each other 
transcriptionally (684). This was confirmed in an immunohistochemical study, 
with low expression of TFAP2A and TFAP2C associated with poor prognosis in 
cutaneous melanoma (685).  
 
Interestingly, TFAP2A inactivation was observed as a consequence of loss 
of RB1 function in retinoblastoma. When TFAP2A expression was restored, 
apoptosis and inhibition of proliferation was induced in retinoblastoma cells 
(686). In the initial study by Onken and Harbour et al that led to the identification 
of class 1 low-risk and class 2 high-risk UM, TFAP2A was identified as one of 62 
discriminating genes that accurately distinguished between the two groups 
(687). This finding is also supported by an earlier study by that identified 
chromosome 3 loss as a molecular classifier for adverse outcome, which also 
found underexpression of TFAP2A in aggressive UM. In our study, TFAP2A was 
found to be downregulated by 1.403 fold (p: 0.004). TFAP2A has been shown to 
interact with pRB in vitro, and associates with pRB in vivo (688). As pRB is 
constitutively hyperphosphorylated and functionally inactivated in UM (689–
691), it is possible that SIPA1L2 is upregulated by loss of pRB and TFAP2A in UM, 
leading to aggressive, metastatic phenotype.  
  
244 
 
4.6. Contactin 3 (CNTN3) 
 
In the bioinformatic reanalysis of gene expression microarray data, 
Contactin 3 showed the third most significant p value (p: 0.000807) where it was 
3.1 fold differentially downregulated in monosomy 3 tumours with metastasis 
(M3M) compared to disomy 3 tumours without metastasis (D3NM). It is located 
at cytoband 3p12.3 and is involved in cell adhesion, although its exact function is 
poorly understood. Tumours with chromosome 3 monosomy are associated with 
high risk for metastasis. Thus, the downregulation of CNTN3 in aggressive UM is 
an interesting finding, and may function as a metastasis suppressor gene. 
However, immunohistochemical staining of CNTN3 on 13 primary UM tumours of 
patients that developed metastatic disease (mUM) and 13 primary UM tumours 
of patients that did not develop metastasis (nmUM) did not show any statistically 
significant difference of expression between the two groups. A trend towards 
lower expression in mUM was found, with 46% of mUM tumours demonstrating 
no CNTN3 expression (no staining) while all nmUM tumours showed positive 
staining for CNTN3. No significant difference was seen when comparing the 
intensity or percentage of staining between mUM and nmUM. CNTN3 expression 
did not correlate with clinicopathological factors such as survival, chromosome 3 
status, cell type or tumour size. The lack of significant results of CNTN3 
expression may be explained by the relatively small sample size of 26 tumours. 
Furthermore, the majority of tumours only showed relatively weak staining in 
both mUM and nmUM tissues. Thus, immunohistochemical expression of CNTN3 
was not evaluated further in the larger cohort of UM tissue microarray samples.   
 
In a GEP microarray study of 46 UM tumours, van Gils et al identified 
downregulation of 2 small regions in chromosome 3, associated with shorter 
survival; 3p12-14 and 3p23-25 (692). This finding is also supported by a 
microsatellite analysis of 52 primary tumours that identified deletions in regions 
3p11-14 and 3p25-26 (693). This suggests that these regions harbour tumour 
suppressor genes, and loss of these genes lead to the aggressive, metastatic 
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phenotype observed. Contactins belong to the immunoglobulin superfamily and 
are involved in cell adhesion. They are located in the cell membrane, and have 
also been found to be expressed in microtubules and occasionally, nucleoli. It has 
only been reported by a few studies. Alterations in CNTN3 gene expression is 
predominantly reported in autistic spectral disorders (694). Loss of 
heterozygosity in chromosome 3p, including CNTN3 has also been described in 
familial renal cell carcinoma (695) while another study identified a variant on 
chromosome 3p12.3 as significantly associated with abdominal aortic aneurysm 
(696) though this was later disputed (697). A study of endometrial carcinoma 
identified CNTN3 to be upregulated in early stage compared to late stage disease 
(698).  
 
Contactin 1 has been shown to promote metastasis in several 
malignancies. The gene encoding for CNTN1 is located in chromosome 12, unlike 
CNTN3. Contactin 1 expression correlated with the expression of VEGF-C and 
VEGF-R-3 in gastric carcinoma (699). This was associated with the presence of 
lymphatic invasion and poor prognosis, suggesting its use as a biomarker to 
predict patients at risk for mortality from lymphatic metastasis. Overexpression 
CNTN1 was also associated with the regional lymph node metastasis of patients 
with oral squamous cell carcinoma (700). In lung adenocarcinoma, several 
studies have shown CNTN1 to promote invasion and metastasis (701–703).  
4.6.1. CNTN3 and PTPRG as tumour suppressors 
 
Although this study did not identify receptor-type protein-tyrosine 
phosphatase gamma (PTPRG), CNTN3 has been shown to bind to PTPRG in vitro 
(704,705). Protein-tyrosine phosphatases (PTPases) play an essential role in the 
regulation of cell activation, proliferation and differentiation, since they 
counterbalance the growth-promoting effects of protein-tyrosine kinases (706). 
PTPRG is a member of the protein tyrosine phosphatase family, located at 
chromosome 3p14.21. Deletions and translocations in this region have been 
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observed in familial renal cell carcinoma (707,708) and breast cancer (709). Its 
expression was also reduced in gastric cancers (710). PTPRG was expressed in 
both normal human lung tissue and non-tumour cells of lung adenocarcinoma 
while in 50% of the lung adenocarcinoma, PTPRG was absent (711). Furthermore, 
mutations of PTPRG were also identified in colorectal carcinomas, suggesting 
that PTPs are tumour suppressor genes regulating cellular pathways (712). 
PTPRG promoter hypermethylation was observed in T-cell lymphomas (713), 
gastric cancer (714), and melanoma cell lines (715), suggesting promoter 
hypermethylation is an important mechanism to silence PTPRG expression. In 
nasopharyngeal carcinoma, decreased expression of PTPRG was associated with 
tumourigenicity while overexpression inhibited cell growth by inducing G1 arrest 
through inhibition of pRB phosphorylation and down-regulation of cyclin D1 
(716). This observation in nasopharyngeal carcinoma is significant, as pRB is 
constitutively hyperphosphorylated and functionally inactivated in UM, with 
cyclin D1 overexpression in about 65% of cases (689–691).  Furthermore, 
increased cyclin D1 protein expression has been associated with larger tumour 
basal diameter, epithelioid cell type, and poor prognosis (691). Thus, CNTN3 and 
PTPRG may play a critical role as tumour suppressors in UM. 
 
In breast cancer cells, PTPRG was downregulated in more aggressive 
phenotype and was shown to prolong doubling times and colony sizes, indicating 
tumour suppressive characteristics (717). Importantly, PTPRG was shown to 
inhibit breast tumour formation in vivo via the ERK1/2 pathway (718). The most 
common known oncogenic mutations occur in GNAQ or GNA11, found in about 
85% of all primary UM irrespective of tumour class or stage (23,24). Constitutive 
activation of the MAP-kinases ERK1/2 plays a crucial role in UM development, 
likely as a consequence of active mutations in the G-proteins GNAQ and GNA11 
(24,34,36,37). Several studies have also found activation of ERK1/2 in UM, 
independent of GNAQ, RAS or BRAF mutational status (34,36,39). Knockdown of 
mutant GNAQ in UM cells resulted in MAP-kinase inhibition and decrease in 
pERK expression, accompanied by reduced growth and induced apoptosis 
(37,38). In an on-going  phase II clinical trial of selumetinib (MEK inhibitor) versus 
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temozolomide in patients with metastatic uveal melanoma (clinicaltrials.gov # 
NCT01143402), preliminary results show sustained inhibition of pERK and 
suppression of cyclin D1 in matched tumour biopsies of patients that showed 
stabilisation and partial response in liver metastases, while progression of 
metastatic disease was observed in a patient that did not demonstrate pERK 
inhibition and cyclin D1 suppression (38). Two different protein kinase C (PKC) 
inhibitors, AEB071 and enzastaurin, were shown to independently increase the 
accumulation of p27Kip1, while decreasing the expression of cyclin D1in three 
GNAQ-mutated cell lines, leading to G1 cell-cycle arrest (40,41). Several studies 
have demonstrated that G1 arrest induced by MEK inhibitors is mediated via 
inhibition of ERK1/2, characterized by decreased expression of cyclin D1 and 
accumulation of p27Kip1 (42–44). The PKC inhibitors also demonstrated 
antiproliferative effects on these cell lines, suggesting that the suppression of 
Erk1/2 phosphorylation may be critical to inhibit proliferation through altering 
the expression of p27, cyclin D1, Bcl-2 and survivin.  
 
Taken together, altered PTPRG expression associated with CNTN3 
downregulation may lead to uncontrolled tumour growth and metastatic 
dissemination in UM. It may be hypothesised that one of the events that enables 
tumours with loss of heterozygosity/loss of chromosome 3 to acquire its 
metastatic propensity is via the loss of this tumour suppressor gene. However, 
the expression or function of CNTN3 or PTPRG has never been studied in UM 
before. Moreover, CNTN3 is a novel gene and its functions are poorly 
understood. Despite the lack of significant difference of immunohistochemical 
expression in this pilot study, future studies to determine its functional 
properties in UM cell lines are warranted. Specifically, the effect of CNTN3 
knockdown on invasion and migration properties of non-invasive cell lines should 
be determined. Currently, no adjuvant therapies are available to decrease the 
risk of metastatic disease following treatment of the primary tumour. This is an 
area with potential clinical significance, as CNTN3/PTPRG may be an important 
target for therapeutic intervention in post-operative high-risk UM patients with 
chromosome 3 abnormalities. 
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4.7. Advantages, limitations and future work 
 
There are several advantages of this study compared to previous 
proteomic studies using cell lines. Cell line models lack the intrinsic tumour 
microenvironment, where cells interact with a plethora of stromal elements. 
Furthermore, the functional significance of biomarkers identified in vitro may not 
be consistent with those identified in in vivo models (606). Tumour 
microenvironment also has a large influence on gene expression (719). In vitro 
culture conditions and long-term cell passages are known to greatly change the 
gene and consequently protein expression patterns for such artificial 
environments (720,721). Due to these intrinsic differences between cell culture 
and tissue studies, biomarkers identified in in vitro studies may not demonstrate 
the desired phenotype in in vivo studies. Short of using in vivo models, UM tissue 
proteomics may facilitate the identification of biomarkers that may be more 
translationally relevant and reliable. This however inevitably also introduces 
other technical difficulties that may yield confounding results due to potential 
contamination of tumour tissues with surrounding non-neoplastic ocular 
structures. Specifically, contamination of UM tissue with blood is difficult to 
avoid and remains a challenge. Techniques such as laser microdissection may 
minimise contamination of tumour samples with surrounding ocular structures. 
Likewise, this technique may also be used to compare tumour tissue to adjacent 
normal uveal tissue as control, which may reveal biomarkers that are intrinsically 
involved in the developmental biology of UM.  
 
The immunohistochemical study of 26 whole UM tissue samples used for 
validation of both proteomic and gene microarray targets did not show any 
substantial statistical significance due to the small sample size. This was intended 
as a pilot study in order to identify targets that showed adequate and 
heterogenous staining that was suitable for assessment and grading. Based on 
this, PRDX3 was selected for validation in the larger cohort of tissue microarray 
samples. However, both proteomic and bioinformatic gene microarray studies 
249 
 
have identified other novel and interesting molecular candidates. Further 
investigations into the properties and effects of these proteins and genes are 
necessary. 
 
To date, tissue studies have only been performed on enucleated samples. 
As these tumours represent advanced disease, future studies using fine needle 
aspiration biopsy samples may further our understanding of the early molecular 
events governing tumour growth, progression and metastasis. Recent advances 
in proteomic profiling of formalin-fixed, paraffin-embedded tissue would provide 
an opportunity to greatly expand the range, variety and availability of both 
primary and metastatic UM tissues available for proteomics analysis. Proteomic 
analysis of other biological material such as matched serum, vitreous and tumour 
tissue would also provide insights into the individual molecular characteristics of 
this disease. This would be an important step towards the identification of 
effective biomarkers and therapeutic targets for personalised medicine in uveal 
melanoma.  
 
Specific areas for further research arising from this project are: 
1. Investigate the effects of PRDX3 inhibition and overexpression in cell lines 
of different metastatic propensity 
2. Investigate the expression of PRDX3 in metastatic uveal melanoma tissue 
samples 
3. Investigate the expression of CNTN3 in a larger cohort of tumour 
samples, given its localisation to chromosome 3 
4. Investigate the effects of CNTN3 inhibition and overexpression in cell 
lines of different metastatic propensity 
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5. Conclusion 
 
To identify differentially expressed proteins between primary uveal 
melanoma tissue of patients that developed metastasis and primary uveal 
melanoma tissues of patients that did not develop metastasis, quantitative label-
free LC-MS proteomic analysis was performed. Thioredoxin-dependant 
peroxidase reductase (PRDX3) was upregulated and cytosolic non-specific 
dipeptidase (CNDP2) was downregulated in primary tumours that developed 
metastasis. To identify differential expressed genes between chromosome 3 
monosomy tumours with metastasis and chromosome 3 disomy tumours 
without metastasis, bioinformatic reanalysis of publically available gene 
expression microarray datasets was performed. Signal-induced proliferation-
associated 1-like protein 2 (SIPA1L2) was upregulated and contactin 3 (CNTN3) 
was downregulated in monosomy 3 tumours with metastasis. Pilot 
immunohistochemical validation studies of all 4 targets were not statistically 
significant. In a larger cohort of primary uveal melanoma tissues, significant 
difference of PRDX3 expression was observed in tissues of patients that did and 
did not develop metastasis. High PRDX3 expression was significantly associated 
with shorter survival, and is predictive of the development of metastatic disease. 
PRDX3 may play a role in the development of metastatic disease by stimulating 
proliferation and inhibiting apoptosis of UM cells. Further, its interaction with 
the MYC and MAPK pathways likely promotes tumour cell survival, proliferation 
and eventually metastatic dissemination. Other proteins and genes that are 
known to be involved in uveal melanoma were also found in this study, along 
with several novel targets for further research. 
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